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Abstract 
 
Community-acquired pneumonia (CAP) is a leading cause of adult morbidity and 
mortality worldwide despite decades of effective antibiotics and vaccination initiatives. 
There have been no recent significant improvements in outcomes, including 30-day 
mortality. The bacterium Streptococcus pneumoniae is the most prevalent causative 
pathogen in CAP, being found in up to half of cases. In September 2006 a childhood 
pneumococcal vaccine (PCV-7) was introduced, leading to reductions in vaccine-type 
(VT) pneumococcal disease in infants, with possible additional benefits reported in 
adults. However, the effect that infant PCV-7 vaccination has on adult disease has to 
date been inadequately described in a small fraction of patients with invasive CAP, 
almost exclusively in populations in the US. These issues are explored fully in the 
literature review, encompassing chapters 1, 2 and 3. 
 
New strategies for CAP are therefore required. The outcome of CAP can be improved 
by a) preventing the disease by vaccination and herd immunity, and b) ameliorating 
the course of the disease after it has been acquired. This thesis presents a collection 
of studies that aim to acquire observational data to investigate these two issues. 
 
The majority of the included studies are drawn from a two year prospective cohort 
study of consecutive adults with CAP admitted to a large UK teaching hospital trust 
between September 2008 and September 2010. After obtaining informed consent, the 
presence of pneumococcal disease in each participant was established by testing 
urine samples for pneumococcal capsular polysaccharide, a test which has a high 
sensitivity and specificity. The urine samples were subsequently tested for 
pneumococcal serotype. A full record of care processes, investigations, and clinical 
outcomes was made, and child contact in the month preceding admission was 
assessed. These methods are described more fully in chapter 4. 
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Chapter 5 presents the data on the pneumococcal serotypes found in the cohort over 
a two year period, and links them to epidemiological characteristics in the study 
population. The most prevalent serotypes were 14, 1, 8, 3 and 19A, with VT serotypes 
less frequent in the second year of the study. Chapter 6 examines the association that 
infecting serotype has with disease manifestation and patient characteristics. Infection 
with a serotype not contained within PCV-7 (NVT) was associated with younger and 
fitter patients, a higher rate of complications such as para-pneumonic effusion, and 
hypotension at admission. The effect of child contact on pneumococcal disease is 
reported in chapter 7. Prior contact with a child aged 8 years was particularly 
associated with pneumococcal aetiology, and contact with a PCV-7 vaccinated child 
independently associated with NVT CAP. The findings from these three chapters are 
unique in that they relate individual pneumococcal serotype to specific clinical disease 
patterns, epidemiology and transmission in both invasive and non-invasive 
pneumococcal CAP for the first time. They show a change in serotype distribution in 
adults following the introduction of PCV-7 in infants, which is important to inform future 
vaccine development for both adults and children. Furthermore, different serotypes 
are associated with different clinical disease patterns, which may have a significant 
LPSDFWRQ WKHGLVHDVH WKDW FOLQLFLDQVVHHDW WKH ³IURQWGRRU´JLYHQ WKDt the serotype 
distribution of pneumococcal CAP may be changing. Finally, the link between child 
vaccination and adult disease provides more direct evidence for the transmission of 
pneumococci from children to adults as a mechanism for the development of CAP in 
adults. 
 
The second part of this thesis looks at current care processes, and how these might 
be improved. Chapters 8, 9 and 10 relate to efforts to better predict prognosis, and 
chapters 11 and 12 with how patents with CAP may be better managed at thH³IURQW
GRRU´ 6\PSWRPV DUH FOHDUO\ LPSRUWDQW WR SDWLHQWV EXW WKH UROH RI V\PSWRPV LQ
management and outcome is unclear. Chapter 8 presents a study validating a 
symptom score that has not yet entered routine use, but which is shown to correlate 
with clinical outcomes, and may be useful in assessing outcome in low severity CAP. 
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The influence that oxygenation status at admission has on outcome is poorly 
understood. Chapter 9 describes a study showing that whilst hypoxaemia does 
positively predict adverse outcome, it is not as predictive as existing severity scores. 
The presence of hypoxaemia may however identify a subset of patients who are 
classified as low severity by existing severity scoring, but are nevertheless at 
increased risk of adverse outcome. 
 
Severity scoring is the cornerstone of management in adult CAP, and is explored in 
chapter 10. Current severity scores adequately predict mortality in CAP, but often 
JHQHUDWH D JURXS RI ³PRGHUDWH VHYHULW\´ ZKHUH DSSURSULDWH PDQDJHPHQW LV RIWHQ
unclear. This study looked at the effect of pre-admission functional status on outcome 
in conjunction with existing severity scores in this difficult group, and validated a novel 
severity score for predicting need for escalation of care, SMART-COP. Incorporation 
of functional status does marginally improve the performance of existing severity 
scores, but may be of more use as a post-severity score test to identify sub-groups of 
patients with moderate severity CAP who are at increased risk of death. 
 
Chapter 11 looks at the influence that making a prompt diagnosis (rather than prompt 
treatment with antibiotics, as has previously been studied) has on outcome, using the 
time between admission and first chest radiograph as a surrogate measure. Whilst an 
early chest radiograph was not associated with an improvement in mortality, it was 
associated with a shorter length of hospital stay, and may therefore be regarded as a 
marker of good quality care. 
 
There is current debate as to the role of the speciality physician in the front-door early 
assessment of patients, and whether early review of patients with CAP may improve 
outcome compared with management by a non-specialty physician. Chapter 12 looks 
at the effect that early specialist senior respiratory review has on outcome for adults 
with CAP, showing a clear benefit on length of hospital stay to early consultant review. 
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In conclusion, this thesis provides an up-to-date picture of the circulating 
pneumococcal serotypes in non-invasive adult CAP, and correlates infecting serotype 
to clinical and epidemiological parameters. It also identifies five areas of clinical care 
where management processes could be improved. By addressing of these aspects 
the outcome of CAP may be improved in the future. 
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Chapter 1: The burden of community-
acquired pneumonia 
 
 
 
 
³,WLVPXFKPRUHLPSRUWDQWWRNQRZZKDWVRUWRISDWLHQW
KDVDGLVHDVHWKDQZKDWVRUWRIGLVHDVHDSDWLHQWKDV´ 
 
Sir William Osler 
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Introduction 
As an introduction to this thesis, this chapter describes the current burden of 
community-acquired pneumonia (CAP) in the UK population and worldwide, with 
particular focus on Streptococcus pneumoniae. 
 
Definition 
CAP is defined by the British Thoracic Society (BTS) DV ³V\PSWRPV DQG VLJQV
consistent with an acute lower respiratory tract infection associated with new 
radiographic shadowing for which there is no other explanation (for example, not 
pulmonary oedema or infarction) where the illness is the primary reason for hospital 
DGPLVVLRQDQGLVPDQDJHGDVSQHXPRQLD´.1 
 
Epidemiology 
Population incidence 
A variety of studies have estimated the incidence of CAP within the general 
population. The most recent study analysed a primary care patient database (The 
Health Information Network; (THIN)) covering the years 1991 to 2003 for diagnoses of 
CAP recorded by general practitioners (GPs),2 representing 56,332 cases in 4% of the 
UK population. The overall annual incidence of CAP in this cohort was 2.33/1000 
population, with CAP being particularly common in those aged less than 5 years 
(1.91/1000 population per year) and more than 60 years (6.66/1000 population per 
year). CAP was more common amongst those of male sex and lower socioeconomic 
status. A similar study performed in another UK primary care database 
(QRESEARCH) included 34,098 cases of CAP, and calculated an overall incidence of 
1.15/1000 patient-years.3 Another study of comparable size was performed in Seattle, 
USA, where 15,141 cases of physician-defined CAP were identified over a twelve 
year period, giving a much higher annual incidence of 12/1000, rising to 34/1000 in 
those aged more than 75 years.4 However, when data were presented in this study 
from a non-influenza pandemic year (1965), the incidence was substantially lower 
17 
 
across all age groups. A smaller Finnish study described a rate of 11.6/1000 amongst 
a smaller population of 46,979 in one calendar year.5 These studies are necessarily 
limited in that the definition used for inclusion was physician reported diagnoses, 
many of which would not have had a confirmatory chest radiograph. A study involving 
a population of 74,368 in Barcelona, Spain, of radiographically confirmed CAP 
suggested a lower incidence of 1.6/1000.6 A UK study of prospectively collected 
patients with lower respiratory tract infection in the community estimated the annual 
incidence of CAP in a much smaller defined population as 4.7/1000.7 
 
The hospitalised population 
Approximately 5% of acute medical admissions to UK hospitals are caused by CAP 
(HESonline.org.uk), resulting in over 100,000 hospital admissions in England and 
Wales annually.8 The most recent study to examine the incidence of CAP estimated 
the annual incidence amongst adults (age 18 years) in Germany to be 2.75-
2.96/1000.9 The number of patients (adults and children) with CAP admitted to UK 
hospitals has risen from 1.48/1000 to 1.98/1000 population between 1997 and 2005, 
with the annual incidence highest in older adults (age 85: 22.2/1000; age 75-85: 
8.8/1000; age 65-75: 3.6/1000).8 There has been a 128% increase in admissions with 
CAP to critical care over a similar period.10 
 
This trend is also seen elsewhere in the world. A Danish study of adults hospitalised 
with CAP showed an increase in hospital diagnoses from 2.88/1000 to 4.42/1000 
population between 1994 and 2004.11 A similar study in the USA in adults aged more 
than 65 years showed an increase in annual incidence between 1988 and 2002 of 
17/1000 to 22/1000.12 
 
Financial cost of CAP 
Due to the high incidence of CAP in the general population, substantial costs are 
attributed to CAP in the UK. The last UK study on this subject was performed in 1997, 
which estimated that the total annual cost to the NHS was £440 million, with 96% of 
18 
 
this cost attributable to hospitalisation and 87% to bed-days used.13 This cost 
assessment was performed on 1992-1993 prices, and so is likely to have increased 
substantially since. A more recent US study suggested that median hospital costs are 
US$8,654 per hospitalisation (interquartile range (IQR) US$5,457-US$16,027).14 
Estimates in the employed population are even higher, with a mean cost US$10,227 
per episode, rising to US$15,822 in those patients who subsequently died.15 As such, 
even small reductions in length of hospital stay (LOS) can have substantial cost 
benefits; a half-day shortening of LOS has been estimated to save US$724 per 
hospitalisation, translating to a potential saving of US$813 million nationally.16 
 
Pneumococcal pneumonia 
Introduction 
Streptococcus pneumoniae RWKHUZLVH NQRZQ DV WKH ³SQHXPRFRFFXV´ LV D *UDP
positive encapsulated organism responsible for the majority of bacterial respiratory 
infection worldwide. In the respiratory tract it causes CAP, otitis media (OM), and non-
pneumonic lower respiratory tract infection (LRTI), but the pneumococcus also causes 
invasive disease such as bacterial meningitis (especially in the very young and old), 
septicaemia and endocarditis. 
 
³5oughly lancet-shaped pairs of coccoid bacteria´ were first described independently 
in human sputum by Louis Pasteur in France and George Sternberg in the USA in 
1881. These organisms demonstrated pathogenic ability when injected into rabbits, 
causing a bacteraemia.17 The capsular polysaccharide was first described by Neufeld 
LQ  ZKHQ REVHUYLQJ PLFURVFRSLF FDSVXODU VZHOOLQJ *HUPDQ ³TXHOOXQJ´ DQG
agglutination of pneumococci when exposed to specific pneumococcal anti-sera. 
 
Even with rigorous diagnostic efforts, one or more causative pathogens may be 
identified in only up to 75% of individuals with CAP.18-25 The pneumococcus is the 
commonest infectious agent responsible for hospitalised CAP and is found in up to 
50% cases.18-25 This remains the case in the more elderly population,26 the more 
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severely ill patients,21, 27 in primary care,23, 28 and in a similar distribution worldwide.19, 
23
 
 
Worldwide impact and distribution 
Pneumococcal disease is estimated by the World Health Organisation (WHO) to 
cause 1.6 million deaths per year worldwide.29 The most recent estimate of 
pneumococcal disease in children aged less than five years was a meta-analysis of 
estimates from different countries of the incidence of meningitis, CAP, and other 
pneumococcal disease in the year 2000.30 This study estimated that 826,000 deaths 
in children annually were attributable to S. pneumoniae, with 91,300 in HIV positive 
children. 741,000 of these deaths were due to CAP. 
 
This burden is borne particularly by the developing world. A study based in a rural 
population in Kenya of 16,570 children who had blood cultures drawn during an 
episode of CAP derived an incidence of community-acquired pneumococcal 
bacteraemia of 213 per 100,000 children aged <2 years, with 8.7% of in-hospital 
deaths attributable to pneumococcus.31 These figures are likely an underestimate, 
because blood cultures have a low sensitivity for microbial aetiology (see chapter 3) 
and the majority of children in rural sub-Saharan Africa are not treated in hospital. The 
corresponding incidence in children aged <2 years in the USA has been estimated at 
167 per 100,000 in 1998,32 and in the UK in children aged <1 year between 1995 and 
2000 was 38.6 per 100,000.33 It has been postulated that the disparity between IPD 
rates in the USA and Europe is attributable to different rates of drawing blood cultures, 
and that there is therefore significant under-reporting of disease in Europe.34 
 
Risk factors 
Pneumococcal disease has specific demographic associations. A study of 609 
subjects with pneumococcal bacteraemic CAP showed associations with those aged 
 \HDUV RGGV UDWLR 25  ODFN RI KLJK VFKRRO HGXFDWLRQ 25  DQG ORZ
income (OR 10.5 for annual income <$US6000).35 Robinson and colleagues found 
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that in a US cohort of IPD, HIV/AIDS, asplenia and significant co-morbidity were risk 
factors (table 1.1), and over 50% of patients aged between 2 and 65 years dying from 
IPD had an identifiable underlying condition for which pneumococcal vaccination 
would be indicated.32 Age-specific incidence of IPD was highest in those aged <2 
\HDUVSHUDQG\HDUVSHUZLWKPRUWDOLW\KLJKHVWLQ
WKRVHDJHG\HDUV2WKHUSXEOLVKHGVWDWLVWLFDOO\VLJQLILFDQW25VLGHQWLILHG
for developing IPD include asthma (2.4),36 diabetes mellitus (1.9),37 and cigarette 
smoking (4.1).38 
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Risk factor for IPD Mortality rate (%) 
None 4.0 
HIV infection 7.1 
AIDS 10.0 
Diabetes mellitus 6.7 
Alcohol abuse / cirrhosis 18.3 
COPD 12.4 
Asplenia 15.1 
Congestive cardiac failure 27.4 
Coronary artery disease 19.2 
Malignancy, excluding haematological 21.6 
$JH\HDUV 16.6 
Any indication for pneumococcal vaccination 11.7 
 
IPD: invasive pneumococcal disease; HIV: human immunodeficiency virus; AIDS: 
acquired immunodeficiency syndrome; COPD: chronic obstructive pulmonary disease. 
Adapted from Robinson et al., 2001.32 
Table 1.1. Mortality for IPD in different at-risk groups. 
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Concluding remarks 
The scale of the challenge posed to health services by CAP is huge. In addressing 
this, a strategy is required which incorporates both improved physician practice and 
enhanced awareness of CAP microbiology (particularly with regards to the most 
prevalent pathogen, Streptococcus pneumoniae, and its prevention with vaccination). 
Chapters 2 and 3 review what is already known about these two issues, and chapters 
4 to 12 describe relevant clinical studies performed as part of this thesis. 
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Chapter 2: Pneumococcal disease and 
vaccination 
 
 
 
 
³«WKHFDSWDLQRIWKHPHQRIGHDWK´ 
 
Sir William Osler 
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Introduction 
This chapter will describe the pathogenesis and transmission of pneumococcal 
pneumonia, and examine the current and future vaccine strategies aimed at its 
prevention. 
 
Colonisation and transmission 
The mechanisms by which S. pneumoniae causes disease and is transmitted are not 
fully understood. It is thought that S. pneumoniae initially colonises the upper 
respiratory tract, and thereafter may spread locally (to cause disease in the sinuses 
and middle ear) or be aspirated to the alveoli (causing CAP and thereafter IPD). 
 
Nasopharyngeal carriage 
Characteristics 
The oral cavity and nasopharynx have a commensal flora comprising hundreds of 
different organisms.39 S. pneumoniae and Haemophilus influenzae are thought to be 
the most pathogenic prevalent commensal organisms carried in the upper respiratory 
tract, and are acquired within the first few months of life.40, 41 Carriage is 
asymptomatic, but disease is usually caused by the same serotype as was previously 
present as a coloniser,41-43 suggesting that colonisation precedes development of 
invasive or local disease. 
 
Prevalence 
Point studies describing rates of carriage vary substantially between different ages 
and geographical locations, but are generally highest around two years of age, at 
around 50% (table 2.1). Higher colonisation rates have been observed in children 
attending day care centres (OR 1.6-3.4),44 in members of families with young 
children,45-49 and in children who have received prior antibiotics.47 Point carriage rates 
in adults (aged >17 years) are substantially lower, estimated at between 2% and 
13%.45, 50-55 This implies that infants may act as a reservoir for pneumococcal disease, 
as carriage precedes disease, and the rate of carriage in adults is low.
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Study Point carriage rate (%) Age (months) Country 
Healthy children 
   
Coles 2009 56 82.9 1-36 Nepal 
Huang 2009 57 23-30 3-84 USA 
Millar 2008 58 59-65 1-60 USA 
Roche 2007 59 51 6-72 UK 
Bogaert 2006 60 55 24 Netherlands 
Hammitt 2006 52 59-61 1-48 Alaska 
Hussain 2005 49 52 1-24 UK 
Regev-Yochay 2004 61 43 1-40 Israel 
Soewignjo 2001 62 48 1-24 Indonesia 
Syrjanen 2001 63 43 24 Finland 
Parry 2000 64 49.4 60 Vietnam 
Lopez 1999 47 36 72 Spain 
Mbelle 1999 65 26-30 1-2 South Africa 
Hendley 1975 45 35 Pre-school USA 
RTI 
   
Coles 2009 56 76.7 1-36 Nepal 
Syrjanen 2001 63 56 24 Finland 
 
RTI: respiratory tract infection 
Table 2.1. Point estimates from nasopharyngeal swab studies of childhood 
pneumococcal carriage rates in children. 
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In contrast to point prevalence studies, longitudinal studies have suggested that due 
to the dynamic nature of pneumococcal colonisation, over a longer period the majority 
of infants will be at least transiently colonised with pneumococcus. A population of 
children in Oxford had acquired pneumococcus at least once in 97% cases by the age 
of two years.66 Children may be colonised sequentially with different serotypes, with 
one study of day care children reporting a mean of 3.6 different strains acquired over 
the course of a year.67 This same study reported that over a course of a year, 46/47 
children attending a single day care centre acquired pneumococcal carriage on at 
least one occasion. In a Gambian population, 97% of children and 87% of adult close 
contacts were colonised at least once over the course of a year.68 
 
Competition 
Due to the large number of different colonising species in the naso-orophaynx,39 
colonisation is a dynamic process, with competition for the niche occurring between 
VSHFLHV &DUULDJH RI Į-Haemolytic Streptococci is associated with lower rates of 
pneumococcal OM in children (65% vs. 14%),69 and these isolates have an inhibitory 
effect on pneumococcal growth in vitro.70 Competition also occurs between 
pathogenic species. Pneumococcal carriage in healthy children is inversely correlated 
with carriage of Staphylococcus aureus, suggesting a mutually inhibitory effect.61, 71 
Lysenko and colleagues showed in a mouse model that co-colonisation with 
Haemophilus influenzae and S. pneumoniae resulted in rapid neutrophil-mediated 
killing of the latter, whereas colonisation persisted when either organism was given 
separately.72 
 
Transmission 
Transmission is thought to occur by direct contact with the respiratory secretions of an 
individual carrying pneumococcus. The highest rates and longest duration of 
colonisation are found in infants, and therefore studies have investigated how infants 
both become colonised with and transmit pneumococci. 
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Transmission between children in day care 
Pneumococcal transmission from child to child occurs readily in a close contact 
situation such as a day care centre. A longitudinal study of 262 toddler day care 
attendees and their 36 younger siblings showed that of 71 newly acquired 
pneumococcal strains in the younger siblings, 54 (76%) were isolated at least once in 
WKHROGHUVLEOLQJ¶VGD\FDUHFHQWUHLQWKHSUHFHGLQJVL[PRQWKV73 A longitudinal study 
in a single day care centre with eleven sampling periods over the course of a year 
described the transmission dynamics of nasopharyngeal carriage of S. pneumoniae.67 
Several pneumococcal clones were identified that colonised a single child, with the 
same clone proceeding to colonise several other children over the course of the study. 
A further study in a Finnish cohort estimated that on average 2.7 new outbreaks of 
pneumococcal colonisation are generated per day care centre per month, involving an 
average of 7.6 children for an average of 2.8 months.74  
 
Transmission from children to adults 
Transmission has been studied between infants and other same-household contacts 
regardless of age. Having a child less than six years old in day care has been 
significantly associated with development of IPD in adult household contacts (OR 
2.3).38 In a Finnish longitudinal study, children aged more than six months were more 
likely to be colonised with S. pneumoniae if a family member was also colonised (OR 
3.6).48 A study of 39 households in a slum community in Brazil showed that nine 
households had more than one family member colonised with the same 
pneumococcal strain, implying transmission between the two members.75 A 
longitudinal study of fortnightly nasopharyngeal swabs in nineteen households in 
Gambia over a twelve month period showed that the odds of being colonised with S. 
pneumoniae were significantly greater if other carriers were present in the household, 
for both adults and children.68 However, neither of these two studies showed a 
correlation between large family size and chance of pneumococcal carriage. A ten 
month longitudinal study of 121 families in the UK showed that 64% of new colonising 
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pneumococcal serotypes within the household were introduced by children aged less 
than three years, compared with 1% for those aged 5-17 years.49 Individual 
pneumococcal carriage was associated with increased age-stratified risk ratios for 
carriage in other family members of 1.42, 1.25, and 2.25 for those aged 0±2, 3±4 and 
 \HDUV UHVSHFWLYHO\. Finally, day care centre employees have a relatively high 
pneumococcal colonisation rate for adults, at around 21.7%,76 suggesting that they 
are continually being exposed to and colonised by pneumococci from children with 
whom they work. 
 
Intra-familial transmission has also been directly linked with disease as well as 
asymptomatic colonisation. A study of eleven families where there were episodes of 
concurrent or closely related acute OM amongst siblings showed that of thirteen 
disease clusters, twelve were of identical nasopharyngeal strains of pneumococcus.43 
However, there have been no similar studies to date for pneumococcal CAP. 
 
Transmission between adults 
Pneumococcal outbreaks amongst adults are rare, implying that pneumococcal 
transmission between adults is limited. The case reports that exist are often in an 
institutional setting. Outbreaks of pneumococcal disease of the same serotype and/or 
clone have been described in hospitals,77-83 nursing homes,84 military barracks,85, 86 
homeless shelters,87, 88 nurseries,89 and prisons.90 In the most comprehensive study to 
date, 17 out of 74 (23%) residents of a nursing home were found to be colonised with 
the same pneumococcal serotype (a drug-resistant 23F) as 7 out of 11 residents of 
the same care home admitted to hospital with CAP.84 The same strain was also found 
in 2 of 69 of the nursing home staff who had close contact with the affected residents. 
 
Summary 
Pneumococcal transmission occurs between infants at day care centres and between 
infants and other family members (both children and adults) within a household. 
Widespread colonisation is also associated with outbreaks of disease in concentrated 
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adult populations, particularly in an institutional setting and those at risk of 
pneumococcal disease such as the elderly and inpatients. 
 
The pneumococcal capsule and serotypes 
Structure and role 
The polysaccharide capsule surrounds the pneumococcus and is covalently bound to 
the cell wall. 91 distinct capsular types have been discovered to date, with each 
serotype defined by the ability to cross-react to mutual immune anti-sera.91, 92 The 
capsule consists of a polysaccharide coat with embedded proteins, and provides 
protection from host defences in a number of ways: 
 
x The polysaccharides are negatively charged,93 potentially helping to repel 
negatively charged nasopharyngeal mucus;94 
x It inhibits opsonisation with complement and phagocytosis;95 
x It reduces bacterial capture in neutrophil extracellular traps.96 
 
The pneumococcal capsule is a key virulence factor for the development of 
pneumococcal disease. This was first demonstrated in 1931 by Avery and colleagues, 
who showed that decomposition of the capsule of a serotype 3 pneumococcal clone 
protected mice against subsequent challenge with the organism.97 Later experimental 
studies in mouse models have shown that invasive disease is impossible for 
pneumococcal mutants where the capsular polysaccharide is no longer bound to the 
cell wall.98 Furthermore, the virulence of a serotype 5 isolate was almost abolished in 
a mouse model by genetic switching of the capsular expression to serotype 3.99 In 
humans, strains lacking a capsule have only been reported to cause superficial 
disease.100 
 
Distribution in disease 
The distribution of serotypes causing pneumococcal disease has been well described 
in IPD. The results from a meta-analysis by Hausdorff and colleagues of over seventy 
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IPD data sets worldwide in adults and children before the introduction of the 7-valent 
childhood pneumococcal vaccine (PCV-7 ± see later in this chapter) are presented in 
table 2.2.101 The most recent study in a pneumococcal UK population of all ages was 
published in 2008, comprising 1388 blood and sputum cultures collected between 
2001 and 2006 (table 2.3).102 The serotype distribution from other major studies 
published since 2000 (and therefore not included in the meta-analysis by Hausdorff 
and colleagues) are also shown in table 2.3. These data suggest substantial variation 
in serotype distribution both geographically and between age groups. This has 
implications for the development of pneumococcal vaccines, a subject discussed in 
more detail later in this chapter. 
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Area of origin Order of invasive serotype by prevalence 
Adults 1st 2nd 3rd 4th 5th 6th 7th 
USA 4 14 9V 6A/B 12F 19A/F 23F 
Europe 14 3 9V 19A/F 1 6A/B 23F 
Oceania 14 4 19A/F 9V 1 6A/C 3 
Asia 1 3 6A/B 6 19A/F 7 14 
Africa 1 19A/F 14 6 3 12 7A/F 
South America 1 6A/B 3 18C 12F 23F 19A/F 
Children 
       
USA 14 6A/B 19A/F 18C 23F 9V 4 
Europe 14 6A/B 19A/F 18C 23F 9V 1 
Oceania 14 6A/B 19A/F 23F 18C 7A/F 4 
Asia 1 19A/F 6A/B 5 14 7A/F 23F 
Africa 6A/B 14 1 19A/F 23F 5 15 
South America 14 6A/B 5 1 19A/F 23F 18C 
 
Adapted from Hausdorff and co-workers, 2000.101 
Table 2.2. Differences in geographical pneumococcal serotype distribution. 
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Study Study year n Location 14 8 9V 23F 3 6A 6B 4 1 19F 7F 19A 
Adults and children 
               
Trotter 2010 103 1998-1999 2011 UK 17.1 7.3 8.5 6.5 5.5 3.5 5.5 5.7 7.3 4.9 3.8 3.4 
Liao 2010 104 2000-2005 221 Taiwan 29.0 0 2.7 14.0 11.3 0 13.1 1.8 0.5 11.3 0.5 0.5 
Farrell 2008 102 2006 354 UK 15.3 5.7 9.0 6.2 5.4 3.4 4.0 6.2 17.2 2.8 5.1 3.1 
Harboe 2009 105 1977-2007 18858 Denmark 9.4 4.6 5.5 3.8 5.7 3.1 3.9 8.9 14.6 3.2 7.6 1.9 
Jansen 2009 106 2004-2006 1107 Netherlands 12.6 7.8 8.8 6.1 6.1 2.8 2.4 9.0 6.0 3.3 12.6 3.0 
Foster 2008 107 1996-2005 2691 UK 18.4 6.2 7.7 6.7 5.4 - 5.9 5.2 7.5 3.8 - 3.8 
Sjöström 2006 108 1993-2000 494 International 14.6 2.8 9.9 8.1 7.7 2.4 4.3 6.3 5.9 4.3 6.9 3.8 
Robinson 2001 32 1998 3610 USA 17.6 - 8.5 7.4 3.3 4.3 7.7 10.5 2.4 5.5 2.8 3.3 
Adults 
               
Chiba 2010 109 2006 303 Japan 7.6 n/a 4.6 5.3 7.9 5.0 10.2 7.3 2.3 5.3 n/a 3.3 
Lujan 2010 110 1999-2009 294 Spain 7.6 n/a n/a n/a 12.3 n/a n/a n/a 18.9 n/a n/a n/a 
Henriques 2000 111 1993-1995 354 International 30.8 4.2 12.1 8.2 13.6 0.8 2.8 5.1 8.5 6.5 8.5 5.9 
Children 
               
Chiba 2010 109 2006 193 Japan 13.0 n/a 6.2 11.9 2.1 6.7 22.3 6.2 2.1 14.0 1.0 6.2 
 
Figures for individual serotypes represent % of each serotype within the pneumococcal cohort. 
Table 2.3. Serotype distribution within pneumococcal bacteraemic cohorts prior to introduction of 7-valent conjugate vaccine. 
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No studies have been performed in cohorts of non-invasive disease; that is to say, 
patients who have evidence of infection with S. pneumoniae, but do not have positive 
blood or sputum cultures. The sensitivity of culture-based investigations is low (see 
chapter 3), and so for a substantial proportion of those patients with pneumococcal 
CAP a serotype is not reported. Thus the serotype distribution for all patients with 
pneumococcal CAP is currently unknown. 
 
Variation in disease spectrum by serotype 
Invasive potential 
The relationship between carriage and invasive disease is complex and not fully 
understood; colonisation in children is common, but invasive disease rare. Estimation 
RIDVHURW\SH¶V³LQYDVLYHQHVV´E\H[DPLQLQJVWXGLHVRI,3'PD\EHPLVOHDGLQJDKLJK
representation of a particular serotype in invasive cohorts may represent high 
exposure of children to the serotype, rather than that serotype having a particularly 
high invasive potential. Brueggemann and colleagues correlated a series of IPD 
serotypes in children with serotypes prevalent in a carriage study within a population 
of young children during the same time period.112 This enabled calculation of ORs for 
³LQYDVLYHQHVV´RUWKHSRWHQWLDOGLIIHUHQWLQGLYLGXDOVHURW\SHVKDYHIRUFDXVLQJLQYDVLYe 
disease if carried in the nasopharynx when compared with all other serotypes. 
Serotypes 4 (OR 12.1), 1 (OR 9.6), 18C (OR 5.8), and 14 (OR 8.8) were the most 
invasive in this study, with 23F being least invasive (OR 0.4). A similar study in 
Finland compared all IPD isolates in children aged <2 years with an age-matched 
point prevalence study from a single town in Finland.113 Serotypes 14 (OR 4.1), 18C 
(OR 3.3), 19A (OR 2.9) and 6B (OR 1.6) were the most invasive, with 6A (OR 0.5), 
35F (OR 0.2) and 11A (OR 0.05) the least. Serotype 1 was not represented in this 
data set, and serotype 7F was of borderline significance. These findings were 
replicated using similar methodology, finding that serotypes 1, 4, 7F and 9V were 
particularly invasive.114 A meta-analysis performed by Brueggemann using seven 
similar international cohorts reported that, using serotype 14 as a comparator, 
serotypes 1, 5 and 7F were the most invasive, 4 equivalent in invasiveness, and all 
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others less invasive, with the least invasive being serotypes 3, 15 and 6A.115 In 
addition, these studies have found that the higher the invasive potential, the lower the 
prevalence of the serotype within carriage studies, suggesting that those serotypes 
carried for a long time have a lower invasive potential. 
 
The only study to estimate serotype invasiveness in adults was conducted by Trotter 
and co-workers, which compared serotype carriage rates in adults from a previous 
study with rates of the same serotypes in contemporaneous national IPD 
surveillance.103 This study found high case:carrier ratios (>100 cases per 100,000 
carriers) for serotypes 4, 8, and serogroup 9. Data for serotypes 1 and 5 were not 
reported, and 7F was not represented within the carriage cohort. 
 
A second way of measuring the invasiveness of a given serotype is to estimate the 
attack rate, or the proportion of each new acquisition of pneumococcal carriage that 
goes on to develop IPD. Sleeman and colleagues showed that certain serotypes were 
associated with attack rates of at least 20 per 100,000 acquisitions (higher invasive 
potential; 1, 5, 9A, 14, 18C, 19A, 9V, 4, 7F, 8, 12F), whereas others were associated 
with an attack rate of <10 per 100,000 acquisitions (lower invasive potential; 19F, 6B, 
23F, 6A, 3).66 A final method for estimating invasiveness is to compare the distribution 
of carriage serotypes between patients with CAP and healthy controls, the assumption 
being that during disease the colonising and infecting serotype will be the same. 
Using this method in children, Greenberg and co-workers found that serotypes 1, 5, 
22F, 7F, 14, 9V, and 19A were more prevalent in disease than health.116 
 
In summary, allowing for heterogeneity between studies, serotypes 1, 5 and 7F seem 
have the highest propensity to cause invasive disease following colonisation, in 
contrast to 3, 6A, and 19F (among others). However, the majority of these data are 
gathered from studies of children, and all compare carriage and IPD data from 
different populations due to the generally low incidence of IPD. 
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Demographics, disease course and outcome 
Brueggemann and colleagues found that invasiveness was correlated with serotype 
rather than clonal type or genotype,112 implying that capsular type rather than 
genotype may produce differences in clinical disease. Therefore investigators have 
examined a variety of other clinical aspects of pneumococcal disease by serotype. All 
of the studies to date have been in cohorts of IPD, and therefore have not included 
the majority of pneumococcal CAP, which is not associated with bacteraemia. 
 
Mortality 
Differences in mortality by serotype are perhaps the best studied of the clinical 
phenotypes in adults. In an early cohort of 325 patients with pneumococcal 
bacteraemia, the highest mortality was associated with serotype 3, but no attempt was 
made to correct for age.117 This finding has been replicated elsewhere.108, 111, 118 A 
retrospective study of 464 IPD isolates did correct for age and other confounders, and 
still found that serotype 3 was associated with higher mortality (relative risk (RR) of 
death 2.54) and serotype 1 lower mortality (RR 0.23) in a multivariate analysis.119 A 
large study from the Active Bacterial Core Surveillance Network in the USA, using 
VHURW\SHDVDUHIHUHQFHVKRZHGVLJQLILFDQWO\LQFUHDVHGDGMXVWHG25¶VIRUPRUWDOLW\
for serotypes 3, 11A, 19F and 23F.120 In a similar study in the Netherlands (n=1142), 
where (in contrast to the other studies mentioned) rates of all pneumococcal 
vaccination in adults are very low, case fatality rates for a group of serotypes with low 
invasiveness (3, 6B, 9N, 16F, 18C, 19F, and 23A) were higher than the reference 
group (high invasiveness; comprising serotypes 1, 5, 7F, 15B, 20, and 33F) in a 
multivariate analysis (adjusted OR 2.6).106 A recent study found that patients with IPD 
from group of low invasiveness serotypes (3, 6A, 6B, 8, 19F and 23F) had an OR for 
30-day mortality in a logistic regression analysis of 10.3 compared with IPD from the 
more invasive serotypes 1, 5 and 7F.110 IPD from highly invasive serotypes was 
associated with younger age, better pre-morbid status and an increased rate of para-
pneumonic effusion or empyema. However, it should be noted that the assumptions 
RQ³LQYDVLYHQHVV´ LQWKLVVWXG\IRUJURXSVRIVHURW\SHVZHUHGHULYHGIURPVWXGLHVRQ
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childhood disease as described earlier, and are not necessarily applicable to adult 
disease. A meta-analysis of IPD studies has also shown that serotypes 3, 6A, 6B, 9N, 
and 19F are associated with increased 30-day mortality, and 1, 7F and 8 with lower 
30-day mortality, using the 30-day mortality for serotype 14 as a comparator.121 In 
addition, 30-day mortality was positively correlated with carriage prevalence, but 
inversely correlated with invasive potential; in other words, a) less invasive serotypes 
were associated with higher mortality, and b) highly invasive serotypes were 
associated with a low duration of nasopharyngeal carriage. However, a study by 
Alanee and co-workers found no association between serotype or serotype group and 
30-day mortality in 796 prospectively recruited adults.122 In summary, the majority of 
studies (albeit in IPD rather than invasive and non-invasive CAP) agree that serotype 
3 is associated with a higher adjusted mortality, and serotypes 1 and 7F with a lower 
mortality. 
 
Age 
The serotypes found in invasive disease in children vary substantially from those seen 
in adults (table 2.3). A retrospective study of over 7,000 patients with invasive 
pneumococcal isolates showed that the relative risk of disease due to serogroup 1 fell 
with increasing age, whereas it increased with age for serogroups 3 and 8,123 a finding 
replicated elsewhere.124 A study of 494 patients with IPD (of which 83% had CAP) 
found that serotype 1 was not represented at all in those aged over 65, in contrast to 
23F which was rarely seen outside of this age group.108 However, for all other 
serotypes in this study the interquartile ranges for age were wide. A recent study 
looked at over 7000 cases of IPD, and found that serotypes 14, 6B, 19F, and 18C 
were more common in children (age 16 years), with serotypes 3 and 4 more 
common in adults.125 When compared with other age groups, the only serotype within 
the age group 16-64 years (including those patients of child-bearing age) that had 
significantl\ ORZHU SUHYDOHQFH ZDV VHURW\SH  ,Q DQRWKHU VWXG\ ³SDHGLDWULF
VHURW\SHV´ (6B, 9V, 14, 19F, and 23F) represented 32.5% of IPD in adults aged 35-
49, compared with 51.2% in adults aged >85 years.126 This re-emergence of 
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paediatric or infant serotypes in the very elderly (particularly with an increase in 
disease due to serogroups 14 and 23) has been reported elsewhere, and perhaps 
reflects either deterioration in the immune system with age, or increased contact with 
young grandchildren in the older age groups.124 It also may support targeted 
vaccination of older people with pneumococcal conjugate vaccines. 
 
Clinical presentation 
A meta-analysis by Hausdorff and colleagues found that serogroups 1 and 14 were 
more often represented in data gathered from blood cultures, serogroups 6, 10 and 23 
in cerebrospinal fluid, and 3, 19 and 23 in middle ear fluid in children.127 A study of 
368 isolates in children found that serotype 1 was the cause in 24.4% of cases of CAP 
complicated by pleural effusion or empyema compared with only 3.6% of patients 
without these complications,128 a finding replicated elsewhere.129 A study containing 
598 IPD isolates suggested that serotype 3 was more associated with septic shock 
(present in 39% of patients with shock vs. 24% in those without shock, OR 2.24), and 
conversely, serotype 1 with not developing shock (present in 2% of patients with 
shock vs. 10% in those without shock, OR 0.26).130 Serotype 3 has also been 
associated with the development of necrotizing CAP in children (79% vs. 20% for 
other serotypes; OR 14.7).131 In a study by Sjöström and colleagues, lower disease 
severity at presentation, as measured by proportion of patients with APACHE II 
scores less than 11, was seen with serotype 1 (21%), 4 (35%) or 7F (26%), compared 
with 3 (63%), 6B (76%) or 19F (71%).108 In addition, patients with infection due to 
invasive serotypes (1 and 7F) had a low rate of co-morbidity (43%) compared with 
less invasive serotypes (3, 6A, 6B, 8, 19F, and 23F: 75%). Experiments using a 
mouse model from the same group showed that intra-peritoneal challenge with 
serotypes 1 and 7F produced a much lower inflammatory response (as measured by 
TNF-Į levels) than serotypes 4, 6B, or 19F.132 The authors therefore concluded that 
highly invasive serotypes such as 1 and 7F act as primary pathogens, but serotypes 
with low invasive potential such as 19F are acting as opportunistic pathogens, a 
concept illustrated in figure 2.1. 
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Adapted from Sjöström and colleagues.108 
Figure 2.1 Illustration of the hypothesis of invasiveness versus carriage affinity. 
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Variation in in vitro characteristics 
The molecular mechanisms underlying the differences in serotype behaviour seen in 
clinical disease are not fully understood, and this section aims to highlight that 
differences are seen by serotype in vitro as well as in vivo. Serotype 3, which seems 
to be associated with a high mortality but low invasive potential in the majority of 
studies described above, is known to have a particularly thick polysaccharide coat,121, 
133
 which helps to resist phagocytosis,134, 135 and this is associated with increased 
virulence in mice.136 Certain serotypes have been found to be more susceptible to 
complement binding (serotypes 3 and 4 more so than 6A and 14).137 Splenic 
clearance of pneumococci is mediated at least in part by SIGN-R1, a C-type lectin 
expressed by splenic macrophages.138, 139 Each of these receptors has affinities for 
particular polysaccharide ligands,140 implying variety in the recognition of different 
pneumococcal serotypes. Furthermore, different serotypes have been associated with 
varying LytA-mediated lytic responses of pneumococcal isolates to penicillin and 
vancomycin.141 In this in vitro study un-encapsulated strains of pneumococcus were 
far more susceptible to lysis than encapsulated strains, and serotypes 3 and 14 were 
more susceptible than 1, 4, 6B and 23F. However, more work in this area is required 
to more precisely define the role of different capsular types in causing pneumococcal 
disease. 
 
Nasopharyngeal carriage 
There are significant differences between the serotype distribution in IPD cohorts and 
carriage cohorts. Point estimates for the distribution of serotypes in pneumococcal 
carriage studies are shown in table 2.4, and comparison can be made with the 
distribution of invasive disease as seen in table 2.3. Of note, serotypes 19F, 6A/B and 
23F are frequently found in carriage point studies in both adults and children, but 
serotypes 1 and 5 are rarely found, even in those populations such as Africa where 
these serotypes are more strongly found in IPD cohorts (table 2.3). 
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Study Country n Order of serotype prevalence 
Children 
  
1 2 3 4 5 
Bogaert 2001 44 Netherlands 259 19F 6B 6A 23F 9V 
Syrjanen 2001 63 Finland 329 6B 6A 11 19F 23F 
Sa-Leao 2008 67 Portugal 414 19F 23F 6A 14 10A 
Parry 2000 64 Vietnam 911 19 23 14 6 18 
Soewignjo 2001 62 Indonesia 484 6 23 15 33 19 
Rusen 1997 142 Kenya 207 13 15 14 6B 19F 
Mbelle 1999 65 South Africa 239 19F 6B 23F 6A 19A 
 
Table 2.4 Point estimates for the distribution of pneumococcal serotypes in 
carriage studies in children before the introduction of the pneumococcal 
vaccine. 
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Larger studies are often confined to children given the much higher carriage 
prevalence/incidence in this age group, and studies in adults are usually limited to 
those with close contact with children rather than age-stratified population-based 
studies. One study in a cohort of children and adults in an Australian indigenous 
population post-licensure of the 7-valent pneumococcal vaccine for children (PCV-7 ± 
see later in this chapter) showed the five commonest carried serotypes in adults were 
6B, 7C, 16F, 19F and 34.143 This study also showed an outbreak of serotype 1 
carriage, which is very rarely seen in any carriage studies in adults or children. A 
study of Alaskan villagers of all ages before PCV-7 was introduced found that the five 
commonest serotypes carried by adults were 11A, 19F, 35B, 6B and 16F.52 
 
Carriage dynamics also vary substantially between serotypes. In a longitudinal pre-
pneumococcal vaccine study in a day care centre some serotypes were carried for a 
short duration but with a high propensity for transmission (10A and 19A) whereas 
others were carried for longer periods (19F and 23F).67 A large longitudinal study from 
Gambia showed that serotype 9V was carried for an average of two weeks and 
serotype 14 for 37 weeks.68 In the same study the average duration of pneumococcal 
carriage was 28 weeks for children aged less than one year, but only three weeks for 
adults forty years or more. In a further study pneumococci were carried for an average 
of 51 days for children aged five years and nineteen days for older family members.144 
 
Summary 
Different pneumococcal serotypes have profoundly different clinical, microbiological, 
and epidemiological characteristics, to the extent where each serotype may be 
thought of as a distinct clinical entity. However, data in these studies are mainly 
derived from IPD or carriage cohorts, and little is therefore known of non-invasive 
disease. 
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Pneumococcal polysaccharide vaccine 
Origin of the vaccine 
Pneumococcal vaccines work by inducing protective antibody responses to the 
capsular polysaccharide antigens, and often are defined by the number of different 
serotypes covered (WKHLU³YDOHQF\´ The first pneumococcal vaccines for adults were 
trialled in 1977 in a cohort of South African gold miners (6- and 13-valent vaccine),145 
and in Papua New Guinea (14-valent vaccine),146 and these trials showed a reduction 
in IPD within the vaccinated populations of 79% and 84% respectively. These 
vaccines were subsequently replaced by a 23-valent pneumococcal polysaccharide 
vaccine (PPV; Pneumovax®) which has been used in the UK since 1983. PPV 
contains capsular polysaccharide components of 23 of the commonest bacterial 
pneumococcal serotypes (table 2.5), in particular those serotypes implicated in 
invasive disease or antibiotic resistance. 
 
Target groups 
In many countries vaccination with PPV is offered to younger adults who are at risk of 
pneumococcal disease (table 1.1) and to older adults (65 years of age or more) 
without specific risk factors.147 It is not appropriate for use in children aged less than 
two years due to their relatively immature immune system, but can be given to 
children aged more than two years who have already received the 7-valent childhood 
pneumococcal conjugate vaccine (PCV-7; see next section). 
 
Duration of protection and re-vaccination 
Antibody levels persist for at least five years in the healthy adult, but start to decline 
from thirty days post-vaccination.148-150 However, a proportion of older patients have 
poor IgG responses to PPV,151 and the elderly may also have reduced 
opsonophagocytic activity from the induced anti-pneumococcal IgG.152 The duration of 
clinical protection is debated. Shapiro and colleagues performed a case control study 
suggesting that protection decreases slowly over time in all age groups, particularly so 
in the elderly (85% protective efficacy in those aged <55 years; 32% in those aged 74-
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85 years).153 However, using an indirect cohort analysis Butler and colleagues 
showed good persistence of vaccine protection up to nine years.154 
 
As PPV induces a T cell-independent response, it is not possible to produce a 
³ERRVWHU´ HIIHFW E\ DGPLQLVWHULQJ D UHSHDW YDFFLQDWLRQ 5H-vaccination at five years 
results in repeated antibody rises, but at a slightly lower level than following the first 
vaccination,148, 149, 155 with a higher rate of local side effects.149, 155, 156 Consequently re-
vaccination should never be offered within three years of first vaccination, and should 
only be considered in patients at high risk of pneumococcal disease. 
 
Vaccine efficacy 
Polysaccharides, as contained in PPV, are poorly immunogenic when compared with 
proteins, and only induce a T cell-independent response.157 A recently updated 
Cochrane review showed a reduction in IPD following PPV (OR 0.26; efficacy 
74%),158 but showed no effect on reducing mortality and was inconclusive concerning 
a reduction in all-cause CAP. A number of other studies, including a further meta-
analysis looking primarily at studies of higher quality, have shown no demonstrable 
reduction in all-cause or pneumococcal CAP attributable to PPV use in the elderly.159-
162
 Indeed, in one large cohort study a trend was seen towards an increase in the 
incidence of CAP following vaccination.163 However, using pneumococcal CAP as an 
outcome is complicated by the lack of a definitive microbiological test for S. 
pneumoniae; therefore most studies either look at radiological CAP of any cause, or 
radiological CAP associated with IPD, which comprises only a small fraction of 
patients with CAP. PPV is not associated with a protective effect in patients who have 
previously had CAP,164 but may reduce severity of hospitalised disease as measured 
by intensive care admission,165 length of stay,166 and time to symptom resolution.167 
Despite these positive findings, at best PPV seems to provide modest protection 
against pneumococcal disease, and therefore efforts have been made to find 
alternative, more efficacious vaccines. 
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Conjugate vaccines 
Origin 
Due to the problems inherent in PPV as described above (in particular the inability to 
use it in children aged less than two years and the lack of efficacy in preventing CAP), 
further vaccine developments were required. The immunogenicity of the 
polysaccharides contained with PPV can be enhanced by conjugating to a highly 
immunogenic protein,168 creating a pneumococcal conjugate vaccine (PCV). 
Conjugation of a protein to the vaccine also promotes a T cell dependant response, 
inducing a memory T cell response, and hence the ability to use multiple doses to 
achieve a booster effect.169 
 
The first PCV to be introduced to vaccination schedules was PCV-7, for use in infants 
less than two years of age, in three doses at two, four, and thirteen months. Only 
seven serotypes are included in the vaccine, in contrast to the 23 in PPV, although 
these seven are thought to include the majority of prevalent and invasive serotypes 
encountered in the USA (table 2.3). However, this is not the case in the rest of the 
world, particularly Africa and Asia, where these seven serotypes represent only 60% 
and 45% of IPD serotypes respectively.101 
 
Efficacy 
Between 92% and 100% infants generate antibody after three PCV-7 doses.169 It has 
proven efficacy in reducing: 
x All-cause and pneumococcal OM in children;170, 171 
x Hospital or outpatient visits due to OM;172, 173 
x IPD in all children;174-176 
x IPD in vaccinated children;177-179 
x CAP in vaccinated infants;179, 180 
x All-cause and pneumococcal CAP hospital admissions in children;173, 181-183 
x PCV-7 serotype (VT) carriage in vaccinated infants;184-187 
x Pneumococcal VT carriage in household contacts of vaccinated infants;58, 184 
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x Pneumococcal VT carriage in unvaccinated infants;188 
x Pneumococcal VT carriage in adults;52 
x VT and all cause IPD in adults;120, 176, 189 
 
A recent meta-analysis incorporating these studies calculated a reduction in 
vaccinated children of 89% for VT IPD, 55-57% in VT OM, and 29-32% in 
radiographically confirmed CAP.190 Of particular note, PCV-7 reduces VT colonisation 
in unvaccinated contacts, and IPD in unvaccinated adults. This suggests that large 
VFDOHYDFFLQDWLRQRIFKLOGUHQPD\EHSURPRWLQJD³KHUG LPPXQLW\´HIIHFW ,QDGdition, 
all pneumococcal disease is thought to be preceded by nasopharyngeal carriage, and 
the highest rates of pneumococcal carriage are in children. Therefore, the reduction in 
pneumococcal carriage in children may be reducing transmission to adults, and 
thereby reducing adult pneumococcal disease. However, this theory is as yet 
unproven. 
 
Serotype shift 
PCV-7 contains only seven of the 91 pneumococcal serotypes.92 Thus while 
significant reductions are expected in VT serotypes across the pneumococcal disease 
spectrum, uncertainty surrounds the impact of vaccination on non-PCV-7 vaccine-type 
(NVT) serotypes. As discussed in the previous section, all-cause IPD rates have fallen 
following introduction of PCV-7. However, an increase in NVT and vaccine-related 
serotypes (defined as the same serogroup as a VT serotype, but different serotype; 
for example, 19A and 19F) at the expense of VT serotypes has also been seen. 
Several carriage studies have shown an increase in NVT serotypes concomitant with 
a decrease in VT serotypes.57, 58, 187, 191 IPD studies have shown an increase in the 
total number and proportion of cultured NVT serotypes, an effect seen in both PCV-7 
vaccinated and unvaccinated children, and adults (table 2.6). Of note, serotype 19A 
has significantly increased in incidence in the majority of IPD studies. Increases in the 
NVT serotype 19A in otitis media in children in one study interestingly started to occur 
before the introduction of PCV-7.192 Antibiotic resistance within this group also 
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increased from 10% to 50% over the study period, implying that this increase may 
have been driven by antibiotic over-use. 
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Vaccine Serotypes covered 
PPV 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F 
PCV-7 4, 6B, 9V, 14, 18C, 19F, 23F 
PCV-9 1, 4, 5, 6B, 9V, 14, 18C, 19F, 23F 
PCV-10 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F 
PCV-11 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F 
PCV-13 1, 3 ,4 , 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F 
 
Shared serotypes are in bold. PPV: pneumococcal polysaccharide vaccine; PCV: 
pneumococcal conjugate vaccine. 
Table 2.5. Pneumococcal vaccine serotype coverage. 
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Study Setting N Time period Emergent serotypes 
Reduction in 
VT disease 
Increase in 
NVT disease 
Lexau 2005 120 86\HDUV 8821 1998-2003 n/a 55% 5% 
Singleton 2007 193 Alaska; infants 1478 1995-2006 19A 96% 140% 
Hicks 2007 194 US; young children 4073 1998-2004 3, 6A, 12F, 15, 19A, 22F, 33F 97% 22% 
Hicks 2007 194 US; adults 6324 1998-2004 12F, 15, 16F, 19A, 23A, 33F, 35 76% 10% 
Jacobs 2008 195 US; all ages 1235 1999-2007 6C, 19A, 22F, 33F 92% 19% 
Tyrrell 2009 196 US; all ages 2768 2000-2006 3, 5, 8, 11A, 12F, 19A, 22F 61% 236% 
Tsigrelis 2009 197 86\HDUV 50 1995-2007 3, 19A 64% 72% 
Salleras 2009 198 Spain, infants 349 1997-2007 19A, 24F 55% 132% 
Hsu 2010 199 US; age <18 years 433 2001-2007 19A n/a 77% 
Park 2010 200 US; vaccinated children 753 2001-2004 3, 6A, 7F, 12F, 15B/C, 19A, 22F, 33F, 38 n/a n/a 
Rodenburg 2010 201 Netherlands; <2 years 110 2004-2008 1, 7F 67% 44% 
Rodenburg 2010 201 Netherlands; >2 years 2419 2004-2008 1, 22F -1% 8% 
Liao 2010 104 Taiwan, all ages 337 2000-2008 19A -6.2% -16.3% 
Pilishvili 2010 202 US; <5 years 2422 1998-2007 3, 7F, 19A, 22F, 33F 100% 38% 
Pilishvili 2010 202 US; aged 5-64 years 5444 1998-2007 3, 7F, 19A, 22F 89% 47% 
Pilishvili 2010 202 86\HDUs 3414 1998-2007 3, 6A/C. 7F, 19A, 22F, 23A 92% 33% 
Kaplan 2010 203 US; <16 years 1029 2001-2008 1, 3, 7F, 19A n/a n/a 
Foster 2011 204 UK; infants 408 1995-2009 7F 83% 57% 
Foster 2011 204 UK, aged >2 years 3382 1995-2009 7F, 19A, 22F 50% 18% 
 
VT: serotype included in PCV-7; NVT: serotype not included in PCV-7 (including vaccine-UHODWHG VHURW\SHV ³LQIDQWV´ FKLOGUHQ DJHG OHVV WKDQ  \HDUV
³FKLOGUHQ´WKRVHDJHGOHVVWKDQ\HDUV 
Table 2.6. Studies showing a serotype shift in invasive pneumococcal disease since introduction of PCV-7.  
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Serotype shift has been implicated in a change in the spectrum of clinical disease, 
primarily in children. An increase has been documented in the incidence of a serious 
complication of CAP, para-pneumonic empyema, in the USA in children from 2.2 per 
100,000 to 3.7 per 100,000 following the introduction of PCV-7,205, 206 and this has 
primarily been caused by NVT serotypes 1, 3 and 19A.207 However, the incidence of 
empyema also increased in the decade prior to introduction of PCV-7 in Israel (from 
0.5 to 4.2 per 100,000 children), mainly due to serotype 1,208 suggesting that 
epidemiological factors may also be implicated in this change. An increase in culture-
positive pneumococcal necrotizing pneumonia from 13% pre-PCV-7 to 33% post-
PCV-7 has been observed in children in Utah, USA, accompanied by an increase 
from 47% to 88% of NVT serotypes.131 Serotype 3 was particularly associated with 
this increase. Reductions in IPD mortality have been seen since the introduction of 
PCV-7 in the USA of between 30 and 45 per 100,000 in adults aged more than 55 
years.209 
 
Therefore PCV-7 appears to be causing a shift in prevalent serotypes in IPD, which 
may be causing changes in the clinical disease spectrum, both by an increase in CAP 
complications such as empyema, and a reduction in mortality. However, the evidence 
for this effect to date is scanty, and may not be representive of non-invasive CAP, 
which forms the majority of disease. A rigorous observational study is required, linking 
the change in pneumococcal serotypes following the introduction of PCV-7 with a 
change in the clinical spectrum and outcome of invasive and non-invasive 
pneumococcal CAP. 
 
Developments in conjugate vaccines 
PCV-9 and -11 
A response to the development of serotype shift has been to broaden the spectrum of 
serotypes covered by PCV. This is of particular interest in the developing world where 
the serotypes contained within PCV-7 do not reflect the serotype distribution of IPD, 
particularly with respect to serotypes 1 and 5 (table 2.2). A 9-valent vaccine 
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incorporating these two additional serotypes has been trialled in 19,922 children in 
South Africa, and found to reduce IPD due to serotypes in PCV-9 by 83% (65% in HIV 
infected children) and radiologically-confirmed CAP by 20-25%.210 A randomised 
controlled trial of PCV-9 in over 17,000 Gambian children showed a vaccine efficacy 
of 37% for radiological CAP and 77% for IPD due to serotypes in PCV-9.211 An 11-
valent vaccine (PCV-11; adding serotypes 3 and 7F), has been trialled in over 12,000 
children in the Philippines.212 This showed a vaccine efficacy in all-cause 
radiographically confirmed CAP of 22.9%. 
 
PCV-13 
The most recent vaccine to be licensed for use in the developed world is the 13-valent 
PCV-13 (table 2.5),213-215 and this vaccine replaced PCV-7 in UK vaccination 
schedules in April 2010. Crucially, this new vaccine contains serotypes 1 and 7F that 
are particularly associated with invasive disease, and serotypes 3 and 19A that have 
been associated with emergent complicated or higher severity CAP. One recent study 
has suggested that the inclusion of the additional six serotypes will increase the 
current coverage of serotypes in IPD in children from 4.5% to 79.1%.129 However, no 
large scale trials have been performed in children to date using this vaccine. 
 
Vaccination of adults with conjugate vaccines 
A randomised controlled trial is currently underway in the Netherlands, vaccinating 
adults with PCV-13 in patients who have not received PPV (CAPITA).216 This trial will 
use IPD and pneumococcal CAP as outcome measures, and crucially will use the 
detection of urinary antigen to have a much higher sensitivity for detecting 
pneumococcal CAP. A barrier to the widespread vaccination of older adults with a 
conjugate vaccine is the presence of high rates of PPV use. As previously mentioned, 
repeat vaccination of adults leads to lower antibody rises, and this may blunt the 
response to conjugate vaccination in adults who have previously received PPV.217 
CAPITA circumvents this problem as few older adults in the Netherlands are 
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vaccinated with PPV, but use of a conjugate vaccine in adults in the UK may be more 
problematic for this reason. 
 
Conclusions 
Pneumococcal CAP is a common cause of mortality and morbidity worldwide, and an 
effective vaccination policy for children is reducing disease in both children and adults. 
Different pneumococcal serotypes show substantial phenotypic differences. However, 
a shift in serotype distribution has been seen following the introduction of the 
conjugate vaccines which may have implications for the spectrum of disease in both 
adults and children. 
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Chapter 3: Diagnosis, assessment and 
management 
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Introduction 
7KLV FKDSWHU UHYLHZV WKH OLWHUDWXUH FRQFHUQLQJ WKH H[SHULHQFH RI &$3 DW WKH ³IURQW
GRRU´IRUWKHKRVSLWDOSK\VLFLDQZKLFKLVUHOHYDQWWRVWXGLHVFRQWDLQHGZLWKLQWKHODWHU
chapters. It principally addresses: 
 
x The most appropriate methods for confirming the microbiological diagnosis of 
pneumococcal CAP; 
x A review of severity assessment, including novel assessment tools; 
x The role of timing of interventions in the admission process and the effect on 
outcome; 
x A review of the commonly used outcome measures in CAP. 
 
Microbiological aetiology and diagnostic techniques 
Rationale for clinical microbiology 
Knowing the infectious agent responsible for an episode of CAP is useful for a number 
of reasons: 
 
x An accurate microbiological diagnosis may allow the physician to change the 
SDWLHQW¶VDQWLELRWLFUHJLPHQIURPEURDGspectrum to a more targeted one. 
x Microbial culture may enable identification of antibiotic resistance, which can allow 
the clinician to change an ineffective antibiotic regimen. Narrowing the antibiotic 
spectrum reduces the volume of antibiotic usage with advantageous 
consequences on the wider microbiological ecology. 
x Local up-to-date microbiologically relevant epidemiological data can help guide 
the selection of empirical antibiotics for CAP. 
x Certain pathogens such as Legionella pneumophila have public health 
implications. 
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A summary of the most commonly used microbiological tests is shown in table 3.1. 
The consensus in the UK is that initial antibiotic regimens should consist of beta-
lactam monotherapy (such as amoxicillin) for CAP of low severity, and a beta-lactam 
plus macrolide (such as clarithromycin) dual therapy for moderate and high severity 
CAP.1 Beta-lactam antibiotics have good activity against Streptococcus pneumoniae, 
and penicillin non-susceptibility rates in the UK are currently below 10%,102 lower than 
those found in many other parts of the world.218-221 The addition of an empirical 
macrolide to the regimen is felt to be necessary to cover Legionella pneumophila, an 
atypical pathogen which despite being of relatively low incidence (around 5%),7, 24, 222 
is not susceptible to penicillin and can cause severe disease. 
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Technique Sensitivity (%) Specificity (%) References 
Streptococcus pneumoniae 
   
Blood culture 8 100 24, 223 
Sputum culture and Gram stain 15-100 15-100 224-227 
Urinary antigen 65-82 82-97 228-231 
RT-PCR 61 87 232 
Legionella pneumophila 
   
Urinary antigen 76-94 100 233, 234 
RT-PCR 86-92 95-98 235 
Serology 63-82 - 236 
Chlamydophila pneumoniae 
   
Serology 87-100 85-97 237, 238 
Mycoplasma pneumoniae 
   
Serology 74 90 239 
 
RT: reverse transcription; PCR: polymerase chain reaction. 
Table 3.1. A summary of the microbiological investigations used for the 
diagnosis of community-acquired pneumonia. 
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In the majority of CAP managed in primary care microbiological aetiology is neither 
sought nor clinically required, as the majority of CAP within this setting is of low 
severity, has a low mortality, and will resolve with empirical antibiotics.240 In the 
hospital setting however a definitive microbiological diagnosis may help focus the 
antibiotic regimen (in particular, to substantially narrow the spectrum of antibiotic 
cover), and thereby improve length of stay or rate of adverse outcomes. 
 
Such improvements in clinical outcomes have not been adequately tested. In one trial 
where pathogen-directed antibiotic treatment was compared with empirical broad-
spectrum treatment, no benefit in length of stay or adverse outcome was observed,20 
although there was significantly lower reporting of adverse events in the pathogen-
directed treatment arm. A further study randomised 177 hospitalised patients to 
receive targeted (based on microbiological diagnosis with pneumococcal urinary 
pneumococcal antigen testing; see later) or empirical oral antibiotic treatment 
following an initial course of broad spectrum intravenous antibiotics.241 Reductions in 
antibiotic use were seen in the active arm, but no benefit in outcome was 
demonstrated, although the trial was small; antibiotic changes were possible in only 
25/88 patients in the targeted group. Crucially a statistically significant rise in the 
clinical relapse rate was observed in the targeted antibiotic group. However, the 
numbers of patients within this study were small (there were only six relapses in the 
entire cohort), and therefore the results should be interpreted with caution. 
Additionally, all patients received the same broad spectrum antibiotic regimen on 
admission, and so antibiotics in the targeted group only reflected the change to oral 
antibiotics following attainment of clinical stability. 
 
Therefore it remains to be seen whether antibiotic strategies based on microbiological 
diagnosis benefit patients; studies so far have shown reduced broad spectrum 
antibiotic use but have failed to demonstrate benefit in terms of patient outcome. 
Further work in this area is required. 
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Culture-based techniques 
Blood cultures 
Blood cultures are mandatory in most forms of sepsis, in addition to culture of the 
relevant infected area, such as urine or stool. Culture provides not only the identity of 
the infecting organism (with a clearly high specificity), but also gives information on 
subtype and antibiotic sensitivities. However, the diagnostic yield of blood cultures in 
CAP is low. In one study looking at this issue, only 5.7% patients presenting with CAP 
had a positive blood culture, and in only 2.0% did this change subsequent 
management.223 These findings were replicated by Abe and colleagues, who recorded 
only six cases of bacteraemia in 164 consecutive CAP cases (3.7%). Of these, two 
were felt to be due to other co-existing disease.242 A third study estimated the rate of 
bacteraemia in a cohort admitted from ED at 4.5%.243 These data have led to 
guidelines recommending the omission of blood cultures for low severity CAP in the 
absence of co-morbid disease.1 
 
Respiratory tract samples 
Sputum samples are relatively quick, cheap, and easy to obtain in many patients with 
CAP. However, there are numerous practical difficulties, such as a patient being 
unable to produce a sputum sample, sample contamination, and delays in transport to 
the microbiology laboratory for prompt analysis. In a recent study on the utility of 
sputum in the diagnosis of CAP,224 only 36% of 116 patients were able to produce a 
sputum sample for a variety of reasons including unproductive cough efforts, 
weakness, and non-compliance. Of these samples, only 55% were judged to be 
microscopically valid as defined by numbers of epithelial cells and leucocytes in a low-
SRZHUPLFURVFRSLFILHOG*UDP¶VVWDLQPD\EHRIJUHDWHUFOLQLFDOXWLOLW\WKDQFXOWXUHDV
results are available more quickly. The benefits of sputum culture DQG*UDP¶VVWDLQ
have been the source of much debate, as there is great heterogeneity amongst 
studies describing the sensitivity and specificity of these tests.225 In a recent study of 
blood culture-proven pneumococcal CAPVSXWXP*UDP¶VVWDLQDORQHKDGDVHQVLWLYLW\
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of DQGWKHFRPELQDWLRQRIFXOWXUHDQG*UDP¶VVWDLQDVHQVLWLYLW\RI, as long 
as the sample was adequate.226 Antibiotic administration rapidly reduces the 
sensitivity of sputum culture.226, 232 In contrast, sputum Gram¶V stain and culture have 
a very high specificity. A prospective study of 533 patients with CAP collected 210 
good quality sputum samples, of which 175 provided a clinically useful predominantly 
single organism result. This study found that the specificity for pneumococcal CAP 
was 97%, and for H. influenzae CAP 99%.227 Therefore sputum GrDP¶VVWDLQ may be 
worth obtaining prior to antibiotic use in a clinical setting, as a positive result for these 
pathogens will secure a diagnosis; but is not sensitive enough to be used as a 
research tool. 
 
Flexible fibreoptic bronchoscopy, especially in combination with quantitative 
bronchoalveolar lavage (BAL) or protected specimen brushes (PSB), is a powerful 
tool for obtaining respiratory microbiological samples, avoiding contamination with the 
upper respiratory tract flora. This technique also enables samples to be obtained in 
those patients without a productive cough. BAL is widely used for the diagnosis of 
CAP caused by Pneumocystis jiroveci or fungal pathogens in immunocompromised 
patients, and both BAL and PSB have been used to investigate the microbial aetiology 
of lung abscesses.244, 245 One study in patients with CAP demonstrated an 
improvement in the microbiological diagnostic rate of 26% and 36% respectively for 
BAL and PSB over sputum cultures.246 In the intubated patient, invasive respiratory 
samples are more readily obtainable, and also improve diagnostic yield.247 However, 
these techniques are clearly not practical for a large scale CAP study. 
 
Non-cultural techniques 
Antigen testing 
Culture techniques have an insufficient sensitivity for use in CAP research. However, 
antigenic components of the infecting organism can be detected in tissue samples 
and this may provide a rapid diagnostic tool, and greatly increase the proportion of 
CAP in which a microbiological diagnosis is made. 
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A commercial immunochromatographic membrane assay (ICT) is available, which 
detects the C-polysaccharide capsule component found in the all Streptococcus 
pneumoniae serotypes, usually from a urine specimen. In patients admitted with CAP, 
this test has a sensitivity of 65-75% and specificity of 94-100%,228, 229 and is positive 
up to a few weeks after admission irrespective of antibiotic treatment.230 The 
sensitivity of this assay is shown in table 3.2, and is clearly superior to culture-based 
techniques. The use of urinary antigen detection in combination with other diagnostic 
tests substantially increases the percentage of patients who receive a definitive 
microbiological diagnosis.231, 248 Antigen testing has also been applied to sputum,249 
and pleural fluid,250 both of which have been shown to increase the diagnostic yield. 
The test is not affected by HIV status.251 
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Study N Comparator Sensitivity (%) Specificity (%) 
Boulware 2007 251 70 Sputum, blood 81 98 
Briones 2006 231 911 Sputum, blood, BAL 81 80-99 
Roson 2004 229 220 Sputum 65.9 100 
Ishida 2004 228 349 Blood, sputum, pleural fluid 75.9 94 
Smith 2003 252 107 Blood 82 97 
Gutierrez 2003 253 493 Sputum, blood 70.4 90 
Straalin 2003 254 215 Sputum, blood, nasopharynx; any line as positive 79 83 
Straalin 2003 254 215 Sputum, blood, nasopharynx; strong line only 54 92 
 
BAL: broncho-alveolar lavage. 
Table 3.2. Published data on the efficacy of the Binax NOW® immunochromatographic assay for testing urine in patients with CAP. 
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Nucleic acid amplification techniques 
There is a great heterogeneity within the literature with regards sensitivity and 
specificity of polymerase chain reaction (PCR), presumably reflecting the wide variety 
of different protocols and assays used. In one study examining the utility of PCR for 
pneumolysin DNA in blood samples from patients with bacteraemic pneumococcal 
CAP it was found to be positive in only 57% of patients and had a sensitivity of 21-
45% depending on the assay used within this population.255 Specificity was high, at 
97-100%. A further study using PCR for S. pneumoniae from a variety of sites 
suggested that the test was inferior to existing microbiological techniques, with only 
19/465 patients with CAP tested having a positive result 256. In contrast, another study 
using pneumolysin gene PCR in serum of patients with CAP identified pneumococcal 
disease in 41/184 patients, compared with 7/184 who had positive pneumococcal 
blood cultures.257 However, two patients with positive blood cultures were negative by 
PCR. Another paper looking at prospectively collected cases of both bacteraemic and 
non-bacteraemic CAP reported sensitivity and specificity for PCR of 55% and 81% 
respectively,258 comparable to standard techniques for identifying pneumococcal 
disease. The most recent paper on this issue examined rapid real-time PCR assays 
for the detection of the genes for the pneumococcal antigens pneumolysin, Spn9802, 
and lytA in serum from patients with CAP, reporting sensitivities of 26%, 32% and 
42% respectively.259 A comparative study of serum PCR for the genes for 
pneumolysin and autolysin with urinary antigen for S. pneumoniae reported 
sensitivities of 53.5% and 88.1% respectively.260 There are clearly a variety of non-
standardised assays in use, and until reliably high sensitivities can be produced blood 
or serum PCR for pneumococcal disease will not become established in the clinical 
environment. 
 
PCR of respiratory secretions is desirable as it can potentially provide a sensitive and 
non-invasive rapid diagnosis. It is of particular advantage for the atypical pathogens, 
which are difficult to culture or lack an antigen test. However, as discussed in chapter 
2, a proportion of healthy adults demonstrate nasopharyngeal carriage of 
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pneumococci,49, 53, 54, 232, 256 and therefore PCR techniques may not distinguish 
pneumococcal disease from carriage. However, quantitative PCR might enable the 
investigator to assess bacterial load, which would be higher in pneumococcal disease 
compared with carriage. Applying real-time quantitative PCR for S. pneumoniae to 
induced sputum samples improves diagnostic rate over sputum culture alone, 
especially in those patients who have had antibiotic treatment prior to hospital 
admission,261 and increases the proportion of all-cause CAP for whom a 
microbiological diagnosis is made to up to 89%.25 Quantitative sputum PCR for S. 
pneumoniae has also been tested in the emergency department setting, showing 
favourable diagnostic rates as compared with convention culture methods, but with 
results available much more rapidly.262 PCR for the pneumolysin gene has been 
applied to lower respiratory tract samples obtained bronchoscopically, but in order to 
obtain a specificity of more than 90%, sensitivity of the assay dropped to only 53%, 
significantly less than the urinary antigen assay.259 Applying quantitative PCR for the 
gene target lytA WREORRGVDPSOHVRI&$3SDWLHQWVDOORZHGTXDQWLILFDWLRQRI³EORRG
'1$ORDG´ZKLFKZDVGHWected in 67% of patients with pneumococcal CAP,263 levels 
of DNA load were also correlated with inflammatory response as measured by C-
reactive protein and white cell count. 
 
In summary, PCR of respiratory tract samples for pneumococcus seems to be a 
sensitive and rapid method for the diagnosis of certain CAP pathogens, but many 
protocols are in use, and techniques have yet to be internationally standardised. 
Therefore it has not entered routine use on most hospital laboratories. Further work in 
this area seems warranted. 
 
Summary 
A variety of diagnostic techniques are available for identifying S. pneumoniae in 
patients with CAP. The most sensitive test to have entered routine clinical use is the 
ICT assay (principally for urine samples) which out-performs standard culture 
techniques. 
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Severity assessment 
Severity assessment is a key stage in the admission process, informing treatment and 
site of care decisions.1, 264 A number of severity scores have been developed to aid 
WKHSK\VLFLDQV¶FOLQLFDOMXGJHPHQWDQGKHOSWRVWUDWLI\SDWLHQWVIRUDYDULHW\RIDGYHUVH
outcomes.265 In addition, a number of other independent markers of disease severity 
have been assessed in the literature that may contribute to the efficacy of severity 
assessment. 
 
Severity scores 
Pneumonia severity index 
The Pneumonia Severity Index (PSI) was the first rigorously derived severity score for 
CAP that entered widespread use. Fine and colleagues derived the rule from a 
retrospectively analysed database of 14,199 patients admitted to hospital with CAP in 
the USA, and validated it in an independent cohort of over 40,000 more inpatients and 
outpatients.266 Easily obtainable, relevant potential variables associated with 30-day 
mortality on univariate analysis were identified, and twenty variables achieved 
significance in predicting 30-day mortality using logistic regression analysis. The 
coefficients from the logistic regression model were subsequently used to generate 
points weighting for each predictor variable, allowing a score to be generated 
reflecting the probability of death 30 days following admission for each patient. These 
scores allow separation into five risk classes (I-V). 
 
The PSI has been validated in numerous international cohorts (table 3.3). The most 
widely used statistical tool to assess the efficacy of severity scores is the receiver-
operating characteristic (ROC) curve, which is a plot of one minus specificity against 
sensitivity of a test for a given outcome. The area under the curve (AUC) of each plot 
gives a measure of the accuracy of a particular tool in predicting the relevant 
outcome.267 A test that perfectly predicts the desired outcome will have an AUC of 1, 
whereas a test with no predictive value will have an AUC of 0.5. A value of 0.8 or 
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more is generally held to be the threshold above which a test predicts the desired 
outcome with sufficient strength. As can be seen in table 3.3, studies generate an 
AUC in predicting 30-day mortality for the PSI of between 0.72 and 0.89, with the 
majority of values falling above 0.8. 
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Paper N Country ROC AUC 
España 2010 268 1501 Spain 0.81 
Menendez 2009 269 453 Spain 0.81 
Phua 2009 270 1242 Singapore 0.86 
Chalmers 2009 271 314 UK 0.79 
Feldman 2009 272 742 South Africa 0.721 
Schuetz 2008 273 371 Switzerland 0.72 
Renaud 2007 274 925/853 France/Spain 0.85-0.89 
Tejera 2007 275 226 Spain 0.752 
Man 2007 276 1016 Hong Kong 0.736 
Spindler 2006 277 114 Sweden 0.85 
Capelastegui 2006 278 1776 Spain 0.888 
Buising 2006 279 392 Australia 0.82 
Aujesky 2005 280 3181 USA 0.81 
 
AUC: area under the curve; ROC: receiver-operating characteristic curve. 
Table 3.3. Efficacy of PSI in different international cohorts. 
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Unfortunately the PSI has a number of problems which has prevented it becoming 
more widely used. As a 20-point, two stage score it is cumbersome to use, and is 
therefore difficult to implement in the setting of a busy acute medical area or 
emergency department. In addition, prediction is only made for 30-day mortality, 
rather than other outcomes of interest (such as admission to critical care or 
pneumonia-specific complications). This is relevant as it has been suggested that of 
patients admitted with CAP who die within 30 days, only 53% of mortality is directly 
attributable to CAP.281 Therefore there is a need for both simpler clinical scoring 
systems and scores that predict other outcomes. 
 
CURB-65 and CRB-65 
These two scores have been developed with the aim of providing a simple tool for use 
in acute hospital areas and primary care, which accurately predicts not only those 
patients of low mortality and therefore who are suitable for management at home, but 
also those of moderate and high severity who require urgent hospital admission or 
access to critical care. 
 
An initial investigation into severity assessment by the British Thoracic Society (BTS) 
using a prospectively collected cohort of 453 patients identified a number of variables 
associated with 30-day mortality on multivariate analysis,282 including age, absence of 
chest pain, absence of vomiting, previous treatment with digoxin, tachypnoea, 
diastolic hypotension, confusion, low or high white cell counts, and raised blood urea 
levels. A patient with two out of three of respiratory rate 30, diastolic blood pressure 
60mmHg and urea >7mmol/l had a 21-fold increase in 30-day mortality. Based on 
these data, three different short prediction rules were generated using three different 
statistical techniques. A rule comprising these three variables was validated in a 
second independent study.283 
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This was developed further by Neill and colleagues,284 who collated four binary 
variables from these three previously generated rules into one modified prediction rule 
(mBTS), consisting of mental confusion, respiratory rate 30/minute, diastolic blood 
pressure 60mmHg, and urea >7mmol/l, and validated this on a separate patient 
cohort (n=316). This rule enabled patients to be divided into mild-moderate (<2 
features) or severe (2 features) CAP based on 30-day mortality. The mBTS rule had 
a higher sensitivity for 30-day mortality than the three previous rules (95%) and 
retained a moderate specificity (71%). However, the stratification of patients into only 
two groups was limiting, and did not identify patients of low severity who might safely 
be discharged (or managed at home if seen in primary care). 
 
The most recent iteration of this severity rule development in the UK consisted of a 
cohort of 1068 patients derived from 3 centres in the UK, Netherlands and New 
Zealand.285 A randomly selected 80% of this cohort was used for derivation, with the 
remaining 20% being used as a validation data set. Using the mBTS rule as a starting 
point, twelve different variables were assessed on univariate analyVLVXVLQJ3HDUVRQ¶V
Ȥ2, of which ten showed a significant association with 30-day mortality. When the 
mBTS score 2 was entered as a single variable plus each of these variables into a 
backward logistic regression model, age 65 and serum albumin <30g/l were found to 
be independently significantly associated with 30-day mortality in addition to the four 
variables already contained within the mBTS rule. However, as albumin is not a 
routinely requested test for patients admitted with CAP, only age 65 was added to 
the mBTS rule. Thus five variables (figure 3.1) were incorporated into this new 
prediction rule, named CURB-65. 
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ITU: intensive therapy unit. Figure derived from Lim et al., 2003.285 
Figure 3.1. Algorithm describing the role of CURB-65 in the admission process 
for pneumonia. 
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This score allowed stratification of patients into three severity groups of low, moderate 
and high severity CAP (figure 2.1). Each group predicts a different level of 30-day 
mortality, and therefore helps to inform management decisions including site of care 
and antibiotic decisions. It has been adopted by the BTS in their most recent 
guidelines as the severity assessment tool of choice in the UK.1 CURB-65 has been 
validated in a variety of different international cohorts, with AUC on ROC curves of 
between 0.69 and 0.87, as summarised in table 3.4. 
 
CRB-65 is an abbreviated version of CURB-65 that is intended for use in primary care 
as it omits the need to measure blood urea, a test not routinely available in the 
community. Its predictive ability as measured by the AUC of a ROC curve for 30-day 
mortality is similar to CURB-65 (table 3.5), and is recommended for use in primary 
care by the BTS.1, 286 As CRB-65 also stratifies patients into three risk groups it can 
help to inform clinical judgement and guide management, as described in figure 3.2. 
 
As previously discussed with the PSI, a criticism of these two severity scores is that 
they only predict 30-day mortality, which may not be the only outcome of interest or 
relevance to the attending clinician, as discussed in the previous chapter. In addition, 
fewer risk classes are present with lower severity CAP compared with PSI, which has 
led to claims that PSI is superior to CURB-65 in predicting those patients who may be 
suitable for management at home (which is what PSI was initially designed to do).280 
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Paper N Country ROC AUC 
España 2010 268 1501 Spain 0.78 
Menendez 2009 269 453 Spain 0.82 
Phua 2009 270 1242 Singapore 0.82 
Feldman 2009 272 744 South Africa 0.736 
Zuberi 2008 287 137 Pakistan 0.863 
Schuetz 2008 273 371 Switzerland 0.69 
Shindo 2008 288 329 Japan 0.835 
Chalmers 2008 289 1007 UK 0.76 
Barlow 2007 290 503 UK 0.78 
Tejera 2007 275 226 Spain 0.784 
Man 2007 276 1016 Hong Kong 0.733 
Challen 2007 291 186 UK 0.788 
Spindler 2006 277 114 Sweden 0.84 
Buising 2006 279 392 Australia 0.82 
Capelastegui 2006 278 1776 Spain 0.870 
Aujesky 2005 280 3181 USA 0.76 
 
AUC: area under the curve; ROC: receiver-operating characteristic curve. 
Table 3.4. Efficacy of CURB-65 in different international cohorts. 
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Paper n Country ROC AUC 
Feldman 2009 272 744 South Africa 0.737 
Menendez 2009 269 453 Spain 0.79 
Schuetz 2008 273 371 Switzerland 0.66 
Chalmers 2008 289 1007 UK 0.74 
Zuberi 2008 287 137 Pakistan 0.835 
Barlow 2007 290 503 UK 0.73 
Man 2007 276 1016 Hong Kong 0.694 
Schaaf 2007 292 105 Germany 0.845 
Spindler 2006 277 114 Sweden 0.83 
Bauer 2006 293 1343 Germany 0.785 
Capelastegui 2006 278 1776 Spain 0.864 
 
UK: United Kingdom; AUC: area under the curve; ROC: receiver-operating 
characteristic curve. 
Table 3.5. Efficacy of CRB-65 in different international cohorts. 
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Figure derived from Lim et al., 2003.285 
Figure 3.2. CRB-65 scoring and outpatient management of community-acquired 
pneumonia.  
73 
 
 
eCURB 
The disadvantage of scores based on binary variables is that they artificially transform 
continuous variables, such as blood urea. Binary variables incorporate an arbitrary 
cut-off point, which improves ease of use in a clinical environment, but may be 
unrealistic; for example, a blood urea level of 7.1 should not be significantly more 
predictive of mortality than 7.0. In addition, this model does not take into account non-
linear distributions of these variables. For example, a high urea is clearly predictive of 
mortality, but an abnormally low urea may also reflect malnutrition, and also put the 
patient at higher risk of death. 
 
A more attractive model would be one which incorporated weighted continuous 
variables into a statistically derived and validated model. However, this could 
potentially reduce clinical utility as it would inevitably involve complex calculations that 
cannot be performed without the aid of a dedicated computer program. However, with 
the increasing presence of computer-based results reporting and clinical note writing 
available at the front door, it is reasonable to expect that a computer based severity 
scoring system is achievable. 
 
Such a model has been derived based on the CURB-65 criteria using a lasso-
penalized logistic regression model, with natural cubic splines with three knots applied 
to the urea, respiratory rate, blood pressure, and age elements (hereafter known as 
³H&85%´7KLVPRGHOZDVGHULYHGRQSDWLHQWVIURPDFRPSXWHULVHGGDWDEDVHLQ
the USA,294 and validated in a cohort from a previous Nottingham prospective CAP 
observational study.24 This score showed an improvement of ROC AUC in the 
derivation cohort over binary CURB-65 from 0.82 to 0.87, and in the validation cohort 
from 0.80 to 0.85. A further advantage of using a computerised severity scoring tool is 
that rather than assigning a patient to a mortality risk category based on the score 
(low, moderate or high severity) eCURB gives a point estimate of mortality. 
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Other severity scores 
PSI, CURB-65 and CRB-65 are the most widely validated and accepted standards 
internationally for predicting 30-day mortality in CAP. However, whilst increasing 
severity as measured by these rules may correlate with other outcomes,278 they are 
less accurate at predicting complications,295 need for mechanical ventilation,296, 297 or 
critical care admission,279, 298, 299 than 30-day mortality. Therefore a number of other 
severity scores have been developed to address these outcomes. 
 
Identifying patients at risk of requiring admission to critical care is important as death 
from CAP is a far less common outcome in the younger population,300 who often score 
inappropriately low on existing severity scores. This is in contrast to the older 
population with severe co-morbidity who represent the majority of admissions with 
CAP,8, 9 but who may have less scope for therapeutic intervention. SMART-COP is an 
eight-point tool derived using a similar methodology to that described earlier.296 The 
derivation cohort consisted of 882 patients with CAP admitted to hospital in Australia, 
and was validated in five other CAP cohorts totalling 7464 patients. The variables 
included in the final model were: 
x Systolic blood pressure <90mmHg (two points) 
x Multilobar chest radiograph involvement (one point) 
x Albumin <35g/l (one point) 
x Respiratory rate PLQ-1 LI DJH  \HDUV PLQ-1 if age >50 years (one 
point) 
x 3XOVHPLQ-1 (one point) 
x New onset confusion (one point) 
x Arterial partial pressure of oxygen (paO2) <70mmHg, or capillary oxygen 
saturation (spO2)  or paO2:fraction of inspired oxygen (fiO2; P/F ratio) 
LIDJH\HDUV paO2<60mmHg or spO2 or P/F ratio <333 if age 
>50 years (two points) 
x Arterial pH <7.35 (two points) 
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This score may be interpreted as follows: 
x Score 0-2: Low risk of mechanical ventilation or inotropic support 
x Score 3-4: Moderate risk of mechanical ventilation or inotropic support 
x Score 5-6: High risk of mechanical ventilation or inotropic support 
x 6FRUH9HU\KLJKULVN of mechanical ventilation or inotropic support 
 
A version of this tool has also been developed omitting albumin, pH and paO2 for use 
in primary care, where these investigations are not readily available (hereafter 
UHIHUUHGWRDV³6057-&2´ 
 
The AUC for this tool in predicting need for mechanical ventilation or inotropic support 
in this cohort was 0.87, in contrast to 0.67 for CURB-65 and 0.69 for PSI.296 This 
reflects the increased importance this score places on physiological variables 
(especially oxygenation) compared with CURB-65 and PSI, with a lesser emphasis on 
patients¶ FR-morbidity and age. These two latter variables if present make a patient 
less likely to be suitable for critical care admission. SMART-COP has been validated 
in only one independent cohort,301 consisting of 335 patients aged less than 50 years. 
This confirmed the improved prognostic value for mechanical ventilation or inotropic 
support compared with CURB-65 or PSI (AUC 0.87 vs. 0.81 and 0.80 respectively). 
 
The limitations of this score are as follows: 
x It is yet to be as extensively validated as CURB-65 and PSI; 
x It is substantially more complicated to calculate than CURB-65 or CRB-65, limiting 
its utility as a front-door assessment tool; 
x Criteria for mechanical ventilation and inotropic support are not standardised 
between health systems, and therefore predictive accuracy will vary between 
countries such as the UK and USA. 
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A second score, SCAP, aims to develop a tool to predict severe CAP, as defined by 
any of the adverse outcomes of inpatient mortality, need for mechanical ventilation or 
shock.268, 297 Using a similar methodology, a Spanish group derived a score that 
predicts any of these adverse outcomes with an AUC of 0.86 in the internal validation 
cohort, compared with 0.75 for CURB-65 and 0.79 for PSI.297 However, when these 
three scores were applied to an external validation cohort the differences in AUC were 
only 0.72, 0.69 and 0.71 respectively. As is shown in table 3.6, SCAP principally adds 
measures of hypoxaemia from arterial blood gas analysis, multilobar involvement on 
chest radiograph and arterial pH to the CURB-65 criteria, whilst increasing the age 
threshold from 65 to 80 years. The same group deriving the score performed a 
validation study,268 which extended the use of this score to predicting 30-day mortality, 
showing non-inferiority to CURB-65 and PSI. This score was also validated by a 
second group, and showed ROC AUCs of 0.746 and 0.760 for admission to critical 
care and mechanical ventilation respectively.302 
 
The criticisms for this score are as follows: 
x Arterial blood sampling is integral to the score; this test is only indicated in 
patients who are suspected to be severely hypoxaemic or at risk of severe 
metabolic derangement;1 
x It remains to be widely validated in numerous international cohorts; 
x It is more complicated to perform or remember than the much simpler CURB-65 
and CRB-65. 
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Severe CAP is defined by any one of: 
x Arterial pH <7.30 
x Systolic blood pressure <90mmHg 
OR 
Any two of: 
x Confusion 
x Urea >30mg/dl 
x Respiratory rate >30min-1 
x Multilobar or bilateral changes on chest radiograph 
x paO2<54kPa or paO2/fiO2 ratio <250mmHg 
x Age 80 years 
 
paO2: arterial partial pressure of oxygen; fiO2: fraction of inspired oxygen. 
Table 3.6. The SCAP severity score. 
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The severity scores presented so far have been used to predict outcome in all 
patients with CAP. The PIRO (predisposition, insult, response, organ dysfunction) 
score was initially developed in a critical care setting to predict mortality from 
ventilator-associated pneumonia (VAP),303 but was further refined for use in patients 
admitted to the ICU with CAP.304 A cohort including 33 intensive care units and 529 
adult patients with CAP identified eight prognostic variables: 
x Co-morbidity (for example, chronic obstructive pulmonary disease) 
x Age >70 years 
x Multilobar changes on chest radiograph 
x Shock 
x Severe hypoxaemia 
x Acute renal failure 
x Bacteraemia 
x Acute respiratory distress syndrome (ARDS) 
 
This allowed stratification of patients admitted to critical care with CAP into 4 groups: 
x Low (0-2 points 
x Mild (3 points) 
x High (4 points) 
x Very high (5-8 points) 
 
Mild, high and very high risk patients were associated with hazard ratios for 28-day 
mortality of 1.8, 3.1 and 6.3 respectively. The AUC for the ROC curve in predicting 28-
day mortality was 0.88. However, this score has not yet been validated in an external 
cohort. It also does not facilitate changes in management, as adjunctive therapies 
beyond antibiotics and supportive therapy have little evidence base. Thus stratifying 
patients already in critical care would currently seem to have little additional value. 
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Oxygenation 
Assessment of oxygenation is essential on admission to hospital,1 and is being 
increasingly incorporated into management in primary care.305 Oxygenation can be 
estimated in several different ways. Measurement of capillary oxygen saturation 
(spO2) may be performed rapidly and non-invasively with a pulse oximeter, which 
utilises the differing spectral characteristics of oxy- and deoxy-haemoglobin. The 
partial pressure of arterial oxygen (paO2) may be measured via arterial blood 
sampling, a significantly more invasive test. 
 
A paO2 of less than 8kPa was found to be independently associated with increased 
30-day mortality in a subsequent analysis of the cohort used by Fine and colleagues 
to derive PSI,266 showing a hazard ratio for pneumonia-related mortality of 1.99.281 A 
subsequent cohort of 533 CAP patients from Spain calculated an OR for mortality of 
4.6 for patients admitted with paO2 <8kPa.306 España and colleagues found that a 
paO2:fiO2 (P/F) ratio of <250 had an OR of 6.5 for inpatient death, mechanical 
ventilation or shock. Mortality has also been associated with low P/F ratios, and failure 
of improvement of P/F ratios with 48 hours.307 Sanz and colleagues analysed a cohort 
of low severity CAP (PSI-III), and found that hypoxaemia (P/F ratio <300) was more 
prevalent in the elderly and those with significant co-morbidity.308 In addition, 
hypoxaemic patients had a significantly longer hospital length of stay (LOS), and 
higher rate of admission to critical care (CC). 
 
As previously mentioned, arterial blood gas analysis is an invasive test, and is not 
appropriate for every patient admitted with CAP. Findings from a US CAP cohort 
demonstrated an association between low spO2 levels measured on admission and a 
higher 30-day mortality and incidence of admission to critical care.309 Low spO2 in the 
emergency department (ED) has been shown to significantly alter physician practice, 
including treatment, investigation and admission decisions,310 and delays in oxygen 
assessment may result in delays in receiving antibiotics and higher mortality.311 
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Studies deriving pneumonia severity scores as described above have found 
hypoxaemia to be an independent predictor of mortality on univariate analysis,24, 266, 
296, 297
 but of the two most commonly used severity scores, one (CURB-65) does not 
contain a measure of oxygenation, and the other (PSI) places relatively low weighting 
overall in the prediction of mortality. Indeed, only those scores that involve prediction 
of critical care admission rely to any great extent on hypoxaemia (SMART-COP and 
SCAP). This at first seems counter-intuitive. However, hypoxaemia seems to be 
different from variables such as blood pressure, mental confusion and respiratory rate 
which are closely linked to systemic disease and sepsis and therefore mortality. 
Hypoxaemia is a disease- and organ-specific measure, primarily of the level of shunt 
within the lungs. Physiological variables such as pulse, blood pressure and respiratory 
rate are unaffected by substantial hypoxaemia in healthy volunteers,312 and correction 
of hypoxaemia has no influence on outcome either in a post-operative setting,313 or in 
moderately hypoxaemic patients with CAP treated with continuous positive airways 
pressure (CPAP).314 This may reflect the oxygen dissociation curve, which suggests 
that oxygen delivery to the tissues is only compromised at levels of SpO2 that are far 
lower than those associated with hypoxaemia as recognised within current practice. 
Therefore it may not be hypoxaemia per se that contributes to mortality, but that low 
spO2 levels allow identification of the sub-group of patients who have severe single 
organ disease that falls short of influencing the sepsis-driven variables identified by 
most current severity scores. Hypoxaemia is however a major criterion for admission 
to critical care and ventilator support, explaining its use in predicting these outcomes. 
 
In summary, the precise role of oxygenation assessment in conjunction with existing 
severity scoring is unknown. Oxygenation seems to be vital primarily to identify those 
hypoxaemic patients who would benefit from critical care admission rather than as a 
tool to predict 30-day mortality. 
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Antibiotic timing 
That antibiotics are mandatory in confirmed CAP is not in question, but the timing of 
antibiotic delivery on arrival to hospital has generated substantial debate in recent 
years. Intuitively it would seem that the earlier antibiotics are delivered the better the 
outcome. Houck and colleagues have proposed the concept of the evolution of CAP 
as a progression through a sequence of states (figure 3.3), where antibiotic delivery is 
required as soon as possible in order to interrupt this progression.315 This concept is 
supported by Kumar and colleagues, who investigated the progression of sepsis using 
a mouse model of Escherichia coli infection.316 This study suggested that the earlier 
along this sequence that the mice were treated with antibiotics, the lower the 96-hour 
PRUWDOLW\ ,Q DGGLWLRQ WKHUH ZDV D ³FULWLFDO LQIOHFWLRQ SRLQW´ IRU DQWLELRWLF GHOLYHU\ LQ
mice treated 12 hours after infection 96-hour mortality was 13%, compared with 80% 
for mice treated at 15 hours. There was no difference in mortality between mice 
treated at 0, 6 or 12 hours after infection respectively. This work is supported by two 
retrospective studies of patients with bacteraemic pneumococcal CAP (step two to 
three in the proposed sequence in figure 3.3), both of which show a strong mortality 
benefit to antibiotic delivery within 4 hours of admission.317, 318 
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SIRS: systemic inflammatory immune response; CRP: C-reactive protein; ARDS: 
acute respiratory distress syndrome. 
Figure 3.3. The concept of progression in CAP and sepsis. 
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This biological plausibility of early antibiotic delivery providing a mortality benefit in 
CAP has been challenged. Symptoms of CAP have often been present for several 
days prior to presentation to hospital,319 and therefore it is difficult to see in patients 
who are not critically ill how a few hours delay may make a significant difference to 
outcome. Additionally, antibiotics do not act instantaneously; although penicillin is 
bacteriocidal, four hours after application in vitro over 50% of bacteria may remain 
viable,320 a figure which may be much higher in vivo. 
 
The data on timing of antibiotics in CAP are similarly conflicting. Short time to first 
antibiotic dose (TFA) for patients hospitalised with CAP was associated with a lower 
mortality in two large database studies. In the first, a cohort of 14,069 patients aged 
more than 65 years was retrospectively analysed.321 Delivery of antibiotics within eight 
hours of presentation was associated with an odds ratio of 0.85 for 30-day mortality. 
However, the demographic parameters of patients with TFA greater or less than eight 
hours were not presented, leading to the possibility of unmatched comparator groups. 
The second study retrospectively examined a cohort of 18,209 Medicare adult CAP 
cases.315 The investigators found a statistically significant odds ratio of 0.90 between 
patients with a TFA greater or less than four hours, and 0.83 with a TFA greater or 
less than eight hours. 
 
There were several major limitations to these studies. The first is that both were 
retrospective studies, with all the limitations such a study design imposes. Secondly, 
in both studies, patients treated within two hours of admission paradoxically had 
significantly higher mortality rates. Third, in only the second study were the clinical 
characteristics of groups with a TFA greater or less than four hours compared, 
showing that a higher proportion of patients in the TFA less than four hours group had 
vital signs abnormalities consistent with CAP or sepsis, such as hypoxaemia and 
tachypnoea. In contrast, patients in the TFA greater than four hours group were more 
likely to present with significant co-morbidity and mental confusion. This suggests that 
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some of the differences seen in these cohorts may have been due to difficulties in 
diagnosis delaying antibiotic delivery; that is to say, patients who present with a 
³FOLQLFDOO\REYLRXV´&$3UHFHLYH WUHDWPHQWHDUOLHU7his finding has been explored by 
Waterer and colleagues using a prospectively collected cohort of CAP patients.322 
This study was much smaller than the studies previously described (n=451), and was 
underpowered to detect a statistically significant mortality difference by antibiotic 
timing. However, what this study does add is confirmation that factors such as 
absence of fever, mental confusion and absence of hypoxia strongly predict a longer 
TFA, thereby confounding any difference in mortality. A second small retrospective 
study reported initial potential diagnostic uncertainty in 19/86 (22%) of patients given a 
diagnosis of CAP, and the presence of this uncertainty was associated with a 
prolonged TFA.323 
 
One prospective study has shown a benefit to early antibiotic delivery and reduced 
hospital length of stay.324 However, several smaller prospective studies have been 
unable to replicate the mortality benefit seen with early antibiotic delivery, possibly 
due to lack of power.319, 325-328 ,QDGGLWLRQIROORZLQJWKHDSSOLFDWLRQRID³IRXUKRXUUXOH´
to antibiotic delivery for CAP in the US, reports emerged that the resulting time 
pressures increased the proportion of patients incorrectly diagnosed with CAP in the 
emergency department from 21% to 29%, and resulted in deteriorating antibiotic 
stewardship,329 a finding replicated elsewhere.330 
 
In summary, antibiotic delivery as early as possible to improve outcome is biologically 
plausible, evidenced based, and therefore desirable in those patients who have 
severe sepsis or septic shock. However, implementing this as a policy for all CAP 
patients and relegating the importance of preceding treatment with diagnosis, 
especially in those patients who are not ill, may lead to poor antibiotic stewardship, 
increased misdiagnosis rates and antibiotic-associated complications, and a resulting 
poorer standard of care. 
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Outcome 
There is debate concerning the most appropriate way to measure outcome for 
patients with CAP. A discussion of the various possible outcome measures is 
presented below to understand why particular outcomes measures have been used 
later in this thesis. 
 
Mortality 
Mortality in the hospitalised population is well described. The 30-day mortality rates 
for previous major CAP cohort and database studies are shown in table 3.7. Whilst 
30-day mortality is an important and well documented outcome in CAP, it is influenced 
by a number of different factors apart from the disease process itself. Mortensen and 
colleagues suggested that mortality is only pneumonia-related in 53% of cases, and 
co-morbidities such as malignancy or cardio-respiratory disease were responsible for 
a large proportion of deaths.281 Mortality also does not provide information on the 
outcome of CAP of low to moderate severity, responsible for around two thirds of 
disease,285 which has a low mortality. Therefore a number of studies have focused on 
other clinical outcomes. 
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Study Country 30-day mortality,% (n) 
Cilloniz 2011 18 Spain 7 (1463) 
Espana 2010 268 Spain 10.9 (1501) 
Ewig 2009 9 Germany 13.7-14.4 (388406) 
Schuetz 2008 273 Switzerland 11 (371) 
Garau 2008 331 Spain 8.7 (3233) 
Chalmers 2008 332 Scotland 9.6 (570) 
Menendez 2008 333 Spain 6.8 (453) 
Charles 2008 296 Australia 5.7 (882) 
Zuberi 2008 287 Pakistan 13.1 (137) 
Tejera 2007 275 Spain 12.4 (226) 
Man 2007 276 Hong Kong 8.6 (1016) 
Buising 2006 279 Australia 9.4 (392) 
de Roux 2006 334 Spain 10 (1511) 
Colice 2004 15 USA 9.1 (1257) 
Basi 2004 335 Canada 9.2 (1795) 
Lim 2003 285 UK/Netherlands/NZ 9 (1068) 
Roson 2001 306 Spain 10 (533) 
Marrie 1989 336 Canada 21 (719) 
British Thoracic Society 1987 282 UK 5.7 (453) 
 
UK: United Kingdom; NZ: New Zealand; USA: United States of America. 
Table 3.7. The range of estimates for 30-day mortality for adults hospitalised 
with CAP. 
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The discharge decision and length of hospital stay 
Following a period of admission for CAP, the discharge decision may be influenced by 
a number of factors. Adverse social circumstances, clinical judgement, persistent 
symptoms, and patient preference may delay discharge beyond objective clinical and 
physiological CAP resolution. The discharge decision is particularly relevant for 
patients with non-severe CAP, who have a low mortality and therefore may be 
suitable to be managed at home or after a short inpatient stay.266, 285 Only a small 
proportion of CAP is managed in hospital,7 but this fraction accounts for the majority 
of the financial burden from this disease.13, 14 Outpatient management of non-severe 
CAP is as safe and effective as hospitalisation,337, 338 and patients often prefer 
outpatient to inpatient treatment.339-342 
 
Clinical stability 
Halm and colleagues were the first to generate data on the time course of the clinical 
resolution of CAP, and postulated five physiological and two other variables that 
should be attained prior to discharge (table 3.8).343 7KLVFRQFHSWRI ³FOLQLFDOVWDELOLW\´
was reached at a median of three days after admission (six days for severe CAP), and 
correlated with CAP severity. In addition, once clinical stability had been reached the 
incidence of subsequent deterioration requiring CC admission was markedly reduced 
to below 1%. Of patients discharged from hospital with at least one or two clinical 
instabilities, 13.7% and 46.2% respectively died or were readmitted at 30 days 
compared with 10.7% of those with no instabilities.344 One or more clinical instabilities 
on discharge were associated with death (adjusted OR 2.1), readmission (OR 1.5), 
and failure to return to normal activities (OR 1.5) within 30 days of discharge. 
International guidelines have adopted these criteria, stating that resolution of these 
parameters is necessary prior to discharge.264 Other studies estimating time to clinical 
stability (TCS) have suggested a mean of 3.19-3.26 days,326 and a median of four 
days.345 
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Parameter Value 
Systolic blood pressure 90 mmHg 
Heart rate 100 min-1 
Oxygen saturation 90% on air, or the same as pre-admission 
Respiratory rate 24 min-1 
Temperature 37.8°C 
Mental confusion Absent 
Oral intake Normal 
 
Table 3.8. The seven factors defining clinical stability. 
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Symptom scores 
Use of a symptom score as an outcome measure in studies of CAP has several 
advantages. A continuous variable such as a symptom score may allow more subtle 
influences on outcome to be detected than a categorical variable such as 30-day 
mortality. It also may allow better estimation of the impact of an intervention in 
patients with low severity CAP, a group which by definition have a low rate of adverse 
outcomes. 
 
Symptoms may persist up to six months after clinical and radiological resolution,346-348 
DQG SHUVLVW EH\RQG ³FOLQLFDO FXUH´ DV UDWHG E\ SK\VLFLDQV349 Respiratory symptoms 
and quality of life (QOL) are rarely reported in CAP studies, despite being in many 
ways the most significant patient-centred outcomes. Scores based on QOL 
(predominantly the short form 36, (SF-36)) have been used as outcome measures in 
CAP clinical trials,350, 351 but are clearly not specific to CAP. El Moussaoui and 
FROOHDJXHV GHYHORSHG D FOLQLFDO VFRUH WKH ³&$3 VFRUH´ EDVHG RQ DQ HLJKW SDUW
questionnaire examining the symptoms of breathlessness, cough, and sputum in 67 
hospitalised patients (appendix 2).352 Scores were divided into respiratory and general 
well-being sections, and were measured at admission, days three, seven, ten, 14 and 
follow up at six weeks. Scores improved during follow-up and deteriorated in the event 
of clinical failure, and correlated with other clinical relevant variables such as 
inflammatory and physiological markers. In a follow up study, symptom scores had 
largely returned to normal within six months.348 This score is yet to be validated in an 
external cohort. 
 
$VHFRQGV\PSWRPVFRUH³&$3-V\P´ZDVGHYHORSHGE\/DPSLQJDQGFROOHDJXHVLQ
33 patients, and validated on 556 patients.353 This score consists of 18 questions, 
many of which are not specific to CAP (such as gastrointestinal disturbance, difficulty 
thinking and concentrating, and headache). However, the score correlated with clinical 
90 
 
cure rates within the study and had similar responsiveness to the score developed by 
el Moussaoui and colleagues. 
 
Length of hospital stay 
Intuitively, LOS is a surrogate measure for the clinical disease course and time to 
clinical stability in hospital following institution of treatment, and therefore a measure 
of disease severity and treatment efficacy. It is easy to measure, applicable to all 
hospitalised survivors with CAP, and is a useful measure in those patients with low 
severity CAP as a quality indicator, as this group should always be considered for 
early outpatient management.341, 342 The majority of the financial cost of pneumonia to 
healthcare institutions is related to the number of hospital bed-days occupied.13, 14, 354 
Typical LOS in some large CAP cohorts is reported in Table 3.9. The disadvantage to 
using LOS as an outcome measure is that a variety of factors cause delays in 
discharge beyond the time taken to reach physiological stability. 
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Study Country Median LOS (days) 
Garde 2008 355 Netherlands 10 
Garau 2008 331 Spain 9 
Barlow 2007 328 UK 5 
Huang 2006 356 Canada 6 
Menendez 2003 357 Spain 9 
Rifkin 2002 358 USA 5 
Lim 2001 24 UK 7 
Dedier 2001 327 USA 4 
Feagan 2000 359 Canada 7 
Fine 1997 266 USA 7 
 
LOS: length of hospital stay; UK: United Kingdom; USA: United States of America. 
Table 3.9. The range of estimates for median length of hospital stay for adults 
hospitalised with CAP. 
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Delays to discharge 
The times quoted for TCS are substantially shorter than those quoted for LOS, and 
significant variability in LOS has been demonstrated between different hospitals.360, 361 
In a questionnaire distributed to hospital clinicians in the US, four factors were 
identified that were thought to delay discharge in clinically stable patients:362 
x Obtaining a diagnosis; 
x Treating co-morbidity; 
x Completing a course of antibiotics; 
x Arranging long-term social care. 
 
Laing and colleagues compared the discharge of patients in two similar hospitals in 
New Zealand, finding that main influence on the different LOS between the two 
hospitals was duration of intravenous therapy, with similar presenting pneumonia 
severity as measured by PSI.363 A small study (n=31) looking at the disparity between 
LOS and TCS identified a measure of mobility and balance, the HABAM score, as a 
significant predictor of discharge delay after clinical stability.364 A randomised 
controlled trial by Marrie and colleagues suggested that use of a CAP clinical pathway 
reduced the admission rate for patients with low severity CAP, and reduced LOS for 
those admitted, with no increase in adverse outcome,351 a finding replicated 
elsewhere,365 suggesting that physician practice is a key determinate of LOS. Finally, 
pre-admission functional status and significant co-morbidity have both been found to 
be independently associated with longer LOS.356 
 
The discharge decision is therefore affected by a combination of physiological 
parameters, physician judgement (informed by guidelines, severity scores and 
experience), and clinical factors unrelated to the admission episode such as co-
morbidity and functional status. These factors all reduce the utility of LOS as an 
outcome measure in CAP. 
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Need for critical care 
30-day mortality for CAP in young patients is low, and as such this group is often 
overlooked when consideration is made of mortality alone. A number of studies have 
attempted to combine one or more outcomes, typically 30±day mortality and 
requirement for mechanical ventilation or inotropic support.268, 297 This is of interest 
FOLQLFDOO\DVLWDOORZVDPRUHUREXVWGHILQLWLRQDQGSRWHQWLDOSUHGLFWLRQRI³VHYHUH&$3´
defined in terms other than mortality alone. The incidence of mechanical ventilation for 
patients with CAP is summarised in table 3.10 below. 
 
However, using CC admission, need for inotropes or need for mechanical ventilation 
as outcome measures reflects the subjective nature of these interventions. For 
example, the rate of admission to CC in the USA is higher across all diseases than in 
the UK due to differences in resource allocation and remuneration for health care, and 
admission criteria for CC are poorly standardised within the UK, let alone 
internationally. 
 
Summary 
,Q VXPPDU\ WKHUH LV QR ³LGHDO´ ZD\ WR PHDVXUH RXWFRPH LQ &$3 )RU WKLV UHDVRQ
outcome is best summarised either by describing all of the possible outcomes, or 
describing outcome in a sub-population of patients admitted with CAP. 
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Study Country Proportion MV (n) 
Singanayagam 2009 366 UK 7.8% (1050) 
Garau 2008 331 Spain 3.1% (3233) 
Charles 2008 296 Australia 4.6% (862) 
Menendez 2008 333 Spain 6.4% (453) 
Man 2007 276 Hong Kong 2.5% (1016) 
Buising 2006 279 Australia 5.8% (3920) 
Capelastegui 2006 278 Spain 1.6% (1100) 
Roson 2001 306 Spain 5.6% (533) 
 
UK: United Kingdom; MV: mechanical ventilation. 
Table 3.10. The range of estimates for need for mechanical ventilation for adults 
hospitalised with CAP. 
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Introduction 
Chapters 2 and 3 have highlighted the current issues surrounding the prevention and 
treatment of pneumococcal CAP following the introduction of PCV-7. This chapter 
describes the study designed to address these outstanding issues. 
 
The current evidence base 
,QRUGHUWRFRPPHQWRQYDFFLQHHIILFDF\YLDDSRWHQWLDO³KHUGLPPXQLW\´HIIHFWDQGWR
inform future vaccine development, it is necessary to know the distribution of 
pneumococcal serotypes causing CAP in the adult UK population. Studies undertaken 
to date on pneumococcal serotype distribution are flawed for a number of reasons: 
 
1. The majority of studies define pneumococcal serotype in cohorts of patients with 
IPD. This group comprises several non-CAP manifestations of pneumococcal 
disease, including meningitis, and septicaemia. The rates of these different 
manifestations are often reported within IPD studies (for example, in a study by 
Harboe and colleagues meningitis accounted for 14.6% of cases,105 and in a 
similar study by Chiba and colleagues, for 17.5% cases,109 but serotypes only 
reported for all-cause IPD). 
2. The majority of studies are retrospective in nature and the diagnosis of CAP is 
therefore determined by retrospective disease coding rather than prospective 
clinical and radiological diagnosis. This is due to the relatively low frequency of 
bacteraemia with CAP (see point 3). 
3. The studies to date have universally determined serotype from a cultured invasive 
sample (sputum, blood or pleural fluid) using the Quellung reaction.367 As 
discussed in chapter 3, these methods have a low sensitivity for pneumococcal 
disease, and hence do not reflect the majority of the burden of pneumococcal 
CAP seen in UK hospitals. 
4. Different serotypes have different invasive potential. For example, serotype 1 is 
thought to be highly invasive, and may therefore be over-represented in cohorts of 
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IPD compared to less invasive serotypes. As we have seen in previous chapters, 
invasiveness inversely correlates with adverse outcome, and therefore an under-
representation of serotypes with low invasiveness in published cohorts may lead 
to the prevalence of these serotypes being underestimated, and a larger 
proportion of this potentially severe disease being missed. 
5. Due to the relatively recent introduction of PCV-7 to infant immunisation 
schedules in the UK, no studies have been published to date including UK 
patients in the post-vaccination period. 
 
Furthermore, as described in chapter 3, there are a number of outstanding questions 
surrounding the processes of care for adults admitted with CAP, and their influence on 
outcome. These include: 
 
1. What is the role of symptom scores for assessing outcome? 
2. How does oxygenation status help with assessment? 
3. Does the multitude of severity scores remain valid in a modern UK cohort given 
the changing admission characteristics of CAP? 
4. Does the timing of specific interventions, such as first antibiotic or chest 
radiograph, influence outcome? 
5. What is the role of early senior respiratory specialist intervention in the 
management of CAP? 
 
Broad objectives of the studies contained within this thesis 
In order to improve outcomes in CAP, studies are required to address the questions 
highlighted above: 
 
a) There is a need to prospectively gather information on the pneumococcal 
serotypes in invasive and non-invasive pneumococcal CAP in the adult UK 
population following the introduction of PCV-7 and PCV-13. This will provide 
information on what serotypes are prevalent, monitor changes in this serotype 
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distribution in the years following the introduction of these vaccines, and link any 
serotype shift to a potential change in the serotype-specific clinical features and 
outcomes of adults admitted with CAP. Such data would also inform 
pneumococcal vaccine research, particularly with respect to which serotypes it 
might be prudent to include within newer conjugate vaccines. 
b) There is a need to clarify the precise role of current processes of care for adults 
admitted with CAP including oxygenation assessment, severity and symptom 
scoring, timing of specific diagnostic and treatment intervention, and utility of 
review by senior respiratory clinicians. This will enhance the front-door 
assessment and management of these patients, and potentially improve outcome. 
 
Methods 
Considered study methodologies 
A variety of methods have been considered. The aims of the study are clearly 
observational, as the outcomes (serotype distribution, clinical features, and outcome 
of invasive and non-invasive CAP) are unknown. This means that controlled 
experimental research methods (such as a randomised controlled trial) are 
impractical. As we are interested in the evolution of disease and patients over a period 
of time, a longitudinal rather than cross-sectional study is the best method to 
approach the questions outlined above. A prospective observational study allows 
many potential clinical associations or risk factors to be gathered, minimising recall 
bias, and is thus a superior methodology to a retrospective study. 
 
Once a cohort has been defined and recruited over a period of time a method is 
required for the purposes of determining clinical differences between serotypes. The 
nested case-control study methodology is essentially a traditional case-control study 
which is performed within a defined cohort.368 The advantages of this method are that 
the cases are from the same population as the controls, and as data are collected 
prospectively there is no danger of recall bias, as with traditional case-control studies. 
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Setting 
For the proposed prospective observational study the setting is the population of the 
Greater Nottingham area. This encompasses a population of over 621,000 (500,746 
adults aged 16 years) at the last census (2001), and includes Nottingham City, the 
Boroughs of Broxtowe, Gedling and Rushcliffe, and the Hucknall part of Ashfield 
District (www.nottinghamcity.gov.uk). The majority of this population are classified in 
WKHFHQVXVDV³:KLWH%ULWLVK´DWMXVWRYHUSHRSOH'DWDDUHQRW
available on migration rates for the greater Nottingham area, but for Nottingham City 
the migration rates of people from outside the area were less than 10% of total 
population. Nottingham therefore represents a stable population in a medium-sized 
UK city, and is ideal for such a population-based study. 
 
7KHKHDOWKQHHGVRIWKLVDUHDDUHVHUYHGE\RQO\WZRODUJHKRVSLWDOV4XHHQ¶V0HGLFDO
Centre (QMC) and Nottingham City Hospital (NCH)) of around 1000 beds each, 
comprising one teaching hospital trust (Nottingham University Hospitals NHS Trust). 
All patients requiring hospitalisation are admitted to one of these hospitals. 
Admissions arrive either via referral from a primary care practitioner or from the 
emergency department (ED). Admissions to the medical directorate come to one of 
three acute medical units on the two sites. 
 
Study design 
Between September 2008 and September 2010, consecutive adult patients DJHG
years) admitted with CAP were prospectively identified on a daily basis from the acute 
medical areas of both trusts. Potential participants were identified by liasing with the 
relevant resident junior doctors. For practical purposes only the respiratory, acute 
medical and critical care wards in both hospitals were visited to recruit patients, and 
weekends and bank holidays were excluded. Only one visit to each ward was made 
daily. This inevitably meant that a number of potential participants were missed. 
However, there should be no systematic reason why missed patients should differ 
clinically or microbiologically from those included in the study. Fifty-nine percent of 
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participants were recruited by the author, with the remainder recruited by the research 
nurse Sonia Greenwood. 
 
Patients were included if they: 
 
1. Had at least one acute symptom in keeping with a lower respiratory tract infection 
(breathlessness, cough, sputum or fever); 
2. :HUHDJHG\HDUV 
3. Had new infiltrates on a chest radiograph; 
4. Were treated by the admitting team for CAP. 
 
Patients were excluded if: 
 
1. They had been admitted to hospital in the preceding 10 days; 
2. Had tuberculosis; 
3. Had post-obstructive pneumonia due to lung cancer. 
 
Patients were not excluded if they were immunosuppressed or if the admission were 
an expected terminal event. Participants were identified by study investigators on a 
daily basis from the acute admitting medical wards and enrolled following informed 
consent. All patients were managed in a similar manner according to hospital CAP 
guidelines at the discretion of the attending clinician. Full ethical approval for the study 
was granted by the Nottingham Regional Ethics Committee. Informed consent was 
obtained from each patient, and if the patient were unable to consent due to a lack of 
capacity, informed assent was sought from a relative. If appropriate, participants were 
seen in an outpatient clinic six to eight weeks following discharge to assess clinical 
and radiological disease resolution. Ethical approval; was also gained for review of the 
medical notes (but not acquisition or retention of clinical samples) of patients in whom 
consent was not available after completion of the admission episode (for example, 
due to early discharge or death). 
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Clinical data and study samples 
Following informed consent, a standard study proforma was used to record data on 
the patient and admission episode. The included fields were: 
 
x Demographics data, including age, sex, and if admitted from a nursing or 
residential home; 
x A record of symptoms as measured by the CAP score (appendix 2); 
x Admission and baseline functional status was estimated using the World Health 
Organisation performance status scoring system.369 Admission performance 
status was determined by the study investigators, whereas baseline performance 
status was estimated from patient descriptions of their functional status prior to 
the onset of disease; 
x Admission blood tests, including full blood count, urea and electrolytes, and C-
reactive protein (CRP); 
x Self reported rates of influenza vaccination in the 12 months preceding admission, 
and PPV in the 10 years preceding admission; 
x Measures of disease severity including CURB-65 and PSI; 
x Co-morbidity; 
x Details of radiographic changes, with timings; 
x Details of antibiotic treatment, with timings; 
x Physiological observations on admission, and for the succeeding three days if 
available; 
x Complications of CAP, including effusion and empyema; 
x Outcomes, such as 30-day mortality, admission to critical care (CC) and need for 
invasive respiratory or vasopressor support (IVRS), 30-day re-admission, and 
length of hospital stay (LOS); 
x Results of microbiological investigations, including those requested by the 
admitting team. 
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Microbiological methods 
To identify those patients who had pneumococcal disease, a urine specimen was 
obtained following informed consent from each patient. This sample was thereafter 
used in two microbiological tests; the immunochromatographic assay Binax NOW® 
and the Bio-Plex assay. The Binax NOW® assay is a microbiological test in current 
routine clinical use (see chapter 3), and was performed on receipt of the study 
samples in the Nottingham University Hospitals Microbiology department, a UK Health 
Protection Agency (HPA) regional laboratory, by the microbiology technicians. The 
urine samples were subsequently stored in a dedicated study freezer at -20°C, and 
transported by the author to the Respiratory and Systemic Infection Laboratory (RSIL) 
at the Centre for Infections (CfI) at the HPA Colindale, London, where they were 
tested by the resident biomedical scientists in batches using the pneumococcal 
serotype-specific Bio-Plex assay, as described below. 
 
Binax NOW® 
During a pneumococcal infection, the polysaccharide coat is shed and excreted in the 
urine, and this antigen persists in the host for at least seven days.370 The efficacy of 
this assay has been described in chapter 3. The test kit consists of a nitrocellulose 
membrane test strip with two lines of adsorbed antibody, one rabbit anti-
pneumococcal C-polysaccharide antibody and one control antibody. Both antibodies 
are conjugated to a substance that colours blue when the antibody is bound. A swab 
is inserted into the device after it is dipped in the test sample, and a citrate/phosphate 
buffer added. If pneumococcal capsular polysaccharide is present, both test and 
control lines will turn blue within 15 minutes. Binax NOW® has a substantially better 
sensitivity for detecting pneumococcal disease than standard cultures, but a further 
assay is required to determine the serotype. 
 
Bio-Plex 
ELISA assays have been developed before for detection of capsular antigen in urine, 
but whilst high sensitivities (>80%) and specificities (>98%) were achieved, the 
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process was laborious and had high volume and reagent requirements.371 In order to 
make the assay more viable for processing of large numbers of samples 
simultaneously, a multiplex ELISA is required. The Bio-Plex assay has recently been 
developed at the Respiratory and Systemic Infection Laboratory (RSIL) at the Health 
Protection Agency (HPA) in Colindale, London,372 and is a modified sandwich ELISA 
assay. Polystyrene microspheres, 5.5µm in diameter (Luminex xMAP beads; Luminex 
Corp., Texas, USA), are labelled with dyes of different colours between red and 
infrared, allowing differentiation into 100 different spectral types. These are then 
conjugated to one of 14 different pneumococcal monoclonal serotype-specific 
antibodies (1, 3, 4, 5, 6A, 6B, 7F/A, 8, 9V, 14, 18, 19A, 19F, or 23F). The conjugated 
microspheres are suspended with the clinical sample and incubated overnight, binding 
any serotype-specific capsular antigen present. Rabbit polyclonal pneumococcal 
antibody is then added and used as a detection antibody, attached to the 
fluorochrome R-phycoerythrin. The sample is then passed through the Bio-Plex multi-
analyte suspension array instrument (Bio-Rad, Hemel Hempstead, UK) which is 
calibrated using the Bio-Plex calibration kit (Bio-Rad). The microspheres are passed 
through two lasers; one classifies each microsphere by the inherent dye colour, and 
the other excites the fluorochromes bound to the sandwich microsphere-antigen-
antibody complex, allowing quantification of the amount of antigen present. The full 
standard operating procedure is included in appendix 1. 
 
The advantage of using this procedure is that it allows the differentiation of multiple 
serotypes within one clinical sample, and as such a multitude of samples can be 
assayed for a variety of serotypes simultaneously, significantly reducing the time 
taken to detect serotype. The sensitivity and specificity of the assay have recently 
been reported as 79.3% and 99.3% respectively using a contemporaneous positive 
pneumococcal blood culture as the gold standard.372 
 
There are several disadvantages to this technique. Compared with Binax NOW® the 
Bio-Plex assay is time consuming and complex. This makes it of more use as a 
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research tool rather than in real-time as part of an admission episode. Secondly, the 
range of detectable serotypes is limited, particularly given the potential emergence of 
some previously rare serotypes following the introduction of PCV-7 and PCV-13. 
 
Other microbiological techniques 
The results from other samples sent as part of routine clinical care using conventional 
microbiological methods were also recorded from the hospital computerised patient 
records. Data collected in this way included the results from sputum and blood 
cultures, and Legionella pneumophila urinary antigen results. These results were only 
available if sent by the clinical team under whose care the participant fell. 
Pneumococcal serotype was also determined in pneumococcal bacteraemic patients 
by means of slide agglutination with the latex pool sera from Staten Serum Institute 
(SSI) and the standard group or factor sera at the RSIL at HPA Colindale, London. 
 
Summary 
This chapter has described the rationale and methodological process for the majority 
of studies contained within this thesis. Successive chapters will describe the results of 
data gathered over the two year period of the study. 
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³7KHFDSVXOHFRQWDLQVDVSHFLILFVROXEOHVXEVWDQFH«RI
high molecular weight and polysaccharide nature, 
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³'LVHDVHVRIWKH&KHVW´'U5REHUW&RRSH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Introduction 
As described in chapter 2, the majority of studies describing the serotype distribution 
for pneumococcal CAP have used data derived from blood cultures.102, 110, 121 
However, blood cultures are positive in around only 5% of adults with CAP,223, 242, 243 
and it is not known if IPD data are representative of non-invasive disease. Non-
cultural methods for determining pneumococcal serotype have a substantially higher 
sensitivity,371-374 but to date there have been no large studies describing the incidence 
of pneumococcal serotypes in non-invasive CAP. 
 
The seven-valent pneumococcal conjugate vaccine (PCV-7) was added to the UK 
immunisation schedule in September 2006. Following its introduction in the USA, 
decreases in PCV-7 vaccine-type (VT) serotypes were seen in invasive 
pneumococcal disease (IPD) in children,199, 375, 376 and adults,194-196 and in 
nasopharyngeal carriage in vaccinated children,186 and non-vaccinated household 
contacts.58 It is not known whether large scale vaccination of children is changing the 
epidemiology of pneumococcal CAP in adults in the UK, and therefore changing the 
spectrum of adult pneumococcal disease. The current study aims to a) describe the 
distribution of pneumococcal serotypes in invasive and non-invasive pneumococcal 
CAP, b) describe the serotype-associated epidemiology, with particular focus on 
seasonality and age, and c) to investigate the attack rates for serotypes of high and 
low invasiveness in different age groups. 
 
Methods 
Patient recruitment 
This study refers to participants recruited as described in chapter 4. 
 
Definitions 
Patients were defined as having pneumococcal CAP if any microbiological test was 
positive for S. pneumoniae, including blood culture, sputum culture, Binax NOW®, or 
Bio-Plex serotype-specific antigen detection. Patients with pneumococcal CAP where 
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no serotype was detected after testing with the Bio-Plex assay (i.e. S. pneumoniae 
detected by Binax NOW® or sputum culture, but no serotype determined by Bio-Plex 
RU EORRG FXOWXUH ZHUH GHVFULEHG DV KDYLQJ ³XQW\SHG´ SQHXPRFRFFDO GLVHDVH
Serotypes included in PCV-7 (4, 6B, 9V, 14, 18C, 19F, 23F) are hereafter referred to 
DV ³YDFFLQH-W\SH´ 97 DQG VHURW\SHV QRW FRQWDLQHG ZLWKLQ 3&9- DV ³QRQ YDFFLQH-
W\SH´ 197 $OO 97 VHURW\SHV DUH GHWHFWDEOH E\ WKH %LR-Plex assay. Invasive 
serotypes were defined as 1, 5, 7F and 8 according to previous publications,103, 115, 121 
with the other detected serotypes defined as less invasive serotypes. 
 
Annual incidence rates for all-cause and pneumococcal CAP was calculated using the 
latest census figures (from 2001) for the greater Nottingham area, with an adult 
population of 500,746 (www.nottinghamcity.gov.uk/index.aspx?articleid=2401). Age 
group thresholds were the same as those used in the Nottingham census data: 
 
x 16-24 years; 
x 25-44 years; 
x 45-59 years; 
x 60-74 years; 
x 75-84 years; 
x 85 years; 
 
Age groups one and two were combined for the purposes of serotype analysis due to 
the low numbers of participants in both groups. Seasons were defined according to 
meteorological convention as follows: 
 
x Autumn: September to November; 
x Winter: December to February; 
x Spring: March to May; 
x Summer: June to September. 
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Statistical considerations 
Statistical calculations were made using SPSS v16.0 (©SPSS Inc., 1989-2007). 
&DWHJRULFDO GDWD ZHUH FRPSDUHG XVLQJ 3HDUVRQ¶V Ȥ2, which was also used for 
univariate analysis and generation of odds ratios (OR). A p-value of less than 0.05 
was taken as statistically significant. A binary logistic regression analysis was used to 
investigate the association between pneumococcal aetiology and season, with 
adjustment made for pneumonia severity as defined by the PSI (see chapter 3). 
 
Results 
Of 1099 patients identified with CAP during the study period, 956 consented to be 
included in the study. Thirty-six patients were unable to provide a urine sample (and 
had no other test positive for pneumococcus), leaving 920 for analysis. Demographic 
data for the cohort are presented in table 5.1. The median age of the cohort was 71.7 
years (interquartile range (IQR) 57.8-80.8), and 64.4% were aged \HDUV7KH-
day mortality for the cohort was 10% (9.5% for patients with pneumococcal CAP), and 
82 patients (8.9%) required IRVS (table 5.1). Median LOS was 7 days (interquartile 
range (IQR) 4-12 days). 
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Patient characteristics Whole cohort (n=920) 
Demographics  
Age, median; years (IQR) 71.7 (57.8-80.8) 
Male (%) 546 (59.3) 
Residential or nursing care home resident (%) 51 (5.5) 
:+23HUIRUPDQFH6WDWXV 138 (15.0) 
COPD (%) 244 (26.5) 
Ischaemic heart disease (%) 145 (15.8) 
Diabetes mellitus (%) 130 (14.1) 
Cerebrovascular disease (%) 103 (11.2) 
Asthma (%) 102 (11.1) 
Congestive cardiac failure (%) 74 (8.0) 
Active malignancy (%) 67 (7.3) 
Dementia (%) 32 (3.5) 
Mean Charlson co-morbidity index (95% CI) 1.48 (1.37-1.59) 
Influenza vaccination in preceding 12 months (%) 558/855 (65.3) 
PPV in preceding 10 years (%) 383/824 (46.5) 
Severity 
 
PSI Class I-III (%) 395 (42.9) 
PSI Class IV (%) 336 (36.5) 
PSI Class V (%) 189 (20.5) 
Outcome 
 
30-day mortality (%) 92 (10.0) 
LOS 7 (4-12) 
IRVS (%) 82 (8.9) 
 
IQR: interquartile range; WHO: World Health Organisation; COPD: chronic obstructive 
pulmonary disease; CI: confidence interval; PPV: pneumococcal polysaccharide 
vaccine; PSI: pneumonia severity index; LOS: length of hospital stay; IRVS: invasive 
respiratory or vasopressor support. 
Table 5.1. Demographic data of the study cohort. 
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Age distribution and incidence 
Annual CAP incidence figures were calculated including the patients with CAP who 
were unable to consent or provide a urine sample (n=1099). The derived annual 
incidence of CAP within this population was 109.8 per 100,000 over the two years 
studied; 124.2 per 100,000 for the first year studied, and 95.3 per 100,000 for the 
second year. The annual incidence of CAP increased with age from 15.8 per 100,000 
for ages 16-24 to 985.9 per 100,000 for those aged more than 85 years (table 5.2). 
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Age group Population CAP (n) Year 1 Annual incidence year 1 (per 100,000) Year 2 
Annual incidence year 2 
(per 100,000) 
16-24 82,471 26 17 20.6 9 10.9 
25-44 181,187 115 58 32.0 57 31.5 
45-59 111,837 140 71 125.2 69 61.7 
60-74 79,737 295 162 203.2 133 166.8 
75-84 34,204 300 173 505.8 127 371.3 
85+ 11,310 223 141 1246.7 82 725.0 
All ages 500,746 1099 622 124.2 477 95.3 
 
³3RSXODWLRQ´UHIHUVWRWKHQXPEHURISHRSOHLQWKHJUHDWHU1RWWLQJKDPDUHDLQWKHFHQVXV³<HDU´UHSUHVHQWVth September 2008 to 9th September 
2009; year 2 represents 10th September 2009 to 10th September 2010. CAP: community-acquired pneumonia. 
Table 5.2. The incidence of community-acquired pneumonia by age group.  
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Pneumococcal CAP 
Of the 920 patients included in the study, pneumococcal CAP was diagnosed in 366 
patients (39.8%); 40 cultured S. pneumoniae from blood and 18 from sputum or 
broncho-alveolar lavage, and 196 (21.3%) patients had a positive Binax NOW® result. 
For 144 patients in whom Binax NOW® testing was negative, a serotype was 
determined by Bio-Plex. Other pathogens identified from routine microbiological 
testing included Legionella pneumophila serogroup 1 (based on urinary antigen 
detection with a Binax NOW® assay) in 17/463 (3.7%) patients tested, Pseudomonas 
aeruginosa, from sputum culture in 24/367 (6.5%) patients, and Haemophilus 
influenzae from sputum culture in 24/367 (6.5%) patients. In four cases Haemophilus 
influenzae was cultured in sputum as a co-pathogen with S. pneumoniae. 
 
The proportion of patients with confirmed pneumococcal CAP compared with CAP of 
unknown aetiology decreased with increasing age group, but only reached statistical 
significance when compared with youngest age group (aged 16-44) for the age group 
60-74 (OR 0.6, 95% CI 0.4-0.9; p=0.027) (table 5.3). Pneumococcal aetiology became 
more prevalent again in the very elderly (age 85 or more). Self-reported influenza and 
adult pneumococcal vaccination (PPV) data were available for 855 (92.9%) and 824 
(89.6%) patients respectively. Vaccination rates were highest in older age groups 
(table 5.4). Prior vaccination with PPV was not associated with infection with lower 
rates of pneumococcal infection (OR 1.0, 95% CI 0.7-1.3; p=0.803), but was 
associated with lower levels of bacteraemia on univariate analysis (OR 0.4, 95% CI 
0.2-0.8, p=0.009). However, after adjustment was made for age group this difference 
was no longer statistically significant (OR 0.6, 95% CI 0.2-1.3, p=0.188). 
 
113 
 
Age group Pneumococcal CAP (%) 
OR of pneumococcal CAP 
vs. all CAP (95%CI) 
P value VT serotypes OR of VT vs. NVT CAP (95%CI) 
P value 
16-44 (n=136) 64 (47.1) 1 - 7 1 - 
45-59 (n=129) 51 (39.5) 0.7 (0.5-1.2) 0.217 10 1.9 (0.6-5.5) 0.255 
60-74 (n=272) 97 (35.7) 0.6 (0.4-0.9) 0.027 21 2.8 (1.1-7.3) 0.037 
75-84 (n=242) 92 (38.0) 0.7 (0.5-1.1) 0.087 18 2.5 (0.9-6.7) 0.066 
85+ (n=141) 62 (44.0) 0.9 (0.6-1.4) 0.606 16 3.8 (1.4-10.6) 0.011 
All ages (n=920) 366 (39.8) - - 72 -  
 
CAP: community-acquired pneumonia; OR: odds ratio; VT: serotypes included within the 7-valent childhood pneumococcal vaccine (4, 6B, 9V, 14, 18C, 19F, 
23F); NVT: serotypes not included within the 7-valent childhood pneumococcal vaccine. P values refer to odds ratios in older age groups when compared with 
age group 16-44. 
Table 5.3. The proportion of pneumococcal disease in the cohort, by age group. 
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PPV (%) 
(n=824) 
Influenza (%) 
(n=855) 
16-44 8 (6.1) 25 (18.8) 
45-59 36 (28.3) 63 (49.6) 
60-74 135 (54.2) 192 (75.0) 
75-84 133 (66.5) 172 (82.3) 
85+ 71 (60.7) 106 (81.5) 
All ages 383 (46.5) 558 (65.3) 
 
Vaccination data are self reported. PPV: pneumococcal polysaccharide vaccine. 
Table 5.4. Proportion of patients receiving pneumococcal and influenza 
vaccination. 
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Serotype distribution 
The distribution of pneumococcal serotypes within the cohort is shown in figure 5.1. Of 
366 patients with pneumococcal CAP, a serotype was determined in 242 patients. 
The serotype with the highest prevalence was 14 (n=45), followed by 1 (n=40), 8 
(n=35), 3 (n=20), and 19A (n=20). For comparison, the distribution of serotypes in IPD 
in the UK prior to the introduction of PCV-7 is shown in figure 5.2. Five patients had 
two serotypes identified; three with serotypes 4 and 8, one with serotypes 6B and 9V, 
and one with serotypes 15A and 18C. Serotypes contained within PCV-7 were found 
in 72 patients. The proportion of disease due to serotypes contained within PCV-7 
increased with age (7/45 (15.6%) for patients aged 16-44; 21/62 (33.9%) for patients 
aged 60-74; 16/39 (41.0%) for patients more than 85 years; p<0.05 for both) (table 
5.3). 
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VT: serotypes included within the childhood pneumococcal vaccine; NVT: serotypes 
not included within the childhood pneumococcal vaccine; PCV-7: 7-valent 
pneumococcal conjugate vaccine; PCV-13: 13-valent pneumococcal conjugate 
vaccine. 
Figure 5.1: Serotype distribution of the study cohort. 
VT serotype 
NVT serotype 
PCV-7 VT s rotype 
PCV-13 VT s rotype 
NVT serotype 
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Adapted from Farrell et al., 2008.102 
Figure 5.2: Serotype distribution of bacteraemic invasive pneumococcal 
disease in a large UK cohort prior to the introduction of the pneumococcal 
conjugate vaccine.  
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Serotype-specific attack rates 
The annual age-specific incidence for both highly invasive and less invasive serotypes 
increased with age (table 5.5). This effect was more marked in the older age groups, 
where the annual incidence of less invasive serotypes was far higher (annual 
incidence in patients aged 85 years: invasive serotypes 30.9 per 100,000; less 
invasive serotypes 141.5 per 100,000). Both increasing age group and co-morbidity 
group were significant predictors of acquisition of a less invasive serotype (OR per 
age group 1.5, 95% CI 1.2-1.9, p<0.001; OR per co-morbidity group 1.4, 95% CI 1.0-
2.0, p=0.036). 
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Highly invasive serotypes, 
n (per 100,000 per year) 
Less invasive serotypes, 
n (per 100,000 per year) 
16-44 28 (5.3) 17 (3.2) 
45-59 24 (10.7) 15 (6.7) 
60-74 27 (16.9) 35 (21.9) 
75-84 21 (30.7) 36 (52.6) 
85+ 7 (30.9) 32 (141.5) 
 
Table 5.5. Serotype-specific attack rates. 
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Seasonality 
Admissions to hospital with CAP were more frequent during the winter months, with 
most admissions between October and January (figures 5.3 and 5.4, table 5.5). 
Pneumococcal disease was more prevalent as a proportion of CAP cases in the 
winter (137/304, 45.1%) when compared with autumn (89/243; 36.6%), spring 
(82/221, 37.1%) and summer (58/152; 38.2%) (p=0.047) (table 5.5). Using admissions 
in January as a comparator, patients admitted in September were significantly less 
likely to have a pneumococcal aetiology (44.1% versus 25.0%; OR 0.39, 95% CI 0.19-
0.79; p=0.009). These observations retained statistical significance at the 5% level 
after adjustment was made for pneumonia severity using PSI class. 
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Figure 5.3. Distribution of proportion CAP admissions by month of year. 
122 
 
 
 
Figure 5.4. Admissions with pneumococcal CAP by month of the year. 
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Population incidence (per 100,000 
per month) Pneumococcal CAP (%) 
January (n=111) 11.1 49 (44.1) 
February (n=87) 8.7 39 (44.8) 
March (n=87) 8.7 35 (40.2) 
April (n=79) 7.9 28 (35.4) 
May (n=55) 5.5 19 (34.5) 
June (n=54) 5.4 19 (35.2) 
July (n=55) 5.5 26 (47.3) 
August (n=37) 3.7 12 (32.4) 
September (n=56) 5.6 14 (25.0) 
October (n=90) 9.0 39 (43.3) 
November (n=103) 10.3 37 (35.9) 
December (n=106) 10.6 49 (46.2) 
Spring (n=221) 7.4 82 (37.1) 
Summer (n=152) 5.1 58 (38.2) 
Autumn (n=243) 8.1 89 (36.6) 
Winter (n=304) 10.1 137 (45.1)* 
 
*:p<0.05 when compared with patients admitted in autumn. 
Table 5.6. Monthly incidence of all-cause CAP admissions.  
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Of the 242 patients in whom a serotype was determined, 145 were in year one and 97 
in year two. Absolute numbers of NVT serotypes remained approximately the same 
between years one and two (83 and 87 respectively), but the numbers of VT 
serotypes fell from 62 to 10 over the same period (figure 5.5). 
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VT: serotypes included within the 7-valent childhood pneumococcal vaccine (4, 6B, 
9V, 14, 18C, 19F, 23F); NVT: serotypes not included within the 7-valent childhood 
pneumococcal vaccine. 
 
Figure 5.5. The distribution of serotypes found in years one and two of the 
study.
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Discussion 
This study is the first to describe the serotype distribution in a cohort of adult 
pneumococcal CAP incorporating both invasive and non-invasive disease. The 
principal findings are as follows: 
 
x The population-specific incidence of CAP increases with age, but the likelihood of 
pneumococcal aetiology falls. However, older patients are more likely to have 
infection with a VT serotype. 
x The commonest serotypes present within this cohort in descending order of 
prevalence were 14, 1, 8, 3, and 19A. These are similar to the findings of previous 
IPD cohorts in the UK, with the exception that VT serotypes (in particular 23F, 
19F, 6B and 9V) are less frequently found, whereas NVT serotypes (particularly 
serotypes 8 and 19A) are more prevalent within this non-invasive cohort. 
x Both pneumococcal and all-cause CAP are more common in winter than other 
seasons. 
x VT serotypes were substantially less prevalent in the second year of the study 
compared with the first, whilst the absolute number of NVT serotypes remained 
approximately the same. 
 
The age-specific incidences found in this study for pneumococcal CAP are 
substantially higher than those suggested elsewhere in CAP database studies.33 This 
may reflect the improved sensitivity of the Binax NOW® and Bio-Plex assays for 
pneumococcal disease over standard culture-based methods. The proportion of 
disease due to serotypes contained within PCV-7 was higher in the older age groups. 
This parallels findings in IPD cohorts, where serotypes commonly seen in childhood 
disease become more prevalent again in the elderly.124 The reasons underlying this 
are not well understood, but potentially this finding could reflect deterioration in 
immune system efficacy with advancing age. Additionally, older people may have less 
exposure in general to younger children. As discussed in chapter 2, children are 
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thought to be the principal reservoir of pneumococcal carriage and therefore 
transmission. Following the introduction of PCV-7 and the reduction in VT serotype 
carriage amongst vaccinated children, NVT serotypes may be preferentially 
transmitted to those adults who have most contact with vaccinated children. This 
possibility will be explored in more detail in chapter 7. 
 
The distribution of serotypes in this study is similar to previously published UK data.102 
This suggests that for the purposes of surveillance, IPD cohorts provide a reasonable 
estimate of the serotype distribution of both invasive and non-invasive pneumococcal 
CAP within the population. Serotypes 8 and 19A have a higher prevalence within the 
current cohort than would be expected from IPD data. There are two possible reasons 
for this finding. These serotypes may be over-represented in our cohort due to 
difficulties in culturing them using standard techniques, and hence the prevalence is 
falsely underestimated in previous IPD studies. Alternatively, these serotypes may be 
preferentially emerging due to vaccine-induced population pressures on child 
nasopharyngeal carriage, and over the coming years may be much more prevalent as 
a cause of adult disease. This is particularly relevant for serotype 8, which is not 
included in either PCV-7 or the newer PCV-13, introduced to childhood vaccination 
schedules in April 2010. 
 
The serotypes which are more prevalent in the pre-vaccine era UK IPD cohorts than 
in the current study are 23F, 19F, 6B and 9V, all of which are VT serotypes. There 
was also a striking difference in the proportions of NVT and VT serotypes between the 
two years studied, with a substantial decrease in the proportion of VT serotypes in the 
second year. It is again tempting to ascribe this difference to the increasing impact of 
PCV-7 on child VT carriage rates over the period of the study, progressively reducing 
transmission of VT serotypes to adults. A concomitant increase in NVT serotypes in 
year 2 was not seen in this study. However, substantial annual variation in serotypes 
in IPD has been documented in the UK in previous years,102 and therefore more years 
of data would be required to demonstrate such an effect with adequate statistical 
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robustness. The H1N1 swine-origin influenza pandemic also occurred in the second 
winter of the study. H1N1 influenza almost completely replaced standard seasonal 
influenza types during this period, and in the majority of cases resulted in a milder 
clinical phenotype.377-380 Therefore this may also have influenced the spectrum and 
number of pneumococcal infections given the association between influenza and 
pneumococcal disease. 
 
Serotype-specific attack rates increased with increasing age group, but much less so 
for the invasive serotypes than other serotypes. Invasive serotypes are thought to act 
DV ³SULPDU\ SDWKRJHQV´ FDXVLQJ GLVHDVH LQVWHDG RI QDVRSKDU\QJHDO FRORQLVDWLRQ108 
perhaps because of the relatively thin capsule that these serotypes possess.121 By 
extension this would imply that the attack rates for invasive serotypes should be 
broadly similar across all age groups, as potential to cause disease is more affected 
by pathogen than host factors. In contrast, less invasive serotypes acting as 
opportunistic pathogens should preferentially affect older patients with higher levels of 
co-morbidity and frailty. This hypothesis is supported by the findings of this study. 
 
The incidence of pneumococcal CAP was highest in the winter months, a finding 
replicated elsewhere.381 There are a number of possible explanations for this. Several 
publications have shown an association between influenza or other respiratory virus 
infection (such as respiratory syncytial virus) and IPD, with a lag time of between one 
and three weeks after viral infection.382-385 Suggested mechanisms for this observation 
have been epithelial damage via removal of sialic acid residues by the neuraminidase 
component of influenza, promoting pneumococcal adherence to infected lungs,386 and 
immune modulation, in particular via excessive IL-10 (an anti-inflammatory cytokine) 
production.387 A number of studies have examined the role of weather and 
temperature in the incidence of pneumococcal CAP, and conclusive correlations are 
yet to be found. However, one recent study did find that low levels of ultraviolet light 
levels correlated with an increase in the incidence of IPD.388 
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PPV vaccination was not protective for pneumococcal CAP in this study. There was 
an association on univariate analysis between bacteraemic pneumococcal pneumonia 
and lack of prior PPV vaccination (p=0.009), but when adjustment was made for age 
and co-morbidity statistical significance was not reached (p=0.17). These findings 
reflect the lack of convincing data for the efficacy of PPV in preventing pneumococcal 
CAP,158 and support the continued development and use of the newer conjugate 
vaccines for use in adults. 
 
Study limitations 
A significant proportion (124/366; 33%) of pneumococcal disease in this study was 
labelled as untyped. This may reflect either the presence of serotypes beyond the 
fourteen detectable by the Bio-Plex assay, or the limited sensitivity of the Bio-Plex 
assay itself. If the former, then there may be significant NVT serotype(s) that are not 
being described by this study. The sensitivity of Bio-Plex has been estimated at 
79%,372 and therefore a proportion of potentially detectable serotypes will inevitably 
have been missed. The untyped group were intermediate between VT and NVT 
serotype groups with regards to 30-day mortality (untyped: 10·8%; VT: 16·7%; NVT: 
5·9%) and co-morbidity (mean Charlson co-morbidity index, untyped 1·68; VT 1·97; 
NVT 1·36). One interpretation of this observation is that the untyped group represents 
a combination of serotypes from both VT and NVT serotype groups. Alternatively, the 
serotypes represented in the untyped group may be associated with CAP with 
different clinical characteristics. Due to the very high specificity of the Bio-Plex assay 
(>99%), it is unlikely that a particular serotype has been mis-assigned. 
 
This study was carried out at two large hospitals covering a relatively stable 
catchment population of approximately 700,000 in Nottingham. As there are no other 
hospitals in the area, all patients with CAP requiring hospitalisation are admitted to 
either of the two study hospitals. Therefore, selection bias due to differences in 
hospital admission practices is unlikely. However, as this study included only 
hospitalised cases these findings may not apply to patients with CAP in the 
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community with less severe disease. Larger, multi-centre studies in more diverse 
populations of patients are therefore required. 
 
Conclusions 
The commonest serotypes implicated in non-invasive pneumococcal pneumonia are 
14, 1, 8, 3 and 19A. The epidemiology of these serotypes varies considerably by age 
and season, with fewer PCV-7 vaccine-type serotypes seen in the second year of the 
study. Invasive serotypes have similar attack rates across age groups whereas less 
invasive serotypes predominantly cause disease in older patients with more co-
morbidity. 
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Chapter 6: Association of 
pneumococcal serotype with clinical 
phenotypes 
 
 
 
 
³«W\SH,II pneumococcus is perhaps the most fatal of all 
types, not because these pneumococci are in 
themselves the most virulent, but because they 
HVSHFLDOO\DWWDFNROGSHRSOH´ 
 
³'LVHDVHVRIWKH&KHVW´'U5REHUW&RRSH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Introduction 
As described in chapter 2, the distribution of pneumococcal serotypes in adult CAP 
may be changing following the introduction of PCV-7. The serotype distribution for the 
current cohort is described in the previous chapter, but the relevance of this is yet to 
be elucidated. The infecting serotype may have implications for the clinical spectrum 
of pneumococcal disease. In cohorts of adults with invasive pneumococcal disease 
(IPD), particular serotypes have been associated with meningitis,103 and development 
of septic shock.130 Furthermore, certain serotypes have been linked to increased 30-
day mortality and higher severity disease.105, 108, 110, 121 
 
The aim of this study was to describe the clinical features and outcomes for adults 
hospitalised with both invasive and non-invasive pneumococcal CAP according to 
pneumococcal serotype. 
 
Methods 
Participants 
Participants were recruited as per the methods described in chapter 4. 
 
Outcome measures 
The main clinical outcome measure correlated with pneumococcal serotype was 
death within 30 days of admission. Secondary outcome measures were the need for 
invasive or non-invasive ventilation or refractory shock requiring vasopressor support 
(IVRS), and length of hospital stay (LOS). Clinical features that were recorded as 
secondary outcomes included presence of hypotension on admission (defined as 
systolic blood pressure <90mmHg), chest radiographic appearances, admission C-
reactive protein (CRP), and co-morbidity estimated using the Charlson co-morbidity 
index.389 Demographic data (including age and sex), disease severity as measured by 
the Pneumonia Severity Index (PSI), co-morbidity, baseline WHO performance status, 
and self reported rates of influenza and PPV vaccination were also recorded. 
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Statistical analysis 
Statistical calculations were made using SPSS v16.0 (©SPSS Inc., 1989-2007). 
&DWHJRULFDO GDWD ZHUH FRPSDUHG XVLQJ 3HDUVRQ¶V Ȥ2, which was also used for 
calculating odds ratios (OR) and 95% confidence intervals (CI). Continuous data that 
were non-normally distributed were compared using Mann-Whitney U test. 
 
The associations between serotypes and outcomes were assessed using a logistic 
regression model, with adjustment made for age (with groups representing ages 16-
49, 50-64, 65-74, 75-84 and 85+ years according to epidemiological convention) and 
co-morbidity (as measured by the Charlson co-morbidity index,389 grouped into no 
(score 0), mild (1-2), moderate (3-4) or severe (5+) co-PRUELGLW\7KH³DGMXVWHGRGGV
UDWLRV´ quoted in the text are following adjustment for age and co-morbidity unless 
otherwise stated. Where appropriate, adjustment was alternatively made using the 
PSI severity group. In comparisons between individual serotypes, the untyped group 
was used as the comparator. 
 
As mentioned in the previous chapter, five patients had two serotypes identified; three 
with serotypes 4 and 8, one with serotypes 6B and 9V, and one with serotypes 15A 
and 18C. These patients were not included in any analyses involving comparisons 
between individual serotypes. As serotypes 6B and 9V are both included within PCV-
7, this patient was included as part of the VT serotype group. 
 
Results 
Vaccine-type serotypes 
VT Serotypes were identified in 72 (29·8%) of 242 patients in whom a serotype was 
determined, excluding the four patients where both a VT and NVT serotype was 
found. Pneumonia with a VT serotype was associated with older age (median 73·5 
years vs. 65·9 years; p=0·003) and higher levels of co-morbidity (mean Charlson co-
morbidity index 1·97 vs. 1·32; p=0·036) compared to NVT serotype pneumonia (table 
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6.1). Pneumonia with a VT compared with NVT serotype was associated with higher 
30-day mortality after adjustment for disease severity (OR 3·0, 95% CI 1·2-7·5; 
p=0·016) or age and co-morbidity (OR 2·8, 95% CI 1·1-7·2, p=0·035) (table 6.1). 
There were no differences in LOS or IVRS for CAP with VT serotypes compared with 
NVT serotypes. NVT disease was associated with a higher proportion of patients 
presenting with hypotension (systolic blood pressure <90mmHg) (17·4% vs. 5·6%; 
adjusted OR 4·1, 95% CI 1·3-12·8, p=0·017) and pleural effusions (34·1% vs.19·4%; 
adjusted OR 2·0, 95% CI 1·0-3·9, p=0·050) (table 6.2). 
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Patient characteristics Whole cohort (n=920) Untyped (n=120) VT (n=72) NVT (n=170) P value* 
Demographics      
Age, median; years (IQR) 71.7 (57.8-80.8) 73.0 (58.9-82.9) 73.6 (60.1-84.7) 65.5 (45.9-77.9) 0.003 
Male (%) 546 (59.3) 63 (52.5) 42 (58.3) 91 (53.5) 0.492 
Residential or nursing care home resident (%) 51 (5.5) 10 (8.3) 4 (5.6) 10 (5.9) 0.979 
:+23HUIRUPDQFH6WDWXV 138 (15.0) 25 (20.8) 9 (12.5) 26 (15.3) 0.561 
COPD (%) 244 (26.5) 39 (32.5) 16 (22.2) 39 (22.9) 0.903 
Ischaemic heart disease (%) 145 (15.8) 25 (20.8) 11 (15.3) 25 (14.7) 0.510 
Diabetes mellitus (%) 130 (14.1) 17 (14.2) 13 (18.1) 22 (12.9) 0.318 
Cerebrovascular disease (%) 103 (11.2) 11 (9.2) 17 (23.6) 16 (9.4) 0.003 
Asthma (%) 102 (11.1) 11 (9.2) 10 (13.9) 26 (15.3) 0.779 
Congestive cardiac failure (%) 74 (8.0) 12 (10.0) 6 (8.3) 8 (4.7) 0.269 
Active malignancy (%) 67 (7.3) 6 (5.0) 3 (4.2) 9 (5.3) 0.712 
Dementia (%) 32 (3.5) 3 (2.5) 11 (15.3) 7 (4.1) 0.002 
Mean Charlson co-morbidity index (95% CI) 1.48 (1.37-1.59) 1.68 (1.35-2.01) 1.97 (1.47-2.47) 1.36 (1.12-1.59) 0.036 
Influenza vaccination in preceding 12 months (%) 558/855 (65.3) 76/114 (66.7) 41/62 (66.1) 98/154 (63.6) 0.729 
PPV in preceding 10 years (%) 383/824 (46.5) 57/108 (52.8) 26/60 (43.3) 61/148 (41.2) 0.779 
Severity 
     
PSI Class I-III (%) 395 (42.9) 42 (35.0) 30 (41.7) 78 (45.9) 
0.545 PSI Class IV (%) 336 (36.5) 48 (40.0) 23 (31.9) 58 (34.1) 
PSI Class V (%) 189 (20.5) 30 (25.0) 19 (26.4) 34 (20.0) 
Outcome 
     
30-day mortality (%) 92 (10.0) 12 (16.7) 12 (16.7) 10 (5.9) 0.035 
LOS 7 (4-12) 7 (4-11) 7 (4-11) 6 (4-10) 0.307 
IRVS (%) 82 (8.9) 7 (9.7) 7 (9.7) 21 (12.4) 0.567 
 
*P value compares VT with NVT serotypes. PPV: adult pneumococcal polysaccharide vaccine; LOS: length of hospital stay; IRVS: need for intensive 
respiratory or vasopressor support; VT: serotypes included within the 7-valent childhood pneumococcal vaccine (4, 6B, 9V, 14, 18C, 19F, 23F); NVT: 
serotypes not included within the 7-valent childhood pneumococcal vaccine; COPD: chronic obstructive pulmonary disease; CI: confidence interval; WHO: 
World Health Organisation; PSI: pneumonia severity index; IQR: interquartile range. 
Table 6.1: Characteristics and outcomes of the study cohort. 
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Whole cohort (n=920) VT (n=72) NVT (n=170) Adjusted OR (95% CI) P value* 
Pleural effusion (%) 209 (22.7) 14 (19.4) 58 (34.1) 0.5 (0.3-1.0) 0.050 
Multi-lobar involvement (%) 284 (30.9) 27 (37.5) 51 (30.0) 1.3 (0.7-2.4) 0.384 
WCC 12 x109/l 579 (62.9) 47 (65.3) 118 (69.4) 0.9 (0.5-1.7) 0.736 
&53100 mg/l (%) 523/826 (63.3) 44/67 (65.7) 112/159 (70.4) 0.9 (0.5-1.7) 0.479 
Confusion (%) 120 (13.0) 21 (29.2) 28 (16.5) 1.6 (0.8-3.3) 0.174 
RR 30 min-1 (%) 152 (16.5) 13 (18.1) 32 (18.8) 0.7 (0.4-1.6) 0.436 
SBP <90 mmHg (%) 82 (8.9) 4 (5.6) 29 (17.1) 0.2 (0.1-0.8) 0.017 
 
*P value compares VT with NVT serotypes. VT: serotypes included within the childhood pneumococcal vaccine (4, 6B, 9V, 14, 18C, 19F, 23F); NVT: 
serotypes not included within the childhood pneumococcal vaccine; IQR: interquartile range; CRP: C-reactive protein; SBP: systolic blood pressure on 
admission. Data on CRP are presented for only those who had this tested on admission. 
Table 6.2: Clinical features for the study cohort. 
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Individual serotypes 
Pneumonia caused by serotype 1 was associated with younger age (median age: 
58.3 years, IQR 39.5-70.6, versus 73.0 years IQR 58.9-82.9; p<0·001) and less co-
morbidity (mean Charlson co-morbidity index: 0.98, 95% CI 0.54-1.41, versus 1.68, 
95% CI 1.35-2.01; p=0·012) compared with untyped pneumococcal disease (table 
6.3; figure 6.1). Serotype 1 pneumonia was also associated with higher rates of para-
pneumonic effusion (adjusted OR 2·6, 95% CI 1·2-5·8, p=0·016) and a higher 
proportion of patients with admission C-UHDFWLYH SURWHLQ &53 OHYHOV  PJO
(89·2% versus 65·7%; adjusted OR 3·6, 95% CI 1·1-11·1, p=0·028) (table 6.4). None 
of the 40 patients with serotype 1 CAP died within 30 days of admission (table 6.5). 
Similarly, serotype 7F pneumonia was associated with younger patient age (median 
age 45.8 years, IQR 32.8-75.8; p=0·013) and less co-morbidity (mean Charlson co-
morbidity index: 0.71, 95% CI 0-1.45; p=0·013), and no patient deaths. 
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Serotype n Median age, years (IQR) Male, n (%) Charlson index, mean (95% CI) PS 2 (%) 
1 40 58.3 (39.5-70.6) 21 (52.5) 0.98 (0.54-1.41) 3 (7.5) 
3 20 78.2 (66.9-86.7) 10 (50.0) 2.35 (1.63-3.07) 5 (25.0) 
4 13 67.6 (52.8-84.2) 5 (38.5) 2.15 (0.48-3.82) 1 (7.7) 
5 18 70.7 (58.7-82.1) 11 (61.1) 1.67 (0.70-2.63) 1 (5.6) 
6A/C 11 78.3 (70.5-82.2) 6 (54.5) 1.82 (0.23-3.40) 4 (36.4) 
7F 14 45.8 (32.8-75.8) 9 (64.3) 0.71 (0-1.45) 0 (0) 
8 35 60.5 (44.0-75.8) 15 (42.9) 1.14 (0.79-1.50) 8 (22.9) 
14 45 77.3 (67.0-84.5) 30 (66.7) 2.13 (1.50-2.76) 7 (15.6) 
19A 20 71.1 (55.1-80.0) 10 (50.0) 1.25 (0.65-1.85) 2 (10.0) 
Untyped 120 73.0 (58.9-82.9) 57 (48.3) 1.68 (1.35-2.01) 25 (20.8) 
 
CI: confidence interval; IQR: interquartile range; PS: performance status. 
Table 6.3: Demographic features by serotype. 
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     (Years, median) 
 
 
Figure 6.1. Distribution of serotypes according to median age and count within 
the cohort. 
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Serotype n Pleural effusion (%) 
Multi-lobar involvement 
(%) 
WCC, x109/l 
(IQR) 
CRP, mg/l 
(IQR) 
Confusion 
(%) 
RR, min-1 
(IQR) 
SBP <90 mmHg 
(%) 
1 40 18 (44) 9 (23) 17.6 (12.1-25.5) 286 (188-446) 5 (12.5) 24 (20-26) 6 (15) 
3 20 8 (40) 7 (35) 13.3 (9.8-17.6) 77 (43-162) 4 (20.0) 24 (22-32) 2 (10) 
4 13 3 (23) 4 (31) 10.7 (9.3-17.7) 127 (41-256) 2 (15.4) 23 (19-26) 1 (8) 
5 18 6 (31) 6 (38) 13.6 (10.7-19.0) 99 (56-188) 3 (16.7) 21 (19-25) 5 (28) 
6A/C 11 1 (9) 4 (36) 15.8 (12.2-19.4) 121 (65-167) 3 (27.3) 18 (16-23) 3 (27) 
7F 14 3 (21) 4 (29) 16.9 (12.0-23.9) 288 (176-443) 0 (0) 20 (19-28) 1 (7) 
8 35 11 (31) 10 (25) 17.5 (11.5-25.3) 173 (64-317) 4 (11.4) 21 (16-28) 5 (14) 
14 45 8 (18) 20 (43) 14.3 (10.3-19.7) 171 (61-268) 13 (28.9) 22 (20-27) 2 (4) 
19A 20 9 (45) 7 (33) 14.7 (11.9-21.5) 184 (106-261) 3 (15.0) 20 (18-26) 6 (30) 
Untyped 120 27 (24) 37 (30) 15.6 (11.0-20.5) 155 (78-249) 14 (11.7) 24 (20-30) 14 (12) 
 
WCC: white cell count; CRP: C-reactive protein; RR: respiratory rate; SBP: systolic blood pressure; VT: serotypes included within the childhood 
pneumococcal vaccine (4, 6B, 9V, 14, 18C, 19F, 23F); NVT: serotypes not included within the childhood pneumococcal vaccine. Data on CRP are presented 
for only those who had this tested on admission. Values are medians unless otherwise stated. 
Table 6.4: Clinical features by serotype. 
140
 
141 
 
 
Serotype n Died by 30 days 
Case fatality rate, % 
(95% CI) 
LOS, days 
(IQR) IVRS (%) 
1 40 0 0 (0, 8.8) 7 (4-10) 4 (10.0) 
3 20 2 10.0 (1.2, 31.7) 9 (5-14) 3 (15.0) 
4 13 3 23.1 (5.0, 53.8) 7 (3-12) 1 (7.7) 
5 18 1 5.6 (0.1, 27.3) 6 (5-11) 3 (16.7) 
6A/C 11 1 9.1 (0.2, 41.3) 7 (5-14) 4 (36.4) 
7F 14 0 0 (0, 23.1) 5 (4-9) 1 (7.1) 
8 35 1 2.9 (0, 14.9) 5 (3-8) 5 (14.3) 
14 45 7 15.6 (6.5-29.4) 9 (5-13) 3 (6.7) 
19A 20 3 15.0 (3.2, 37.9) 5 (4-14) 0 (0) 
Untyped 120 13 10.8 (5.9-17.8) 7 (4-12) 14 (11.7) 
 
LOS: length of hospital stay; IRVS: need for respiratory or vasopressor support; IQR: 
interquartile range; CI: confidence interval, binomial, exact. 
Table 6.5: Disease outcome by serotype. 
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In contrast, patients with serotype 3 pneumonia had higher levels of co-morbidity than 
the untyped pneumococcal group (p=0·028). Serotype 6A/C was associated with an 
increased need for IRVS (36·4%, adjusted OR 4·3, 1·1-16·9, p=0·034), and serotype 
19A pneumonia was associated with para-pneumonic effusion (adjusted OR 2·8, 95% 
CI 1·1-7·7, p=0·039). Serotype 19A was also associated with a higher proportion of 
patients who were hypotensive on admission (systolic blood pressure <90mmHg: 
adjusted OR 3·6, 95% CI 1·1-11·6, p=0·035), as was serotype 5 (adjusted OR 3·6, 
95% CI 1·0-12·9, p=0·049). These statistically significant associations between 
serotype and clinical features persisted after adjustment for PSI instead of age and 
co-morbidity (table 6.6). 
 
After adjusting for age, serotype 14 was significantly associated with cerebrovascular 
disease (OR 2.7, 95% CI 1.0-6.9; p<0.05) and dementia (OR 10.7, 95% CI 2.5-46.0; 
p=0.001), serotype 3 with diabetes mellitus (OR 3.3, 95% CI 1.1-9.6; p<0.05), and 
serotype 8 with asthma (OR 3.8, 95% CI 1.4-10.0; p=0.008) (table 6.7). 
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Association PSI adjusted OR (95% CI) P value 
NVT serotype with admission SBP <90mmHg 4.6 (1.5-14.1) 0.008 
NVT serotype with pleural effusion 2.3 (1.1-4.4) 0.018 
NVT serotype with PPV vaccination 1.0 (0.5-1.9 0.954 
Serotype 1 with pleural effusion 3.1 (1.5-6.8) 0.004 
Serotype 1 with CRP >100mg/l 4.2 (1.4-12.9) 0.011 
Serotype 6A/C with IRVS 4.5 (1.1-18.7) 0.037 
Serotype 19A with pleural effusion 3.1 (1.1-8.2) 0.027 
Serotype 19A with admission SBP <90mmHg 4.7 (1.4-15.5) 0.012 
Serotype 5 with admission SBP <90mmHg 3.1 (0.9-11.1) 0.075 
 
OR: odds ratio; NVT: serotypes not included within the childhood pneumococcal 
vaccine; CRP: C-reactive protein; IRVS: intensive respiratory or vasopressor support; 
SBP: systolic blood pressure. 
Table 6.6. Associations presented in the text, adjusted for Pneumonia Severity 
Index rather than age and co-morbidity 
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Serotype n Active malignancy (%) COPD (%) Asthma (%) Dementia (%) CVA (%) DM (%) CCF (%) 
1 40 2 (5.0) 8 (20.0) 6 (15.0) 0 (0) 2 (5.0) 2 (5.0) 1 (2.5) 
3 20 1 (5.0) 6 (30.0) 3 (15.0) 3 (15.0) 3 (15.0) 7 (35.0) 2 (10.0) 
4 13 2 (15.4) 3 (23.1) 2 (15.4) 1 (7.7) 2 (15.4) 1 (7.7) 0 (0) 
5 18 1 (5.6) 4 (22.2) 3 (16.7) 0 (0) 0 (0) 2 (11.1) 2 (11.1) 
6A/C 11 2 (18.2) 2 (18.2) 0 (0) 1 (9.1) 1 (9.1) 3 (27.3) 1 (9.1) 
7F 14 1 (7.1) 3 (21.4) 0 (0) 0 (0) 1 (7.1) 2 (14.3) 0 (0) 
8 35 0 (0) 7 (20.0) 11 (31.4) 2 (5.7) 4 (11.4) 4 (11.4) 0 (0) 
14 45 1 (2.2) 11 (24.4) 6 (13.3) 9 (20.0) 11 (24.4) 12 (26.7) 4 (8.9) 
19A 20 1 (5.0) 5 (25.0) 3 (15.0) 0 (0) 4 (20.0) 2 (10.0) 2 (10.0) 
Untyped 120 6 (5.0) 39 (32.5) 11 (9.2) 3 (2.5) 11 (9.2) 17 (14.2) 12 (10.0) 
 
COPD: chronic obstructive pulmonary disease; CVA: Cerebrovascular disease; DM: diabetes mellitus; CCF: congestive cardiac failure. 
Table 6.7. Distribution of co-morbidity by serotype. 
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Bacteraemic patients 
Of the 40 patients with pneumococcal bacteraemia, 35 were of NVT serotypes 
compared with three VT serotypes (OR 6·0, 95% CI 1·8-20·0, p=0·001) (table 6.8). In 
one patient no serotype was available, and in a second patient the Bio-Plex and blood 
culture serotypes were different (serotype 15A from blood culture and 18C from Bio-
Plex). The proportion of VT serotypes within the bacteraemic patients was significantly 
lower than in the non-bacteraemic patients (3/38 (7·9%) versus 69/204 (33·8%), 
p=0·001). Bacteraemic patients did not have higher disease severity (by PSI) or 
worse disease outcomes compared to non-bacteraemic pneumococcal CAP patients 
(30-day mortality: 5.0% versus 11.0%; IVRS: 10.0% versus 9.5%; p>0·2 for each). 
Bacteraemia was associated with lower rates of influenza and pneumococcal 
polysaccharide vaccination, but this difference was not maintained after adjusting for 
age (pneumococcal vaccination: OR 0·7, 95% CI 0·3-1·8, p=0·461; influenza 
vaccination: OR 0·7, 95% CI 0·3-1·4, p=0·299). 
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Bacteraemic 
(n=40) 
Non-bacteraemic 
(n=326) P value 
VT (%) 3 (7.5) 69 (21.2) 0.040 
PSI Class I-III (%) 21 (52.5) 130 (39.9) 
0.296 PSI Class IV (%) 11 (27.5) 121 (37.1) 
PSI Class V (%) 8 (20.0) 75 (23.0) 
30-day mortality (%) 2 (5.0) 90 (11.0) 0.281 
IRVS (%) 4 (10.0) 78 (9.5) 0.805 
Influenza vaccination in the preceding 12 months (%) 14/34 205/300 0.002* 
Pneumococcal vaccine in the preceding 10 years (%) 8/33 139/287 0.008* 
 
*:statistically significant association was not maintained after adjusting for age (see text). IRVS: need for respiratory or vasopressor support; PSI: pneumonia 
severity index; VT: serotypes included within the childhood pneumococcal vaccine (4, 6B, 9V, 14, 18C, 19F, 23F); NVT: serotypes not included within the 
childhood pneumococcal vaccine. 
Table 6.8: Univariate analysis comparing pneumococcal bacteraemic and non-bacteraemic patients. 
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Serotypes of lower prevalence 
The study has so far concentrated on serotypes with a number 10 within the cohort. 
The clinical features for the other serotypes (n<10) are presented in tables 6.9 to 6.12. 
As the numbers of each individual serotype are low, statistical comparison is not 
possible. However, these data are included within the VT or NVT groups as 
appropriate in the previous analyses. 
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Serotype n Median age, years Male, n (%) Charlson index, 
mean (95% CI) PS 2 (%) 
18C 4 71.5 3 1.00 0 
12F 2 66.3 2 1.00 1 
15A+18C 1 90.7 1 2.00 0 
19F 3 65.1 1 1.00 0 
22F 3 79.1 3 1.33 1 
33F 3 50.6 2 2.00 1 
35F 1 89.5 0 2.00 0 
4+8 3 77.5 1 0.67 1 
6B 2 87.9 1 1.50 1 
6B+9V 1 34.1 0 0 0 
9V 4 60.2 2 2.00 0 
28F 1 37.7 1 1.00 0 
35B 1 86.7 1 5.00 0 
9N 1 34.9 0 0 0 
 
CI: confidence interval; PS: performance status. 
Table 6.9. Demographic features by serotype. 
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Serotype n Active malignancy (%) COPD (%) Asthma (%) Dementia (%) CVA (%) DM (%) CCF (%) 
18C 4 0 0 1 0 2 0 1 
12F 2 0 1 0 0 0 0 0 
15A 1 0 0 0 0 0 1 0 
19F 3 0 0 0 0 0 0 0 
22F 3 0 2 0 0 1 0 0 
33F 3 1 0 0 1 0 0 0 
35F 1 0 0 0 0 0 0 0 
4+8 3 0 0 0 0 1 1 0 
6B 2 0 0 0 1 1 0 0 
6B+9V 1 0 0 0 0 0 0 0 
9V 4 0 2 1 0 1 0 1 
28F 1 0 0 0 0 0 0 0 
35B 1 0 1 0 0 0 0 0 
9N 1 0 0 0 0 0 0 0 
 
COPD: chronic obstructive pulmonary disease; CVA: Cerebrovascular disease; DM: diabetes mellitus; CCF: congestive cardiac failure. 
Table 6.10. Distribution of co-morbidity by serotype. 
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Serotype n 30-day mortality LOS, days IVRS 
18C 4 1 6.5 1 
12F 2 1 6 1 
15A 1 0 10 0 
19F 3 0 6 0 
22F 3 0 15 0 
33F 3 0 4 0 
35F 1 0 9 0 
4+8 3 0 25 1 
6B 2 1 12.5 0 
6B+9V 1 0 3 0 
9V 4 0 5 2 
28F 1 0 11 0 
35B 1 1 6 0 
9N 1 0 10 0 
 
LOS: length of hospital stay; IVRS: need for respiratory or vasopressor support. 
Table 6.11. Disease outcome by serotype. 
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Serotype n 
Pleural 
effusion 
(%) 
Multi-lobar 
involvement 
(%) 
CRP, mg/dl WCC, x109/l Haemoglobin, g/dl 
Temperature, 
°C 
RR, min-
1
 
Pulse, min-
1
 
SBP, 
mmHg 
18C 4 0 0 111 11.9 14.1 37.3 28 96 132 
12F 2 0 1 305 8.0 14.1 37.8 33 102 159 
15A 1 0 0 399 17.8 11.6 36.8 15 61 218 
19F 3 1 1 267 11.8 12.1 37.8 20 90 110 
22F 3 0 1 171 18.0 13.9 37.5 28 111 138 
33F 3 1 1 268 19.2 13.0 38.3 22 91 116 
35F 1 0 0 362 17.0 11.8 36.2 16 87 138 
4+8 3 1 1 500 21.2 12.8 36.6 20 74 111 
6B 2 0 1 396 15.0 14.1 38.7 29 127 142 
6B+9V 1 1 0 450 22.0 11.3 39.2 26 136 126 
9V 4 1 1 120 20.4 11.9 37.6 22 115 140 
28F 1 0 0 20 13.3 11.7 37.9 18 170 80 
35B 1 0 0 17 18.9 13.0 38.8 36 145 190 
9N 1 1 1 268 1.1 15.0 38.6 30 140 100 
 
Admission variables are described, and presented as median values. CRP: C-reactive protein; WCC: white cell count; RR: respiratory rate; SBP: systolic 
blood pressure. 
Table 6.12. Clinical features by serotype. 151
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Discussion 
This is the first study to demonstrate differences in clinical features and outcomes 
according to pneumococcal serotypes in adults with both non-invasive and invasive 
pneumococcal CAP. These findings are likely to be more representative of adult 
pneumococcal pneumonia than studies based solely on IPD. 
 
Important differences were noted in the clinical disease and characteristics of the 
patients infected with VT versus NVT serotypes. Infection with NVT serotypes was 
associated with a younger, fitter population, with lower adjusted 30-day mortality, but 
higher prevalence of shock on admission and para-pneumonic effusions. 
Observational data from IPD cohorts in children,194, 198, 201 and adults,194, 202 have 
indicated a recent shift towards NVT serotypes after introduction of the childhood 
pneumococcal conjugate vaccine. Changes in clinical presentation due to PCV-7-
induced changes in serotype distribution have not been observed to date in adults. 
However, in children an increase has been documented in the incidence of empyema 
in the USA from 2·2 per 100,000 to 3·7 per 100,000 following the introduction of PCV-
7,205 primarily caused by NVT serotypes 1, 3 and 19A.207 An increase in necrotizing 
pneumococcal CAP from 13% pre-PCV-7 to 33% post-PCV-7 has been observed in 
children in Utah, accompanied by an increase from 47% to 88% of NVT serotypes.131 
Our results suggest that a shift towards NVT serotypes could potentially mean fewer 
cases of pneumococcal CAP in the most vulnerable adults (those of older age and 
those with higher levels of co-morbidity) as well as a reduction in pneumococcal 
related mortality. This would be an added and unexpected benefit of childhood 
pneumococcal vaccination. However, there may also be an increase in the incidence 
of more complicated CAP in younger adults. 
 
Serotypes 1 and 7F were associated with CAP in younger patients with lower levels of 
co-morbidity. These findings are similar to four studies confined to adult IPD that 
consistently found that serotypes 1 and 7F were associated with younger and fitter 
patients.106, 108, 110 A correlation between the invasive potential of serotypes and the 
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pattern of clinical disease has been postulated to explain these observations. Thus, 
serotypes with greater invasive potential, such as 1 and 7F, may be more likely to 
cause primary disease in younger, previously fit patients, whereas serotypes with low 
invasive potential, such as 6A, colonise older patients with higher levels of co-
PRUELGLW\WKHUHE\DFWLQJDVµRSSRUWXQLVWLF¶SDWKRJHQV108 
 
However, the definition of invasive potential across serotypes is mostly based on 
studies comparing nasopharyngeal carriage with IPD rates in children or infants.113-115 
Serotypes with high invasive potential identified in this way include serotypes 1, 4, 5, 
7F and 9V. In contrast, serotypes 3, 6A, 6B, and 15 have been consistently described 
as being less invasive. The only study to examine invasive potential and include 
adults used a similar methodology to generate case-carrier ratios for IPD. That study 
identified serotype 8 as having the highest ratio.103 Serotypes 1, 5, 7F were not 
represented at all in adult carriage, implying high case-carrier ratios, while serotypes 
3, 4 and 9V had intermediate case-carrier ratios. The serotypes identified in the 
current study based on their association with different clinical features and outcomes 
of CAP are strikingly similar to serotype groups identified by studies of invasive 
potential. This supports the concept of correlations between capsular type, invasive 
potential and disease characteristics. 
 
The proportion of VT serotypes isolated in the bacteraemic cases within the current 
cohort was significantly lower than for the non-bacteraemic cases. For example, VT 
serotype 14 was the most prevalent serotype within the cohort, but in none of these 
cases was bacteraemia detected; in contrast, ten (25%) cases of NVT serotype 1 
pneumonia were bacteraemic. This finding suggests that reliance on studies of IPD for 
a surrogate estimate of the serotype distribution for invasive and non-invasive 
pneumococcal CAP may underestimate the proportion of cases of VT serotype CAP, 
and that further surveillance using non-culture based methods is needed. 
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Of the urine specimens from patients who tested negative using Binax NOW®, 144 
had a pneumococcal serotype detected by Bio-Plex. Binax NOW® remains a useful 
and rapid means of identifying pneumococcal infection, but these results suggest that 
a negative result should not be used to exclude pneumococcal disease. 
 
As of April 2010 PCV-7 was replaced in the UK paediatric immunisation schedules 
with a 13-valent pneumococcal conjugate vaccine (PCV-13). This contains (in addition 
to the types in PCV-7) serotypes 1, 3, 5, 6A, 7F, and 19A, all of which have been 
shown in our study to contribute to CAP in adults. Ongoing culture and non-culture 
surveillance of pneumococcal CAP is essential to determine the impact of PCV-13 on 
adult pneumococcal CAP presentations and outcomes. 
 
Study limitations 
Many of the limitations are similar to those described in the previous chapter. This 
study had limited power to detect differences in clinical features of individual 
serotypes due to the small numbers involved. Additionally, despite adjustment for 
potential confounding variables, the observed clinical differences between individual 
serotypes or groups of serotypes may nevertheless be residually confounded. 
Attempts have been made to minimise this potential limitation using two models for 
most analyses: a) adjusting for age and co-morbidity alone, and b) adjusting for 
disease severity using the well-validated Pneumonia Severity Index which includes 
age, co-morbid illness and clinical factors. The consistency of results in both models 
adds to the reliability of the associations observed. 
 
Conclusion 
Pneumococcal serotypes are associated with different clinical patterns for both 
invasive and non-invasive adult CAP and there are clear differences in clinical 
outcomes. A higher proportion of NVT serotypes represented in adult CAP through a 
shift in serotype distribution caused by the introduction of the childhood pneumococcal 
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conjugate vaccine may lead to lower overall 30-day mortality, but also a higher 
hospitalised population of younger patients with low levels of co-morbidity. 
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Chapter 7: The effect of child contact 
on adult pneumococcal disease 
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Introduction 
As discussed in chapter 2, pneumococci are spread by contact between infected 
persons or with asymptomatic carriers, especially children with nasopharyngeal 
colonisation. However, to date studies have only investigated the transmission of 
pneumococcal carriage between children and adults, and the role contact with 
children plays in the development of adult pneumococcal disease has not been 
elucidated. 
 
The previous chapter has shown considerable differences between the characteristics 
of pneumococcal CAP in adults between different serotypes. However, it is not known 
whether these differences may be explained by factors intrinsic to the pneumococcal 
serotype or predisposing features of the host. For example, are serotypes 1 and 7F 
seen more frequently in disease in younger adults because of some characteristic 
feature specific to these serotypes, or are younger adults exposed to (and therefore 
develop infection with) more NVT serotypes because they are more likely to have 
young children in the household, who in turn are more likely to carry these NVT 
serotypes post PCV-7 vaccination? 
 
This study aims to a) test the hypothesis that contact with a vaccinated child could 
result in prospectively more non-vaccine type (NVT) adult pneumococcal CAP, b) to 
assess the impact of vaccination of child contacts with the 7-valent childhood 
pneumococcal vaccine (PCV-7) on serotype in adult CAP, and c) to explore the link 
between changes in the epidemiology of vaccine-type (VT) disease in adults and 
contact with PCV-7 vaccinated children. 
 
Methods 
A questionnaire (see appendix 3) was completed for each of the patients recruited in 
the cohort study as described in chapter 4. Contact with children was estimated by 
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patient or relative interview at the time of recruitment. Close social contact was 
defined as living in the same household as a child or spending more than eight hours 
in the company of a child in the four weeks preceding admission. If such contact was 
present, child demographic details were requested from the participant. If of an 
appropriate age, data concerning PCV-7 vaccination were obtained from primary care 
vaccination records via the regional Health Protection Agency. Participants where 
vaccination data were available for child contacts were split into three groups: 
 
x group A, contact with a PCV-7 vaccination child; 
x group B, contact with an unvaccinated chiOGDJHG\HDUV 
x group C: no child contact preceding admission. 
 
$³FKLOG´ LVGHILQHGDVDSHUVRQDJHG\HDUVEXWIXUWKHUDQDO\VHVZHUHSHUIRUPHG
IRUFRQWDFWVDJHG\HDUV 
 
Statistical analysis 
Statistical calculations were made using SPSS v16.0 (©SPSS Inc., 1989-2007). 
Differences between continuously distributed and categorical variables were analysed 
using Mann-:KLWQH\8WHVWDQG3HDUVRQ¶VȤ2 respectively. Odds ratios (OR) and 95% 
FRQILGHQFH LQWHUYDOV &, ZHUH FDOFXODWHG XVLQJ 3HDUVRQ¶V Ȥ2 when performing 
univariate analysis. A p value of less than 0.05 was taken to represent statistical 
significance. 
 
The association between child contact and pneumococcal CAP or individual serotypes 
were assessed using a logistic regression model, with adjustment made for age (with 
groups representing ages 16-49, 50-64, 65-74, 75-84 and 85+ years) and co-
morbidity (as measured by the Charlson co-morbidity index,389 grouped into no (score 
0), mild (1-2), moderate (3-4) or severe (5+) co-morbidity), or pneumonia severity 
using the Pneumonia Severity Index (PSI)7KH ³DGMXVWHGRGGV UDWLRV´quoted in the 
text are following adjustment for age and co-morbidity unless otherwise stated. In 
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comparisons between individual serotypes, the untyped group was used as the 
comparator. 
 
Results 
Of 1099 patients identified with CAP during the study period, 956 patients consented 
to be included in the study. Thirty-six patients were unable to provide a urine sample, 
and full data on child contacts were not available in a further 52, leaving 868 for 
analysis. 
 
Child contact and risk of pneumococcal CAP 
The demographic profiles of these two groups are shown in table 7.1. Significant 
differences were found between participants who did and did not have close social 
contact with children 8 years with regards to age, co-morbidity and outcome, with 
child contact being associated with younger age and less co-morbidity. A higher 
proportion of women had preceding close contact with a person 8 years than men 
(136/357 (38.1%) vs. 126/511 (24.7%); OR 1.9, 95% CI 1.4-2.5, p<0.001). Of the 262 
(30.2%) patients who had close social contact with a child 8 years in the four weeks 
preceding admission, 225 had contact with a child aged 5 years. 
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 Child contact (n=262) No child contact (n=606) P value 
Median age (IQR) 60.5 (43.5-75.6) 74.9 (65.2-84.1) <0.001 
Male (%) 166 (50.5) 362 (64.4) <0.001 
Median LOS (days) 5 (3-9) 8 (4-13) <0.001 
30-day mortality (%) 12 (4.6) 70 (11.6) 0.001 
IVRS (%) 19 (7.3) 56 (9.2) 0.338 
Care home (%) 0 (00) 49 (8.1) <0.001 
PPV 92/245 (37.6) 274/544 (50.4) 0.001 
Influenza vaccination 138/253 (54.5) 397/565 (70.3) <0.001 
COPD (%) 60 (22.9) 172 (28.4) 0.094 
Asthma (%) 41 (15.6) 56 (9.2) 0.006 
Cerebrovascular disease (%) 22 (8.4) 73 (12.0) 0.114 
CCF (%) 12 (4.6) 59 (9.7) 0.011 
Active cancer (%) 13 (5.0) 49 (8.1) 0.101 
Dementia (%) 1 (0.4) 28 (4.6) 0.001 
Diabetes mellitus (%) 31 (11.8) 93 (15.3) 0.143 
Mean CCI (95% CI) 1.18 (1.00-1.35) 1.62 (1.48-1.76) <0.001 
Pneumococcal aetiology 123 (46.9) 223 (36.8) 0.005 
 
$³FKLOG´LVGHILQHGDVDFRQWDFWDJHG8 years. IVRS: need for invasive respiratory or 
vasopressor support; IQR: interquartile range; LOS: length of hospital stay; CC: 
critical care; PPV: polysaccharide pneumococcal vaccine; COPD: chronic obstructive 
pulmonary disease; CCF: congestive cardiac failure; CCI: Charlson co-morbidity 
index; CI: confidence interval. 
Table 7.1 Demographic comparison of patients with confirmed CAP with and 
without preceding child contact. 
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Of 346/868 (39.9%) patients with pneumococcal CAP, a serotype was determined in 
229 (66.2%). There was history of pre-admission child contact in 123/346 (35.5%) 
patients with pneumococcal CAP. Contact with children was associated with 
pneumococcal CAP when compared with non-pneumococcal or unknown aetiology 
(OR 1.5, 95% CI 1.1-2.0; p=0.005) (table 7.1). This statistically significant association 
was maintained after adjustment for age, adult pneumococcal vaccination status and 
co-morbidity (OR 1.6, 95% CI 1.1-2.2, p=0.006). Fourteen patients within the cohort 
worked with children on a daily basis; of these, seven (50%) had evidence of 
pneumococcal CAP. A serotype was determined for all seven patients; the most 
prevalent was serotype 1 (n=3), the others being one each of serotypes 8, 14, 9V and 
19A. 
 
Effect of childhood vaccination on adult VT disease 
Infection with a VT serotype was present in 63/225 (28.0%) cases where a single 
serotype was determined (in the remaining four cases both a VT and NVT serotype 
were found concomitantly). Contact with any child 8 years or 5 years was not 
associated with the development of NVT disease (p=0.913 and p=0.889 respectively; 
table 7.2). However, contact with a PCV-7 vaccinated child was significantly 
associated with CAP due to NVT serotypes when compared to contact with a child 
aged 8 years who had not been vaccinated (group A versus group B: OR 2.7 95% CI 
1.1-7.1; p=0.035). This association was maintained after adjustment was made for 
PSI class in a logistic regression analysis (OR 2.8, 95% CI 1.1-7.5; p=0.033), but not 
when adjusted for age and co-morbidity (OR 2.2, 95% CI 0.8-6.1; p=0.142). In this 
second analysis, neither age nor co-morbidity were significantly associated with NVT 
CAP (age group: OR 0.7, 95% CI 0.5-1.1; p=0.106; CCI group: OR 0.8, 95% CI 0.4-
1.4; p=0.413). 
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 NVT serotype (%) OR for VT CAP (95% CI) P value 
Contact age 8 years (n=88) 63 (71.6) 1.0 (0.5-1.8) 0.913 
Contact age 5 years (n=73) 53 (72.6) 1.0 (0.6-1.9) 0.889 
Group A: contact, vaccinated (n=54) 43 (79.6) 1 - 
Group B: contact, unvaccinated (n=34) 20 (58.8) 2.0 (1.1-7.1) 0.035 
Group C: no child contact (n=137) 99 (72.3) 1.5 (0.7-3.2) 0.294 
Group B+C (n=171) 119 (69.8) 1.7 (0.8-3.6) 0.152 
 
VT: serotype contained within PCV-7; NVT: serotype not contained within PCV-7; OR: unadjusted odds ratio; CI: confidence interval; CAP: community-
acquired pneumonia. 
Table 7.2. Comparison of child contact status with risk of developing NVT CAP for patients in whom a pneumococcal serotype was determined. 
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Association of contact with a PCV-7-vaccinated child with adult CAP serotype 
The most prevalent serotypes in patients who had been in close social contact with 
PCV-7 vaccinated children were 1 and 7F, and the most prevalent in those with no 
prior contact with children were 3, 8, and 14 (table 7.3). After adjustment for age and 
co-morbidity, serotypes 1 and 7F were associated with higher rates of patient contact 
with vaccinated children compared with patients with untyped pneumococcal disease 
(group A versus group B and group C combined; p<0.05 for each serotype) (table 
7.4). When limiting the analysis to group A versus group B (i.e. only patients who had 
close contact with children aged 8 years), serotype 1 was associated with contact 
with vaccinated children after adjustment for age and co-morbidity with borderline 
significance (OR 3.9, 95% CI 0.9-15.7; p=0.059). 
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 Serotype 
1 
(n=38) 
3 
(n=18) 
4 
(n=13) 
5 
(n=18) 
6A/C 
(n=10) 
7F/A 
(n=13) 
8 
(n=35) 
14 
(n=36) 
19A 
(n=19) 
Untyped 
(n=110) 
Group A: contact, vaccinated 18 2 2 2 3 7 5 4 6 15 
Group B: contact, unvaccinated 4 1 3 2 0 1 9 8 2 12 
Group C: no child contact 16 15 8 14 7 5 21 24 11 83 
Groups B and C 20 16 11 16 7 6 30 32 13 95 
 
VT: serotype contained within the 7-valent pneumococcal conjugate vaccine (4, 6B, 9V, 14, 18C, 19F 23F. 
Table 7.3. Comparison of serotype distribution with child contact, including the nine most prevalent serotypes in the current cohort. 
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Serotype OR 95% CI P value 
1 4.1 1.7-10.1 0.002 
3 1.5 0.3-8.1 0.643 
4 2.0 0.5-9.2 0.352 
5 1.0 0.2-5.2 0.975 
6A/C 4.2 0.9-20.5 0.077 
7F/A 5.2 1.3-20.6 0.020 
8 0.9 0.2-2.4 0.753 
14 1.2 0.3-4.0 0.814 
19A 3.1 0.9-10.2 0.065 
Untyped 1 - - 
Age group 0.6 0.4-0.7 <0.001 
CCI group 0.6 0.4-0.9 0.015 
 
Odds ratios represent the odds of adult CAP with each serotype for patients with close 
social contact with a PCV-7-vaccinated child (group A) compared with patients with no 
contact with a vaccinated child (groups B and C combined). 
 
OR: odds ratio compared with untyped pneumococcal CAP; CI: confidence interval; 
CCI: Charlson co-morbidity index. 
Table 7.4. Multivariate analysis of the association of serotype with contact with 
a PCV-7-vaccinated child, after adjustment for age, co-morbidity. 
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Discussion 
The main findings of this study may be summarised as follows: 
 
a) Close social contact with children aged 8 years is an independent risk factor for 
pneumococcal CAP; 
b) Contact with PCV-7 vaccinated children is associated with an increased severity-
adjusted risk of NVT CAP when compared with patients who have close contact 
with an unvaccinated child; 
c) The NVT serotypes 1 and 7F are particularly associated with prior contact with 
PCV-7-vaccinated children. 
 
Child contact as a risk factor for adult pneumococcal CAP 
A link between pneumococcal disease and contact with children has previously been 
indirectly demonstrated in a study by Nuorti and colleagues. In this study, 228 patients 
with invasive pneumococcal disease (IPD) were compared with 301 control subjects 
who were age- and sex- matched healthy members of the population.38 The presence 
of children <6 years of age attending day care in the household of the index case was 
associated with a 3-fold increased risk of IPD. Association between day care 
attendance and development of IPD has also been seen in children,390, 391 but this is 
the first study showing a direct link between adult pneumococcal CAP and contact 
ZLWK DQ\ FKLOGUHQ DJHG  \HDUV $ SODXVLEOH PHFKDQLVP IRU WKLV HIIHFW LV WKDW DV
nasopharyngeal colonisation rates in children of this age are far higher than in adults, 
a significant mode of acquisition of pneumococci by adults is through contact with 
children, in contrast to other microbiological causes of CAP. 
 
Child contact as a risk factor for NVT disease 
Within the group of patients who have close contact with children, this study has 
shown that adult contacts are more likely to contract NVT pneumococcal CAP if they 
have contact with a child who has been vaccinated with PCV-7. This implies that the 
transmission of VT serotypes is reduced from children who have been vaccinated. 
This is supported by data showing a reduction in child nasopharyngeal carriage of VT 
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serotypes compared with unvaccinated children,57, 185 and a subsequent reduction in 
carriage of VT serotypes by adult family contacts.52, 58 However, no study has yet 
looked at the direct influence of contact with vaccinated children on adult VT disease 
rather than carriage. This study therefore adds to the knowledge concerning the mode 
of pneumococcal transmission and disease acquisition by adults. 
 
The previous chapter has shown that NVT disease is associated with patients who are 
younger and fitter, but with a higher chance of pleural effusion and shock on 
admission. NVT serotypes have also been shown previously in adult IPD cohorts to 
be associated with low severity disease in younger people.106, 108, 110, 392 However, it is 
not known whether this is due to factors intrinsic to the organism or serotype, or 
whether host factors are involved, or both. This study shows that child contact is a risk 
factor for NVT disease regardless of disease severity, but not when adjustment is 
made for age and co-morbidity (although a non-significant positive association is still 
seen). This suggests that, at least in part, the predisposition of younger and fitter 
patients to acquire NVT pneumococcal CAP as seen in the previous chapter is 
explained by the increased likelihood of contact with young children within this patient 
group. 
 
Potential mechanisms for inter-serotype variation in acquisition 
This study has suggested that not all NVT serotypes are equally associated with PCV-
7 vaccinated child contact; serotypes 1 and 7F in particular show a clear association 
with contact with a vaccinated child, whereas other NVT serotypes prevalent within 
this cohort (notably 3, 5 and 8) shown no such association. The reasons behind this 
are unclear, but a number of mechanisms may contribute. 
 
Prevalence within child disease 
Since the introduction of PCV-7 there has been an increase in NVT serotypes in 
pneumococcal disease in children. However, not all NVT serotypes have increased by 
equal degree. In several recent child IPD cohorts, serotypes 1 and 7F have 
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conspicuously increased in prevalence when compared with other NVT serotypes.201, 
202, 393, 394
 Conceivably, adult disease may be preceded by pneumococcal disease 
(rather than colonisation) in contact children, and by this means common serotypes in 
child disease have become more common in close adult contacts. Data on the health 
of the child at the time of contact within this cohort are not available, but would be an 
interesting area of future work. 
 
Selective expansion of nasopharyngeal carriage prevalence 
Serotypes 1 and 7F were very rare within carriage studies in children prior to 
introduction of PCV-7 (see table 2.4), but some more recent studies in PCV-7 
vaccinated children have shown evidence of increasing prevalence.57, 143 Vaccination 
may therefore be driving a selective increase in certain NVT serotypes, which is 
reflected in increased transmission and adult pneumococcal disease. To confirm or 
refute this hypothesis it would be necessary to obtain nasopharyngeal samples from 
child contacts of adults with CAP in whom the infecting pneumococcal serotype was 
known. This would be an interesting area for future work. 
 
Variation in capsular thickness 
It has previously been shown that pneumococcal capsular thickness correlates with 
risk of death, but inversely correlates with invasive potential,121 which may explain 
why the serotype prevalence in IPD and carriage studies is markedly different. 
Serotypes 1 and 7F have particularly thin capsules.395 This may have two 
implications. A thin capsule may promote development of disease following carriage; 
of all the NVT serotypes adults are exposed to during social contact with children, it 
may be these that preferentially progress to cause disease. Alternatively, their thin 
capsule, whilst hindering persistent colonisation, may predispose to transmission from 
child to adult, explaining the increased prevalence in contact adults. 
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Study limitations 
Many of the limitations described in the preceding two chapters also apply to this 
study. In particular, the sub-group analyses presented in this chapter have relatively 
low numbers, and the results should therefore be interpreted with caution. In addition, 
child contact was ascertained by patient recall at the time of admission, and therefore 
may be subject to bias either in patients with severe disease, or imperfect recall of the 
weeks preceding the admission. The authors have omitted from analysis any 
participants who were unsure of the details of their child contacts, and any from whom 
inaccurate data on child contacts were supplied. However, the only rigorous way to 
confirm direct transmission from colonised child to adult contact would be to obtain 
rapid nasopharyngeal swabs from contact children of adults admitted with CAP, 
thereby confirming the presence of the same strain or serotype in both. This may be a 
useful area of future work. 
 
Conclusion 
Child contact is independently associated with pneumococcal disease, and contact 
with PCV-7 vaccinated children predicts infection with NVT serotypes independent of 
pneumonia severity, in particular serotypes 1 and 7F. This reinforces the mechanism 
of acquisition of pneumococcal pneumonia, and may inform future conjugate vaccine 
development. 
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Chapter 8: The value of symptom 
scoring on outcome 
 
 
 
 
³+HVXGGHQO\IHHOVVKLYHU\DQGLOODQGKXddles in front 
RIWKHILUHORRNLQJJUH\DQGVKRFNHG«´ 
 
³'LVHDVHVRIWKH&KHVW´'U5REHUW&RRSH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Introduction 
Research in community-acquired pneumonia (CAP) requires reliable outcome 
measures by which clinical studies may be powered and efficacy of interventions 
compared. However, many of the routinely used outcome measures are flawed. 
Mortality is confounded by factors such as frailty, co-morbidity and age, and it has 
been estimated that deaths from CAP are attributable to the acute illness in only 
around half of patients.281 Length of hospital stay (LOS) is a useful outcome to 
measure in patients with low severity CAP, but may be prolonged by physician 
practice,363, 365, 396 and functional status pre-admission and during admission.356, 364 
Significant variability in LOS has also been demonstrated between different 
hospitals.360, 361 Time to reach clinical stability, as defined by normalisation of a 
number of routinely measured physiological variables,343, 344 approximates the effect 
of treatment on objective measures of disease such as respiratory rate, temperature 
and pulse rate. It has been correlated with LOS,356 treatment failure, and CAP 
complications.345 
 
However, morbidity due to CAP may persist long after clinical and radiological 
resolution, up to six months in some cases.346-348 Respiratory symptoms and quality of 
life are rarely reported in CAP studies, despite being significant patient-centred 
outcomes. Measuring symptoms may also allow good estimation of the impact of an 
intervention in patients with low severity CAP, a group which by definition has a low 
UDWH RI DGYHUVH RXWFRPHV $ UHFHQWO\ GHULYHG V\PSWRP VFRUH ³&$3 VFRUH´352 has 
been shown to accurately map changes in symptoms between admission, days 3, 7, 
10, 14, and at 6 week follow-up. It correlates with individual physiological variables 
and inflammatory markers, and may be divided into two components which reflect 
respiratory symptoms and general well-being respectively. However, the CAP score 
has yet to be validated in an external cohort, and it is not known whether it may be 
useful in detecting changes in symptoms on a daily basis. 
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The aim of this study was to validate the CAP score in an independent cohort of 
patients with CAP, in particular to: a) determine the association with physiological 
stability in the first few days following hospital admission; and b) to determine if 
improvements in symptom scores correlate with other clinical outcome measures. 
 
Methods 
Patient recruitment 
A random sample of patients enrolled in the cohort study described in chapter 4 were 
recruited between January and June 2010. Patients were included if they met the 
inclusion criteria for the cohort study, and were not confused (and therefore unable to 
accurately report symptoms) or too ill to answer the CAP score questionnaire. Eligible 
participants were approached on a daily basis for four days following admission and 
the CAP score questionnaire completed.352 The score assigns points based on the 
presence or absence of breathlessness, cough, sputum, and general well-being 
(appendix 1), with a higher score denoting less severe symptoms (maximum score 
100). A good symptomatic improvement between admission and day four was defined 
as a twenty point improvement in CAP score. This score can be sub-divided into two 
components, one describing the purely respiratory symptoms of breathlessness, 
FRXJKDQGVSXWXP³UHVSLUDWRU\VFRUH´DQGWKHVHFRQGGHVFULELQJJHQHUDOZHOO-being 
³ZHOO-EHLQJ VFRUH´ 7HPSHUDWXUH SXOVH UDWH UHVSLUDWRU\ UDWH EORRG SUHVVXUH DQG
oxygen saturations with fraction of inspired oxygen (f iO2) were prospectively recorded 
from the first set of observations of the morning for each of the four days on which a 
symptom score was recorded. Participants who were discharged within four days from 
admission were excluded from analysis. 
 
Definitions 
³&OLQLFDOVWDELOLW\´ZDVGHILQHGDV the presence of heart rate <100 beats/min, systolic 
blood pressure >90 mmHg, respiratory rate <24 breaths/min, oxygen saturation >90% 
(and not using supplemental oxygen), and temperature <37.8°C. These criteria have 
been described elsewhere,343, 344 and have been included in international guideline 
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statements.1, 264 Pneumonia severity was estimated using the Pneumonia Severity 
Index (PSI). 
 
Outcome measures 
The clinical outcome measures assessed were death within 30 days of admission, re-
admission within 30 days of discharge, and admission to a critical care area. An 
³DGYHUVHRXWFRPH´ZDVGHILQHGDVDQ\RQHRIWKHVHRXWFRPHV 
 
Statistical considerations 
All statistical analyses were performed using SPSS v16.0 (©SPSS inc., 1989-2007). 
&DWHJRULFDO GDWD ZHUH FRPSDUHG XVLQJ 3HDUVRQ¶V Ȥ2 test. Non-normally distributed 
continuous variables were compared using Mann-Whitney U test, or Kruskal-Wallis 
test when comparing the four consecutive days of symptom scores. Correlation of two 
non-normally distributed continuous variables was assessed using Spearman's rank 
correlation coefficient. A p value of <0.05 was taken as statistically significant. A 
logistic regression analysis was used to investigate the association between clinical 
stability and symptom score, with day of admission used as a co-variate. 
 
Results 
Over this study period 131 patients were admitted with CAP. Of these, 64 were 
eligible for inclusion, and 50 completed CAP scores for the four consecutive days 
following admission. Of the fourteen patients who did not complete four days of CAP 
scores, seven were discharged, four were lost to follow up, and three became too 
unwell to continue following recruitment. The median age of participants was 64.7 
years (interquartile range (IQR) 44.9-75.5). Demographic and clinical features of the 
study cohort are shown in table 8.1. Thirty-five patients (70%) were classified by PSI 
into class I-III (low severity), 11 (22%) class IV (moderate severity), and 4 (8%) class 
V (high severity). Thirty-day mortality was 6% (n=3) and 8% (n=4) were admitted to a 
critical care area. Median LOS for survivors was 7 days (IQR 5-13). 
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Demographics 
 
Median age (years) (IQR) 64.7 (44.9-75.5) 
Male (%) 24 (48) 
COPD (%) 15 (30) 
Asthma (%) 6 (12) 
Other chronic lung disease (%) 4 (8) 
CCF (%) 1 (2) 
Current smoker (%) 10 (20) 
PSI class 
 
I-III (%) 35 (70) 
IV (%) 11 (22) 
V (%) 4 (8) 
Admission clinical variables 
 
Temperature °C, median (IQR) 37.4 (36.9-38.4) 
Pulse rate min-1, median (IQR) 112 (101-122) 
Systolic blood pressure mmHg, median (IQR) 126 (104-139) 
Respiratory rate min-1, median (IQR) 24 (20-25) 
C-reactive protein, median (IQR) 179 (32-300) 
 
IQR: interquartile range; COPD: chronic obstructive pulmonary disease; CCF: 
congestive cardiac failure; PSI: pneumonia severity index. 
Table 8.1. Clinical and demographic features of the study cohort. 
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Change in symptom scores from admission and correlation with outcome 
The CAP score and its two constituent component scores (the respiratory and well-
being scores) had improved significantly by day four of admission (table 8.2, figure 
8.1) (p<0.05 for all three scores). The well-being score improved rapidly compared 
with the respiratory symptom score, but reached a lower absolute level by day four. In 
eight patients the CAP scores were lower at day four than admission; half of these 
patients (n=4) were either admitted to critical care, were readmitted following 
discharge, or died within 30 days (table 8.3). In contrast, eighteen patients (36%) had 
an improvement in CAP score of more than twenty points between admission and day 
four; of these, none had an adverse outcome. Patients without an increase in CAP 
score of at least twenty points were more likely to suffer an adverse outcome (OR 1.9; 
95% confidence interval (CI) 1.4-2.6, p=0.003). The magnitude of change in CAP and 
respiratory scores between admission and day four did not correlate with LOS (CAP 
score: correlation coefficient -0.083, p=0.578; respiratory score: correlation coefficient 
-0.063, p=0.673). In contrast, there was a trend towards a correlation in the 
improvement in well being score with LOS (correlation coefficient -0.255; p=0.084). 
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Day CAP score (IQR) Respiratory score (IQR) Well-being score (IQR) 
Admission 28.4 (9.5-53.4) 21.8 (9.4-68.4) 11.5 (0-33.7) 
2 29.6 (16.1-60.7) 24.8 (12.6-73.3) 26.9 (11.5-48.1)* 
3 47.0 (24.4-63.3)* 41.5 (17.1-75.2) 42.3 (21.2-55.8)* 
4 53.8 (28.4-62.4)* 62.4 (21.4-75.2)* 48.1 (21.2-63.5)* 
 
IQR: interquartile range; CAP: community-acquired pneumonia; *:p<0.01 compared 
with admission value. 
Table 8.2. Changes in median symptom scores by day following admission. 
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Boxes represent median scores and interquartile ranges, with bars representing 
maximum and minimum scores. 
Figure 8.1. Comparison of CAP score, respiratory score and well-being score 
over the first four days of admission. 
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*: p<0.05, Ȥ2 test compared with >20 point improvement group; IQR: interquartile range 
Table 8.3. Comparison of change in symptom scores over the course of the admission with outcome.  
 
 
n Died Critical care Readmission Any adverse outcome (%) Median LOS (IQR) 
CAP score 
      
>20 point improvement 18 0 0 0 0 (0) 8 (4-11) 
0-20 point improvement 24 2 3 4 8 (33)* 9 (6-13) 
Deterioration 8 1 1 2 4 (50)* 5 (5-16) 
Respiratory score 
      
>20 point improvement 13 0 0 1 1 (8) 7 (4-11) 
0-20 point improvement 28 2 3 3 7 (25) 8 (5-13) 
Deterioration 9 1 1 2 4 (44)* 5 (5-15) 
Well-being score 
      
>20 point improvement 29 2 3 2 7 (24) 7 (5-9) 
0-20 point improvement 18 1 1 2 4 (22) 9 (5-16) 
Deterioration 3 0 0 2 2 (67) 14 (n/a) 
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Association with physiological and inflammatory parameters 
Full physiological data for all four days of admission were missing for six patients (a 
total of 14/200 (7%) sets of observations). The presence of clinical stability was 
consistently associated with higher median symptom scores across all four days 
(table 8.4). When adjustment was made for day of admission using a logistic 
regression analysis, CAP score remained independently associated with clinical 
stability (OR 1.02, 95% CI 1.00-1.04; p=0.042). Of patients who were clinically stable 
by day four, 8/19 (42%) had also shown an increase in CAP scores by over twenty 
points, compared with 8/25 (32%) of patients who were not clinically stable (p=0.490). 
There were significant negative correlations between CAP score and respiratory rate, 
but not with temperature, heart rate or blood pressure (table 8.5). 
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Clinically stable (n=38) Clinically not stable (n=148) OR (95% CI) P value 
Median CAP score (IQR) 52.7 (39.3-70.4) 35.8 (14.8-60.8) 1.03 (1.01-1.04) 0.002 
Median respiratory score (IQR) 62.4 (34.2-76.5) 29.1 (12.8-72.7) 1.02 (1.01-1.03) 0.004 
Median well-being score (IQR) 48.1 (25.5-57.7) 21.2 (11.5-48.1) 1.02 (1.01-1.04) 0.006 
 
IQR: interquartile range; OR: odds ratio; CI: confidence interval. 
Table 8.4. Distribution of symptom scores by clinical stability. 
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Temperature P value HR P value RR P value SBP P value 
CAP score -0.034 0.647 -0.095 0.196 -0.223 0.002 0.058 0.433 
Respiratory score -0.039 0.594 -0.043 0.557 -0.161 0.029 0.070 0.344 
Well-being score -0.013 0.866 -0.219 0.003 -0.315 <0.001 0.023 0.759 
 
HR: heart rate; RR: respiratory rate; SBP: systolic blood pressure. 
Table 8.5. Correlation between CAP, respiratory and wellbeing scores with physiological parameters. 
181
 
182 
 
C-reactive protein levels and PSI class were not correlated with CAP, respiratory or 
well-being scores at admission. Similarly, the CAP score did not correlate with any 
individual physiological parameter measured at the time of hospital admission, 
including temperature, respiratory rate, pulse or blood pressure. 
 
Discussion 
The principal finding of this study is that the CAP score at any stage within the first 
four days of hospital admission correlates with clinical stability. Failure of symptom 
scores to improve by at least twenty points is also associated with a higher incidence 
of adverse outcomes. In addition, changes in the CAP score were observable on a 
daily basis after admission with CAP, and symptom scores correlated with 
physiological parameters. These data suggest that the CAP score is a responsive and 
clinically relevant measure of response to treatment. 
 
The use of symptom scoring as an outcome measure would have particular benefit in 
studies of low to moderate severity CAP, complementing traditional outcome 
measures of mortality, re-admission or critical care admission. The CAP score is 
difficult to use with patients with high severity CAP as very sick patients are unable to 
answer the relevant questions, and the presence of confusion also restricts its use. 
Symptom scores do however represent a meaningful patient-centred outcome, in 
contrast to physiological stability and may also be useful in the community by means 
of self-completed questionnaires. 
 
In order for the CAP score to be useful as an outcome measure in clinical studies, it 
should correlate with other clinically relevant outcomes. This study has shown that 
clinical stability at any stage during the first four days of admission is associated with 
higher symptom scores (in other words, less frequent or severe symptoms). The 
183 
 
principal physiological marker that correlated with symptoms was respiratory rate, and 
to a lesser extent heart rate. The derivation study for this score showed strong links 
between improving symptoms and physiology,352 but in contrast to the current study 
showed that temperature was a strong predictor of symptoms. This may reflect the 
relatively small samples sizes of both studies, and further larger studies may help to 
clarify this area. In addition this study also found a statistically significant association 
between the failure of symptom scores to improve by at least twenty points after 
admission with an adverse outcome comprising 30-day mortality, re-admission to 
hospital following discharge or admission to a critical care area. The respiratory 
component of the CAP score seemed to be more predictive than the well-being 
component, as deterioration in respiratory score was associated with adverse 
outcome, whereas deterioration in well-being score was not. 
 
The well being score has the lowest absolute value of the scores at admission, rose at 
a faster rate during the first four days of admission, but did not reach the same level 
as the respiratory score by day four. This finding is in keeping with other published 
studies. El Moussaoui and colleagues followed patients up for six months after 
admission, and found that the well-being component of the CAP score took longer to 
resolve than the respiratory component.348 Marrie and colleagues showed that fatigue 
was slower to resolve than any respiratory symptom such as cough or 
breathlessness.347 This finding is relevant in that general well-being is perhaps the 
most important symptom for patients, but it is difficult to measure objectively with 
physiological or radiological parameters or clinical outcome measures, and is 
therefore not measured as an outcome in most CAP studies. 
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Study limitations 
The main limitation with this study was the relatively small sample size with 
correspondingly small numbers of patients with high severity CAP. This precluded 
detecting a correlation with individual outcomes such as 30-day mortality. However, in 
our experience, the CAP score was less practically applicable in very ill patients. 
Therefore, validation of the CAP score in such patients will not necessarily be of 
value. While the CAP score is mainly of utility in patients with low and moderate 
severity CAP, this study took place in a hospitalised cohort, and the results are not 
applicable to a primary care population without further validation. 
 
Conclusion 
This study validates the CAP symptom score as a simple tool to monitor treatment 
response in the first few days of hospital admission that correlates with physiological 
parameters and other commonly used CAP outcomes. It may be of particular value in 
patients with low-moderate severity CAP. 
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Chapter 9: The value of oxygenation 
assessment in predicting outcome 
 
 
 
 
³«%ORRGJDVDQDO\VLV«LVQRWIHDVLEOHLQFOLQLFDO
ZRUN«+DSSLO\FHUWDLQVLPSOHREVHUYDWLRQVDUH
sufficient; the appropriate (oxygen) dosage is that which 
provides relief of the cyanosis, restlessness and 
GHOLULXPWRJHWKHUZLWKDIDOOLQWKHSXOVHUDWH´ 
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Introduction 
There remains substantial uncertainty regarding the role of pulse oximetry in the 
context of the CRB-65 score for disease severity assessment in patients presenting to 
primary care with CAP. In particular, there is uncertainty regarding the thresholds of 
SpO2 that are associated with clinically significant outcomes. The aims of this study 
were a) to assess the utility of different thresholds of SpO2 in predicting adverse 
outcomes in CAP; b) to assess the utility of low SpO2 as a prognostic tool in sub-
groups such as the young and those without respiratory co-morbidity; and c) to 
compare the prognostic value of oxygenation assessment for mortality with existing 
clinical severity scoring. 
 
The ideal study design to address these questions would be a large cohort study 
conducted in primary care with follow-through in the hospital. A sample size of several 
thousand would be required to capture enough patients with an adverse outcome 
(admission to critical care or death) to enable a robust analysis. There are major 
practical and feasibility hurdles in mounting such a large study. The current study 
design which focuses on a cohort of patients hospitalised with CAP has design 
limitations but still offers important and useful data that might inform further studies. 
 
Methods 
Patient population and recruitment 
Patients for this analysis recruited in the prospective observational study (chapter 4) 
between September 2008 and February 2010. Demographic, co-morbidity and 
severity data were collected for all patients, and SpO2 levels with the fraction of 
inspired oxygen (FiO2) as first measured by the triage nurse team were documented. 
 
Statistical considerations 
The primary outcome measure was a combined end point of inpatient mortality within 
30 days of admission or admission to a critical care area. Other outcomes examined 
were length of hospital stay (LOS) and need for mechanical ventilation (MV). Patients 
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were only included in the current study if the initial oxygen assessment was performed 
on room air. 
 
Data were analysed using SPSS v16.0 (©SPSS inc., 2007). The association of SpO2 
with the primary outcome measure was examined with and without adjustment for 
disease severity using a logistic regression analysis, from which odds ratios were 
calculated. Groups of patients were further analysed according to admission SpO2 
WKUHVKROGVFRPPRQO\XVHGLQJXLGHOLQHVWDWHPHQWVDQG
XVLQJ 3HDUVRQ¶V Ȥ2 test, and measures of performance including sensitivity and 
specificity were calculated. Using the most suitable SpO2 threshold, patient sub-
groups were compared in a similar manner. Continuous variables of other outcomes 
VXFKDV/26ZHUHQRUPDOLVHGORJDULWKPLFDOO\SULRUWRDQDO\VLVXVLQJ6WXGHQW¶V7WHVW
The utility of CRB-65 as a predictor for 30-day mortality was analysed using receiver-
operating characteristic (ROC) curves. A binary measure for each of the oxygenation 
thresholds was added to the individual CRB-65 scores and areas under the curve 
(AUC) calculated for each ROC curve. 
 
Results 
Patient population 
Of 832 patients analysed, 365 received pre-admission supplemental oxygen and 
therefore did not have SpO2 levels measured on room air at the time of hospital 
admission, leaving 467 patients in the study cohort. Mean age was 66.7 years 
(standard deviation 20.1) and 30-day inpatient mortality was 10.3%. Further 
demographic and clinical features of the patient cohort are described in table 9.1. 
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Characteristic Total 
SpO2>90% 
(n=336) 
SpO2 
(n=131) 
p value 
Mean age (years) 66.7 64.5 72.3 0.001 
Male (%) 57.0 58.9 51.8 0.17 
Care home resident (%) 12.6 9.8 19.8 0.003 
Clinical features     
Dyspnoea (%) 88.2 87.2 96.7 0.35 
Cough (%) 77.4 75.2 83.7 0.08 
Productive sputum (%) 59.4 56.6 67.3 0.06 
)HYHU&RQDGPLVVLRQ 37.3 36.1 40.2 0.43 
Co-morbid illness     
COPD (%) 17.8 13.7 28.2 0.001 
Asthma (%) 9.9 11.9 4.6 0.001 
CVD (%) 14.2 14.0 14.6 0.86 
Dementia (%) 8.1 6.3 13.0 0.017 
Chronic renal impairment (%) 7.5 7.4 7.6 0.94 
Active malignancy (%) 7.1 6.0 10.0 0.13 
CCF (%) 6.9 5.1 11.5 0.014 
Chronic liver disease (%) 1.3 1.8 0 0.13 
Oxygenation     
Median SpO2 (IQR) (%) 94 (90-96) 95 (93-96) 87 (82-89) <0.001 
CRB-65 risk class (%)     
0 131 (28.1) 116 (34.5) 15 (11.5)  
<0.001 1 186 (39.8) 129 (38.4) 57 (43.5) 
2 119 (25.5) 76 (22.6) 43 (32.8) 
3 31 (6.6) 15 (4.5) 16 (12.2) 
4 0 (0) 0 (0) 0 (0) 
Miscellaneous     
Mean haemoglobin (SD) 12.7 (1.9) 12.8 (1.9) 12.5 (2.0) 0.22 
Mean urea (SD) 10.1 (10.5) 9.8 (11.2) 10.7 (8.3) 0.03 
Mean creatinine (SD) 120 (96) 118 (83) 123 (100) 0.45 
 
SpO2: capillary oxygen saturations; SD: standard deviation; COPD: chronic obstructive 
pulmonary disease; CCF: congestive cardiac failure; CVD: cerebrovascular disease. 
Symptoms exclude those who were unable to communicate through confusion or 
disease severity. 
Table 9.1. Patient demographics. 
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Utility of different thresholds of SpO2 in predicting adverse outcomes 
SpO2 measured at the time of admission was found on univariate analysis to be 
inversely associated with the combined outcome of 30-day mortality and critical care 
admission (per unit decrease in SpO2, odds ratio (OR) 1.09, 95% confidence interval 
(CI) 1.05-1.14, p<0.001). This association was maintained after adjustment for 
disease severity using the CRB-65 score (CRB-65 0 or 1, OR 1.11, 95% CI 1.05-1.17, 
p<0.001; CRB-65 2 and above, OR 1.06, 95% CI 1.00-1.11, p=0.04). All four 
commonly used thresholds for hypoxaemia were associated with poorer outcomes 
(table 9.2). There was a statistically significant association between decreasing 
thresholds of SpO2 and incidence of adverse outcome (for each decrease in threshold, 
OR 1.42, 95% CI 1.22-1.66, p<0.001). SpO2  ZDV IRXQG WR KDYH PRGHUDWH
discriminatory value (specificity >75%) while still applying to a reasonable proportion 
of patients (131/467, 28%). This threshold was therefore chosen for further analysis. 
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Died/CC (%) OR 95% CI p value Sensitivity (%) Specificity (%) PPV (%) NPV (%) 
SpO2 <88% (n=69) 36.2 3.3 1.9-5.7 <0.001 29.8 88.5 36.2 85.2 
SpO2 Q  29.8 2.7 1.7-4.5 <0.001 46.4 76.0 29.8 86.6 
SpO2 Q  26.7 2.6 1.6-4.3 <0.001 59.5 64.2 26.7 87.9 
SpO2 <95% (n=271) 22.5 2.2 1.3-3.7 0.003 72.6 45.2 22.5 88.3 
 
CC: critical care; OR: odds ratio; CI: confidence interval; SpO2: percentage of capillary haemoglobin saturated with oxygen; PPV: positive predictive value; 
NPV: negative predictive value. 
Table 9.2. Sensitivities and specificities for 30-day inpatient mortality or critical care admission by thresholds of hypoxaemia. 
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Utility of SpO2 DVDSURJQRVWLFWRROLQVXE-groups 
The specificity of SpO2 DVDSUHGLFWRURIPRUWDOLW\RUFULWLFDOFDUHDGPLVVLRQZDV
improved when applied to sub-groups of patients, in particular those aged less than 
50 years (90.0%) and in patients with asthma (92.3%) (table 9.3). SpO2 ZDVD
less reliable predictor in patients admitted from nursing or residential homes and 
those with chronic obstructive pulmonary disease. In patients with SpO2 
admission to critical care, need for mechanical ventilation and LOS were each 
significantly increased (table 9.4). 
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 Died or CC (%) Sensitivity (%) Specificity (%) PPV (%) NPV (%) 
All (n=467) 18.0 46.4 76.0 29.8 86.6 
Age <65 (n=179) 14.5 50.0 87.6 38.5 91.2 
Age <50 (n=92) 13.0 41.7 90.0 38.5 91.1 
Age <65 and no COPD (n=161) 13.7 40.9 87.9 34.6 90.5 
COPD (n=83) 18.1 53.3 57.4 21.6 84.8 
Asthmatic (n=46) 15.2 42.9 92.3 50.0 90.0 
Care home resident (n=59) 27.1 56.3 60.5 34.8 78.8 
 
CC: critical care; PPV: positive predictive value; NPV: negative predictive value; COPD: chronic obstructive pulmonary disease. 
Table 9.3. Value of SpO2 LQSUHGLFWLQJPRUWDOLW\RUFULWLFDOFDUHDGPLVVLRQLQVXEJURXSVRISDWLHQWVZLWK&$3 
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SpO2 >90% (n=336) SpO2  (n=131) p value 
Inpatient death by 30 days (%) 6.8 19.1 <0.001 
Critical care admission (%) 7.4 15.3 0.01 
MV (%) 1.8 5.3 0.04 
Median LOS in days (IQR) 6.56 (8.54) 9.75 (10.33) <0.001 
 
CC: admission to any critical care area. MV: mechanical ventilation. LOS: length of 
hospital stay. 
Table 9.4. Value of low oxygen saturations in predicting outcome. 
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Comparison of the prognostic value of SpO2 ZLWKH[LVWLQJVHYHULW\VFRULQJ 
The area under the curve (AUC) of the receiver-operating characteristic (ROC) curve 
for CRB-65 in predicting 30-day inpatient mortality in this cohort was 0.768. When the 
binary measure of SpO2  RU ! ZDV DGGHG WKH $UC was not substantially 
improved (0.785). For patients with low to moderate severity CAP based on a CRB-65 
score of 0 or 1, SpO2 ZDVLQRIWKRVHZKRVXEVHTXHQWO\GLHGRU
were admitted to critical care. The sensitivity of CRB-DQG2 in predicting 30-
day mortality in this cohort was 97.9% and 70.8% respectively, but was only 52.1% for 
SpO2  
 
Discussion 
This study explored the utility of pulse oximetry in predicting outcome for patients 
admitted to hospital with CAP. Increasing levels of hypoxaemia were found to be 
significantly associated with higher odds of either 30-day mortality or critical care 
admission, even after adjustment for disease severity using the CRB-65 score. This is 
consistent with findings from a US CAP cohort that also demonstrated an association 
between low SpO2 levels measured on admission and a higher 30-day mortality and 
incidence of admission to critical care.309 Compared to other threshold levels of 
hypoxaemia, SpO2  ZDV IRXQG LQ D VLJQLILFDQW SURSRUWLRQ RI SDWLHQWV DGPLWWHG
with CAP (28%) whilst retaining a reasonably good specificity (76%) for 30-day 
mortality or critical care admission. The specificity for adverse outcomes was 
particularly good when applied to patients with asthma (92%) and those who were 
<50 years (90%). 
 
Proposed practical use of pulse oximeters 
Measures of SpO2 DUHLQFUHDVLQJO\EHLQJXWLOLVHGE\JHQHUDOSUDFWLWLRQHUVDVWKH³ILIWK
YLWDO VLJQ´.397 Various pRVVLEOH LQWHUSUHWDWLRQVRI WKLV VLJQDUH WKDW ³KLJK´6pO2 levels 
might be reassuring in a patient who would otherwise cause clinical concern, or that 
³ORZ´6pO2 levels predict higher severity and therefore need for admission to hospital. 
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The results from this study suggest that a threshold of SpO2 PD\EHXVHG WR
³UXOHLQ´KLJKVHYHULW\&$3HYHQLQSDWLHQWVWKDWGRQRWPHHWWKHKLJKVHYHULW\FULWHULD
of clinical scores such as CRB-65. This would apply especially to younger patients, 
those with asthma, or those without pre-existing significant lung disease. However, 
the poor sensitivity of hypoxaemia in the identification of patients at risk of adverse 
outcomes means that pulse oximetry cannot be relied upon as the sole means of 
severity assessment in CA3,QSDUWLFXODULWPHDQVWKDWLWLVQRWSRVVLEOHWR³UXOHRXW´
an adverse outcome in a normoxaemic patient with CAP. Instead, clinical severity 
scores such as CRB-65 should remain the primary method for severity assessment of 
CAP in primary care, with pulse oximetry used as a secondary measure to inform 
clinical judgment in those patients who are of clinical concern in the face of a CRB-65 
score of 0 or 1. 
 
Mechanism of the association of hypoxaemia with adverse outcomes 
These data suggest that hypoxaemia should be considered separately to variables 
such as blood pressure, mental confusion and respiratory rate which are incorporated 
into CRB-65. The latter variables are closely linked to systemic disease and sepsis 
(and therefore mortality) whereas hypoxaemia is a disease- and organ-specific 
measure, primarily of the level of shunt within the lungs. Physiological variables such 
as pulse, blood pressure and respiratory rate are unaffected by substantial 
hypoxaemia in healthy volunteers,312 and correction of hypoxaemia has no influence 
on outcome either in a post-operative setting,313 or in moderately hypoxaemic patients 
with CAP treated with continuous positive airways pressure (CPAP).314 This may 
reflect the oxygen dissociation curve, which suggests that oxygen delivery to the 
tissues is only compromised at levels of SpO2 that are far lower than those associated 
with hypoxaemia as recognised within current practice. Therefore it may not be 
hypoxaemia per se that contributes to the adverse outcome, but that low SpO2 levels 
allow identification of the sub-group of patients who have severe single organ disease 
that falls short of influencing the sepsis-driven variables identified by most current 
severity scores. In patients with chronic respiratory disease such as COPD, there is 
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significant pre-existing ventilation/perfusion mismatch which means that hypoxaemia 
LV D IHDWXUH RI ³QRUPDO´ SK\VLRORJ\ Thus in these patients, a low SpO2 is not 
necessarily an acute pathological feature (in contrast to confusion, high respiratory 
rates or hypotension), and might explain why hypoxaemia was found to be less 
discriminatory for clinical outcomes. 
 
Study limitations 
This study was performed in an exclusively hospitalised cohort of patients and 
therefore raises questions regarding the applicability of these data to a primary care 
population. However, only patients whose admission SpO2 values were recorded on 
room air were studied and it is likely that these values would have been similar to 
values that might have been obtained in a primary care environment. In addition, a 
wide range in SpO2 levels, disease severity and clinical outcomes were represented in 
the study cohort. These features further increase the potential generalisation of the 
results. We are unable to comment on those patients with CAP who were not admitted 
to hospital, and a further study involving such patients is warranted. This study also 
allows no comment to be made concerning the value of pulse oximetry in 
discriminating pneumonic from non-pneumonic lower respiratory tract infection. A 
separate study in a cohort with suspected CAP, which will potentially include patients 
with non-pneumonic lower respiratory tract infection as well as other diagnoses, is 
also of great interest and would be important to enable the results of the current study 
to be applied more widely. 
 
Conclusion 
SpO2 KDVJRRGVSHFLILFLW\EXWORZVHQVLWLYLW\IRUDGYHUVHRXWFomes in CAP, and 
therefore complements rather than replaces clinical severity scoring tools. It is 
particularly useful in patients with asthma or younger patients who do not have 
chronic respiratory disease. 
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³:LWKWKHSDWKRORJLFDOEDFNJURXQGLQPLQGWKHVWXGHQW
must try to translate the symptoms and signs which are 
present into a picture of what is happening ± the extent, 
LQWHQVLW\DQGVWDJHRIWKHGLVHDVH´ 
 
³'LVHDVHVRIWKH&KHVW´'U5REHUW&RRSH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Introduction 
Severity scoring for CAP is a key part of the admission process.1, 264 The CAP severity 
scores in widest use currently are summarised in chapter 2. The pneumonia severity 
index (PSI),266 CURB-65, and CRB-65,285 have been widely validated in a multitude of 
international cohorts, with the newer SMART-COP and SMRT-CO less so. However, 
the demographic distribution of patients admitted to hospitals is changing, with levels 
of age and co-morbidity increasing, incurring a rising mortality.9 Therefore existing 
severity scores may underestimate the effect on mortality of the increasing levels of 
frailty within the population of patients with CAP. Pre-admission functional status as 
measured by the Katz index,398 and Barthel score has been independently associated 
with mortality.399, 400 Additionally, CURB-65 was originally derived from a population 
excluding patients admitted from care homes, a population that make up a 
considerable proportion of medical admissions with CAP. 
 
The aims of this study are to a) validate the scores CURB-65, CRB-65 and PSI for 
predicting 30-day mortality in a new cohort of patients to ensure ongoing clinical utility; 
b) to validate the newer SMART-COP and SMRT-CO for predicting the need for 
intensive respiratory or circulatory support in a UK patient cohort; and c) to 
incorporate a measure of baseline functional status into CURB-65 to attempt to 
improve mortality prediction in a more frail population. 
 
Methods 
Patient recruitment 
Data on the three severity scores were calculated in patients recruited in the 
prospective observational study described in chapter 4. 
 
Definitions 
Pneumonia severity by risk group is defined as per the most recent British Thoracic 
Society guidelines:1 
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x Low severity pneumonia: CRB-65 0, CURB-65 0 or 1, PSI classes I, II or III 
x Moderate severity pneumonia: CRB-65 1 or 2, CURB-65 2, PSI class IV 
x High severity pneumonia: CRB-65 3 or 4, CURB-65 3, 4 or 5, PSI class V. 
 
Intensive respiratory or vasopressor support (IVRS) is defined as the need for 
invasive or non-invasive ventilation, or shock requiring the use of vasopressors for 
blood pressure support.296 Baseline performance status (PS) was estimated by the 
study investigator at recruitment as described in chapter 4. A PS of 3 or 4 was 
incorporated as a binary variable into CURB-65, producing a six point score that was 
evaluated using ROC curve analysis. 
 
Statistical considerations 
All statistical analyses were performed using SPSS v16.0 (©SPSS Inc., 1989-2007). 
Categorical variables, such as mortality, were compared between severity groups 
using Ȥ2. Odds ratios for mortality were calculated on univariate analysis by comparing 
lowest severity group to each higher group in turn. 
 
The performance of the severity scores under examination was assessed using 
receiver-operating characteristic (ROC) curves. These are plots of sensitivity vs. 1-
specificity, typically of a clinical test for a given outcome.401 A measure of the efficacy 
of the test is the area under the curve (AUC) of the resultant plot; an AUC of 1 reflects 
a perfect test, whereas an AUC of 0.5 suggests no predictive ability. It is generally 
thought that values of 0.8 or higher reflect a good value for a clinical prediction rule. 
 
For the purposes of validation of SMART-COP and SMRT-CO, scores based on 
escalation to critical care, patients aged more than 65 years were excluded from the 
analysis. The reason for this is that patients above this age are less likely to be 
admitted to critical care or be deemed appropriate for mechanical ventilation, or 
inotropic or vasopressor support, which conceivably could reduce the efficacy of the 
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score. In a number of patients oxygenation data were not available as an arterial 
blood gas sample was not performed (n=529). 
 
Results 
Cohort demographics 
One thousand and ninety-nine patients admitted with CAP were included in this 
analysis. Full data for the three severity scores were available in 1088 (99.0%) 
patients; admission observations were unavailable in eight cases, haemoglobin not 
measured in one case, and blood urea not measured on admission in two cases. The 
mortality for the cohort was 14.6%. Mean age was 69.7 years (95% confidence 
interval (CI) 68.6-70.8), and median age was 73.6 years (interquartile range (IQR) 
59.6-83.5). 12.7% patients were admitted to a critical care area. 144 (13.2%) patients 
were admitted from a nursing or residential home. 
 
Comparison of the CURB-65, CRB-65 and PSI 
The distribution of patients for each severity score class is shown in table 10.1. In all 
cases, higher severity CAP was associated with higher 30-day mortality, with odds 
ratios reaching statistical significance for each increasing risk group. The sensitivity, 
specificity, positive predictive value (PPV) and negative predictive value (NPV) for 
predicting 30-day mortality are presented for the high severity groups for each score 
in table 10.2. CURB-65 3 had the best sensitivity for 30-day mortality, but this value 
was still only 57.9%. The predictive values for CURB-65 3 and PSI class V were very 
similar, with CRB-65 3 less sensitive (28.9%) but more specific (93.2%). 
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Severity score class N Mortality (%) OR (95%CI) P value 
CURB-65 
    
0 195 1 (0.5) 
1 - 
1 218 12 (5.5) 
2 356 54 (15.2) 5.5 (2.9-10.2) <0.001 
3 226 52 (23.0) 
12.5 (6.8-22.8) <0.001 4 83 36 (43.4) 
5 10 4 (40.0) 
CRB-65 
   
 
0 238 2 (0.8) 1 - 
1 434 48 (11.0) 
20.8 (5.1-84.7) <0.001 
2 307 63 (20.5) 
3 97 42 (43.3) 
86.2 (20.4-364.6) <0.001 
4 12 4 (33.3) 
PSI 
   
 
I 103 1 (1.0) 
1 - II 130 0 (0) 
III 180 12 (6.7) 
IV 393 57 (14.5) 5.2 (2.8-9.7) <0.001 
V 282 89 (31.6) 12.1 (6.9-21.0) <0.001 
Total 1088 159 (14.6) - - 
 
PSI: pneumonia severity index; OR: odds ratio for 30-day mortality; CI: confidence 
interval. 
Table 10.1. Comparison of the distribution of severity score groups and 
mortality. 
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Sensitivity (%) Specificity (%) PPV (%) NPV (%) 
CURB-65 3 57.9 75.6 28.8 91.3 
CRB-65 3 28.9 93.2 42.2 88.5 
PSI class V 56.0 79.2 31.6 91.3 
 
PSI: pneumonia severity index; PPV: positive predictive value. NPV: negative 
predictive value. 
Table 10.2. Comparison of the characteristics of the high severity pneumonia 
groups in predicting 30-day mortality. 
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7KH 52& FXUYHV IRU HDFK VHYHULW\ VFRUH DUH VKRZQ LQ ILJXUH  $8&¶V ZHUH RI
comparable magnitude for each severity score (PSI 0.747; CURB-65 0.748; CRB-65 
0.738). Both CURB-65 and PSI classified 416 patients as low severity, compared with 
238 for CRB-65. None of these severity scores adequately predicted the need for 
admission to a critical care area (ROC AUCs: PSI 0.585; CURB-65 0.575; CRB-65 
0.551) or a combined endpoint of 30-day mortality or critical care admission (ROC 
$8&¶V36,&85%-65 0.688; CRB-65 0.671). 
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ROC AUC 95% CI 
PSI 0.747 0.711-0.783 
CURB-65 0.748 0.711-0.785 
CRB-65 0.737 0.698-0.776 
 
Figure 10.1. ROC curves and AUC for PSI, CURB-65 and CRB-65 in predicting 
30-day mortality. 
 
PSI: pneumonia severity index; ROC: receiver-operating characteristic curve; AUC: 
area under the curve; CI: confidence interval. 
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Validation of SMART-COP 
SMART-COP (and its derivation SMRT-CO for use in primary care) were validated in 
those patients aged less than 65 years. 370 patients were available for analysis. The 
outcomes for each score point are shown in table 10.2, and the ROC curve for 
prediction of IVRS is shown in figure 10.2. AUC for the ROC curve of SMART-COP 
was 0.801, and for SMRT-CO was 0.719. The ROC AUC for predicting IVRS for 
CURB-65 in the same population was 0.617, and PSI 0.628. Both SMART-COP and 
SMRT-CO were inferior to CURB-65 in predicting 30-day mortality in the 370 patients 
aged 65 years (ROC AUC for CURB-65 0.798; for SMART-COP 0.620; for SMRT-
CO 0.591). 
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SMART-COP score n IVRS (%) 30-day mortality (%) 
0-2 205 4 (2.0) 4 (2.0) 
3-4 115 13 (11.3) 3 (2.6) 
5-6 37 8 (21.6) 2 (5.4) 
7 13 5 (38.4) 1 (7.7) 
SMRT-CO score    
0 147 4 (2.7) 2 (1.4) 
1 86 6 (7.0) 3 (3.5) 
2 58 4 (7.0) 2 (3.4) 
3 45 8 (17.8) 1 (2.2) 
4 34 8 (23.5) 2 (5.9) 
 
IVRS: intensive ventilatory or vasopressor support. 
Table 10.2. Distribution of patients as scored by SMART-COP and SMRT-CO. 
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 ROC AUC 95% CI 
SMART-COP -------- 0.801 0.720-0.881 
SMRT-CO -------- 0.719 0.624-0.814 
 
Figure 10.2. ROC curves and AUC for the SMART-COP and SMRT-CO scores. 
 
ROC: receiver-operating characteristic curve; AUC: area under the curve; CI: 
confidence interval. 
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Augmentation of CURB-65 using pre-admission performance status 
Data on baseline PS were available on 1040 (95.6%) participants (table 10.3). Care 
home resident status was closely linked to PS (proportion of care home residents of 
patients at each PS level: PS 0, 2.2%; 1, 6.6%; 2, 34.3%; 3, 46.0%; 4, 68.6%). 
Incremental odds ratios for 30-day mortality were seen per point increase in 
performance status. PS of 2, 3, or 4 was strongly associated with increased 30-day 
mortality when compared with PS of 0 on univariate analysis (odds ratio 5.9, 95% CI 
3.7-9.4; p<0.001). PS alone predicted 30-day mortality, with an AUC on ROC curve 
analysis of 0.695. Using a logistic regression model, PS predicted 30-day mortality 
independent of disease severity as measured by CURB-65, with each point increase 
in PS associated with a statistically significant rise in mortality (table 10.3). When PS 
2 was incorporated into CURB-65 as a sixth predictor variable, the ROC AUC for 30-
day mortality improved in this subset of 1040 patients from 0.741 to 0.761 (table 10.4). 
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 Univariate analysis Multivariate analysis 
PS n 30-day mortality (%) OR (95% CI) P value OR (95%CI) P value 
0 496 31 (6.3) 1 - 1 - 
1 317 46 (14.5) 2.5 (1.6-4.1) <0.001 1.8 (1.1-2.9) 0.024 
2 105 23 (21.9) 4.2 (2.3-7.6) <0.001 2.4 (1.3-4.4) 0.006 
3 87 26 (29.9) 6.4 (3.6-11.5) <0.001 3.5 (1.9-6.5) <0.001 
4 35 15 (42.9) 11.3 (5.3-24.1) <0.001 4.5 (2.0-10.2) <0.001 
 
Multivariate analysis represents PS adjusted for CURB-65 score as a single co-variate. PS: performance status; OR: odds ratio for 30-day mortality compared 
with PS=0; CI: confidence interval. 
Table 10.3 Baseline performance status and 30-day mortality in a logistic regression analysis model. 
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ROC AUC 
All patients (n=1040) 
 
CURB-65 0.741 
CURB-65 plus PS 2, 3 or 4 0.761 
CURB-65 plus PS 3 or 4 0.759 
 
PS: performance status; ROC: receiver-operating characteristic curve; AUC: area 
under the curve; NH: admitted from nursing or residential home. 
Table 10.4. Performance of prediction rules incorporating performance status. 
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PS would be expected to be of more utility in predicting mortality in those patients with 
more severe disease (those with CURB-65 scores 2 and above). When applied as a 
³VHFRQGVWHS´DIWHUVWUDWLI\LQJSDWLHQWV LQWRVHYHULW\JURXSVZLWK&85%-65, using PS 
cut-offs of 2 or 3 showed highest performance in patients with moderate severity 
CAP (table 10.5). In patients with moderate severity CAP, death within 30 days was 
2.5 and 3.3 times more likely with PS of 2 and 3 respectively. Similarly, the absence 
of PS 2 in moderate or high severity CAP was associated with substantially 
decreased mortality (negative likelihood ratios of 0.44 and 0.55 respectively). 
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PS 2, 3, or 4 N Died (%) Sensitivity Specificity +LR -LR 
Severity 
      
Moderate (CURB-65 2) 69 19 (27.5) 67.9 72.8 2.50 0.44 
High (CURB-65 3-5) 120 45 (37.5) 75.0 45.3 1.37 0.55 
PS 3 or 4 
      
Severity 
      
Moderate (CURB-65 2) 40 15 (37.5) 28.8 91.3 3.31 0.78 
High (CURB-65 3-5) 67 26 (38.8) 33.8 81.1 1.79 0.82 
 
PS: WHO performance status; +LR: positive likelihood ratio; -LR: negative likelihood 
ratio. 
7DEOH8VHRISHUIRUPDQFHVWDWXVDVD³VHFRQGVWHS´IROORZLQJDVVLJQPHQW
of patients to moderate and high risk groups. 
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Discussion 
In this large UK CAP cohort CURB-65, CRB-65 and PSI adequately predict 30-day 
mortality, with similar efficacy to previous studies. CURB-65 and PSI have an almost 
equivalent predictive ability, with CRB-65 slightly less effective. These severity scores 
are not accurate at predicting the need for respiratory or circulatory support, a finding 
replicated in other published CAP cohorts.276, 296 However, SMART-COP does predict 
IVRS with good efficacy, as does SMRT-CO to a lesser degree. 
 
CURB-65 and PSI are both widely used in hospitalised patients, with the former more 
prevalent in the UK and the latter in North America. Calculation of PSI involves input 
of more variables than CURB-65 (20 compared with 5), and whilst this allows 
inclusion of more data in the generation of the score (in particular, co-morbidity) it 
renders calculation of the score cumbersome for use as a front door assessment tool 
when compared with CRB-65 or CURB-65. PSI has previously been shown to identify 
more patients as low severity than CURB-65 or CRB-65, which may be useful in 
informing safe discharge decision.276 In this study, no such effect was seen (413 vs. 
413 vs. 238). 
 
A problem with tri-modal severity scoring highlighted by this cohort is the proportion of 
patients identified as moderate severity (CURB-65 2, 356; CRB-65 1 or 2, 741; PSI 
class IV, 393). Such classification neither identifies patients with high severity CAP 
(and therefore in need of consideration of escalation of treatment) or low severity CAP 
(and therefore suitable for consideration of discharge).The ideal score would classify 
as few patients in the intermediate group as possible; for this cohort, the best 
performing score in this regard is therefore CURB-65. 
 
SMART-COP is poorly predictive of 30-day mortality, but predicts the need for IVRS 
well, in contrast to CURB-65 and PSI. The potential reasons for this may lie in the 
causes of the two outcomes under study. 30-day mortality is primarily determined by 
sepsis or co-morbidity, which are heavily represented either directly or as surrogate 
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variables in CURB-65 and PSI. By contrast, the need for IVRS is often determined by 
oxygenation status or respiratory failure, and may not be deemed appropriate in the 
subset of frailer patients admitted to hospital. The three main predictor variables in 
SMART-COP are acidosis, hypoxaemia and systolic hypotension. In a study by 
Mortensen and colleagues, only 38% of deaths within 30-days of admission with CAP 
were attributable to respiratory failure.281 Furthermore, as discussed in chapter 9, 
oxygenation status on admission does not improve the predictive ability of existing 
severity scores for 30-day mortality. SMART-COP places heavier weighting on 
oxygenation status and circulatory failure, and this may explain the improved 
predictive ability of SMART-COP over CURB-65 and PSI for the need for IVRS; as it 
places no weight on co-morbidity or frailty, it poorly predicts 30-day mortality. In 
clinical practice there is a need to be able to accurately predict both 30-day mortality 
in all patients with CAP and the potential need for IVRS in those patients where it is 
appropriate. Therefore both CURB-65/PSI and SMART-COP are useful front-door 
tools which give the clinician different information about a patient and may be used 
effectively in parallel. 
 
The predictive ability of SMART-COP for IVRS was only validated in this study in 
those patients aged less than 65 years. In one of the only other studies to externally 
validate SMART-COP the analysis was restricted to patients aged less than 50 
years.301 There are several reasons for this. Firstly, outcomes such as IVRS may be 
more relevant in a younger population where mortality LVORZLQWKRVHDJHG
years in this cohort). Secondly, older patients referred to hospital are more likely to 
have severe co-morbidity which makes mechanical ventilation or vasopressor support 
inappropriate. There are no firm guidelines on which SDWLHQWV DUH ³DSSURSULDWH´ IRU
management in a critical care setting, and policy varies greatly between different 
countries. A potential surrogate for marker for patients who are deemed inappropriate 
for escalation to a critical care area is the decision not to resuscitate in the event of a 
FDUGLRSXOPRQDU\ DUUHVW ,Q WKLV FRKRUW   RI SDWLHQWV KDG D ³GR QRW
UHVXVFLWDWH´ IRUP ILOOHG RXW ZLWKLQ WKH ILUVW IHZ GD\V RI DGPLVVLRQ DQG RI WKHVH 
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(97.4%) were aged more than 65 years. Thus the investigators feel justified in using 
this age as a cut-off. 
 
CURB-65 includes no measure of frailty, which may have considerable relevance in 
the older population. The PSI does allocate points for patients admitted from a care 
home, but this is an inaccurate measure of premorbid status, and is given low 
weighting in the overall calculation of the score. The original CURB-65 derivation 
study excluded patients admitted from nursing homes, and therefore may have 
represented a less frail population. In this study we have shown a modest 
improvement in the performance of CURB-65 by incorporating baseline PS of 2, 3, or 
4 as an additional binary variable, despite strong prediction of 30-day mortality 
independent of CURB-65. The magnitude of this improvement is such that it is difficult 
to justify recommending widespread changes to CURB-65. This may reflect the fact 
that PS strongly correlates with age, and therefore adds little beyond age to the 
existing severity score. Future studies may consider the use of other objective 
measures of frailty to investigate this issue further. 
 
Performance status may be useful in stratifying patients after application of CURB-65, 
SDUWLFXODUO\LQWKHJURXSRIPRGHUDWHVHYHULW\%\XVLQJDFXWRIIRI36IRUSDWLHQWV
with CURB-65 2 CAP we have shown a higher post-test likelihood ratio for 30-day 
mortality of 2.5 times that of those with PS of 0 or 1, giving a mortality similar to that 
seen in high risk patients (CURB-65 3-5). To illustrate, patients with moderate severity 
&$3DQG36KDGD 30-day mortality of 27.5%, compared with 6.3% for those with 
PS 0 or 1. This has clinical utility in that it may be used to decide whether more 
intensive management (for example, using intravenous antibiotics) would be more 
appropriate in patients with a higher PS. Therefore PS is a straightforward bedside 
test that would seem to have immediate clinical utility. 
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Strengths and limitations 
The strengths of the current study are that it contains relatively large numbers of 
patients compared with contemporary cohorts, and has a prospective methodology. 
However, there are a number of limitations. Firstly, arterial blood gas data were not 
available for roughly half of the patients; this means that the values for SMART-COP 
and SMRT-COP may have been underestimated. Whilst this highlights a significant 
problem with the routine use of this score in clinical practice, it is less likely that 
patients who were significantly hypoxaemic would not have had an arterial blood gas 
sampled, minimising this potential bias. Furthermore, this study population had a 
higher mortality and was of older age than other published cohorts investigating 
severity scoring in CAP. This may explain why the values for ROC AUC were at the 
lower end of that expected from other cohorts. Interestingly, in another large cohort 
study which found lower than expected AUCs for the common severity scores, a 
similarly older demographic was seen (Man and co-workers; mean age 72 years,276 
compared with Lim and co-workers; mean age 64 years.285 
 
Conclusion 
In this validation study, PSI, CURB-65 and CRB-65 all performed equally well in 
predicting 30-day mortality. SMART-COP was more accurate predicting the need for 
intensive respiratory or circulatory support, and is a useful tool for those patients for 
whom such intervention is appropriate. Addition of a binary measure of poor 
performance status to CURB-65 modestly improved performance of the score, but 
when used as a post-test assessment, can identify a sub-group of patients of 
moderate severity CAP that are at much higher risk of death. 
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Chapter 11: The effect of timing of first 
chest radiograph on outcome 
 
 
 
 
³5DGLRORJ\RIWKHFKHVWLVDPDWWHUIRUWKHH[SHUW´ 
 
³'LVHDVHVRIWKH&KHVW´, Dr Robert Coope (1944) 
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Introduction 
In recent years controversy has surrounded the prognostic benefit conferred by early 
antibiotic treatment of CAP on arrival to hospital (see chapter 3 for a full discussion). A 
short time to first antibiotic dose (TFA) for patients hospitalised with CAP was initially 
suggested to decrease mortality,315, 321 and later hospital length of stay (LOS),317, 324, 
356
 findings which have since been vigorously disputed.322, 325-328, 402, 403 A number of 
reports have also been published showing an increase in both the CAP misdiagnosis 
rate and the proportion of patients inappropriately administered antibiotics following 
the introduction of clinical care pathways advocating a short TFA in all patients with 
suspected CAP.323, 329, 330 
 
Early diagnosis with chest radiograph is desirable for a number of reasons. It 
facilitates a confident, appropriate management approach and the early use of 
appropriate antibiotics and severity scoring. It should also prevent the over-diagnosis 
or misdiagnosis of CAP based on clinical signs alone.7, 404, 405 The British Thoracic 
Society has recently recommended that a diagnostic chest radiograph should be 
performed in patients admitted with suspected CAP as promptly as possible following 
admission (preferably within four hours) and that antibiotics should be administered as 
soon as possible after radiographic confirmation of CAP.1 However, there are no 
published data demonstrating that early diagnosis of CAP as measured by time to first 
chest radiograph (TXR) is associated with improved clinical outcome. 
 
The aim of this study was to determine whether a short TXR in patients hospitalised 
with CAP is associated with shorter hospital LOS and more appropriate timing of 
antibiotic administration in relation to chest radiography. 
 
Methods 
Patient data 
Data collected between September 2008 and June 2009 from the prospective 
observational study described in chapter 4 were analysed. For the purposes of this 
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analysis, patients were also excluded if they were admitted from a nursing home. The 
time of first chest radiograph was retrieved from Radiology Department computerised 
records (all chest radiographs are digitally stored together with the exact timing of the 
investigation). All chest radiographs were reviewed by the duty radiologist, and 
patients were excluded if the radiograph reports were not in keeping with CAP. The 
time of first antibiotic administration was prospectively determined by drug chart 
review during the admitting episode (the exact timing of first antibiotic dose is usually 
recorded by the health care professional administrating the drug(s)). The time to first 
chest radiograph (TXR) and the time to first antibiotic dose (TFA) were defined as the 
time from arrival to hospital to first chest radiograph and to first antibiotic dose 
respectively. 
 
Data analysis and statistical considerations 
The primary outcome measure was hospital LOS, and the secondary outcome 
measures were a) timing of antibiotic administration in relation to chest radiography, 
b) 30-day mortality and c) 30-day readmission rates. ³7KLUW\-GD\ PRUWDOLW\´ ZDV
ascertained from computerised hospital records, and was defined as death within 30 
GD\V RI DGPLVVLRQ ³5HDGPLVVLRQ´ ZDV GHILQHG DV UHDGPLVVLRQ WR KRVSLWDO IRU DQ\
reason within 30 days of discharge. 
 
For the analyses of TXR and TFA in relation to outcome, data for TXR and TFA were 
converted to categorical variables using four hours as the threshold value. This 
WKUHVKROGYDOXHZDVFKRVHQWRUHIOHFWWKHµfour KRXUWDUJHW¶RIDGPLVVLRQWRWUHDWPHQW
that is applied to all acute medical admissions in England and Wales. All non-normally 
distributed continuous data were transformed logarithmically prior to statistical 
analysis with Student¶VWWHVW&DWHJRULFDOGDWDZHUHDQDO\VHGXVLQJ3HDUVRQ¶VȤ2 test, 
RU)LVKHU¶VH[DFWWHVWLIVDPSOHVL]HVZHUHVPDOO$OODQDO\VHVLQYROYLQJ/26H[FOXGHG
those that had died prior to hospital discharge. 
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A sample size of 500 patients would have 80% power to detect a fall in LOS of 1.26 
days with a significance level of 5%. Assuming a mortality of 15% within the same 
population, a mortality difference of 7% would be required to achieve statistical 
significance with 80% power. 
 
Results 
Patient characteristics 
Five hundred and forty-six patients were included in this analysis. Eighty-five patients 
were excluded for a variety of reasons (table 11.1), leaving 461 for analysis. Of these, 
64 died in hospital and were not analysed for LOS. The median age of the study 
cohort was 72 years (range 17-102 years) and 60.7% were male. Median LOS for the 
entire cohort was 6.59 days (interquartile range (IQR) 9.45 days), mortality was 
13.7%, and readmission rate was 16.2% for those patients who survived to discharge. 
Median TXR was 1.91 hours (IQR 3.60 hours), with 333 (72.2%) radiographs 
performed within four hours of admission and 236 (51.2%) within two hours. 49.8% 
patients received both their chest radiograph and antibiotics within four hours of arrival 
to hospital. For 35 patients there was uncertainty in the medical records regarding the 
exact time the first dose of antibiotic was administered, and these patients were 
therefore excluded from any analyses relating to TFA.  
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Reason Number excluded 
Patient admitted from a nursing home 74 
Admitted directly from outpatient clinic 2 
Exact time of admission unclear from clinical records 5 
Chest radiograph performed by GP prior to hospital admission 4 
 
Table 11.1. Distribution and explanation of patients excluded from analysis. 
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Comparison of groups 
No differences in age, sex, performance status, or co-morbidity were found between 
SDWLHQWVZLWK7;5KRXUVDQG7;5KRXUV WDEOH11.2). Patients with a TXR <4 
hours were more likely to be short of breath (92.4% vs. 85.4%, p=0.052, odds ratio 
(OR) 2.1), but in other respects the prevalence of lower respiratory tract symptoms 
was not statistically different between these groups. There was a significantly lower 
rate of antibiotic use in the two weeks prior to hospital admission in patients with TXR 
<4 hours (30.1% vs. 41.7%; p<0.05). Patients with more severe disease (CURB-65 3-
5) had a significantly shorter median TXR and TFA compared to patients with low 
severity CAP (CURB-65 0-1) (for TXR: 1.55 hours vs. 2.01 hours, p<0.05; for TFA: 
2.80 hours vs. 3.67 hours, p<0.05). However, no difference in disease severity was 
noted between groups according to TXR of greater or less than four hours. 
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 Survivors to discharge (n=397)  
Characteristic 
TXR <4hours 
(n=291) 
7;5KRXUV 
(n=106) 
p value 
Demographics 
   
Median age (IQR) (years) 70 (26) 72 (23) 0.191 
Male (%) 61.2 56.7 0.377 
Mean smoking history in pack years (SD) 29.6 (33.1) 27.6 (24.2) 0.585 
Proportion of admissions between 9am and 
5pm (%) 46.0 48.1 0.715 
Received antibiotics in the 2 weeks prior to 
admission (%) 30.1 41.7 <0.05 
Admitted to a critical care area (%) 11.2 14.8 0.388 
Symptoms 
   
)HYHU& 40.9 36.2 0.398 
Productive cough (%) 66.0 62.9 0.601 
Short of breath (%) 92.4 85.4 0.052 
Confused (%) 18.6 21.7 0.484 
Severity 
   
CURB-65 score 0-1 (%) 43.3 45.3 
0.750 CURB-65 score 2 (%) 32.3 34.0 
CURB-65 score 3-5 (%) 24.4 20.8 
Co-morbidity 
   
Airways disease (%) 27.5 19.8 0.120 
Cerebrovascular disease (%) 11.7 18.9 0.065 
Active neoplasia (%) 6.2 9.4 0.263 
Heart failure (%) 5.5 8.5 0.278 
Renal disease (%) 6.2 4.7 0.580 
Liver disease (%) 1.0 0.9 0.938 
At least one of the above co-morbidities (%) 45.0 43.4 0.774 
Admission performance status 3 or 4 (%) 49.1 46.2 0.959 
Baseline performance status 3 or 4 (%) 3.2 5.8 0.452 
 
Symptom data exclude those patients who were unable to communicate at admission. 
TXR: time from admission to first chest radiograph; SD: standard deviation; IQR: 
interquartile range. 
Table 11.2. Characteristics of patients admitted to hospital with CAP who 
survived to discharge according to TXR. 
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Outcome measures 
Median LOS was significantly shorter for patients with a TXR <4 hours compared to 
7;5  KRXUV  GD\V YV  GD\V S WDEOH 10.3) and TFA <4 hours 
FRPSDUHG WR 7)$  KRXUV  GD\V YV  GD\V S )RUW\-four (9.5%) 
patients were hypotensive on admission (SBP<90mmHg). As these patients might 
have been treated differently from the other patients, a sub-analysis was performed 
with these patients excluded. In this sub-analysis, the association of TXR <4 hours 
with a reduced median LOS was maintained (5.63 days vs. 7.01 days, p<0.01). 
Antibiotics were administered after the radiograph (rather than vice versa) in 
VLJQLILFDQWO\ PRUH SDWLHQWV ZLWK D 7;5  KRXUV FRPSDUHG WR SDWLHQWV ZLWK 7;5 
hours (89.8% versus 40.7%, odds ratio 12.8, p<0.001). 
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Survivors to discharge (n=397)  
Outcome 
TXR <4hours 
(n=291) 
7;5KRXUV 
(n=106) 
p value 
Median hospital length of stay (days) 5.75 7.13 <0.01 
Interquartile range (days) 8.77 12.56  
30-day readmission rate (%) 16.6 15.2 0.754 
Chest radiograph before antibiotics (%) 89.5 41.7 <0.01 
TFA <4hours (%) 69.2 30.1 <0.01 
 
TXR: time from admission to first chest radiograph; TFA: time to first antibiotic dose. 
Table 11.3. Comparison of outcome according to time to first chest radiograph. 
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No statistically significant association was observed between 30-day mortality and 
TXR or TFA <4 hours, although there was a trend towards a lower mortality in both 
groups (table 11.4). Of patients who had low severity CAP (CURB-65 of 0 or 1), 4 
 GHDWKV DW  GD\V ZHUH QRWHG LQ WKRVH ZLWK 7;5  KRXUV FRPSDUHG WR QR
deaths in those who had both a TXR <4 hours (p<0.01). Having a chest radiograph 
before antibiotic administration was not associated with a decrease in mortality. 
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Total (n=461) TXR <4hours (n=333) 7;5KRXUV (n=128) TFA <4hours (n=245) 7)$KRXUV (n=181) 
CURB65 0-1 Mortality (%) 4/180 (2.2) 0/127 (0)* 4/53 (7.5)*   
CURB65 2 Mortality (%) 24/151 (15.9) 15/107 (14.0) 9/44 (20.5) 9/74 (12.2) 12/68 (17.6) 
CURB65 3-5 Mortality (%) 35/130 (26.9) 26/99 (26.3) 9/31 (29.0) 20/80 (25.0) 11/37 (29.7) 
Total (%) 63/461 (13.7) 41/333 (12.3) 22/128 (17.1) 29/245 (11.8) 27/181 (14.9) 
 
TXR: time from admission to first chest radiograph; TFA: time to fiUVWDQWLELRWLFGHOLYHU\S)LVKHU¶VH[DFWWHVW 
Table 11.4. Association of mortality with time to chest radiograph or antibiotic administration, stratified by pneumonia severity. 
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Discussion 
The main finding of this study is that a TXR of less than four hours is associated with 
a shorter hospital LOS. A decrease in median LOS of just over a day may seem like a 
modest figure, but it has been shown that with a condition as common as CAP, small 
changes in LOS can result in substantial cost benefits nationally.16 Furthermore, 
significantly more patients received antibiotics after chest radiography if the chest 
radiograph was performed within four hours of admission rather than beyond four 
hours. 
 
The link between early chest radiography and length of stay 
This is the first paper to our knowledge to demonstrate that TXR is associated with 
benefits in terms of clinical outcome. There are several potential explanations for this 
finding. There may be clinical factors that we have not controlled for which are 
affecting both TXR and LOS, such as higher clinical complexity of patients producing 
delays in care processes including subsequent hospital discharge. However, no 
differences were observed between the early and late TXR groups in terms of the 
presence of co-morbidities, performance status and disease severity. An alternative 
explanation is that an early chest radiograph is a surrogate marker of quality of care in 
the management of CAP. This complements a previous study which suggested that 
prompt diagnostic assessment as measured by early oxygenation assessment for 
CAP was associated with better quality of care and consequently improved 
outcomes.311 
 
Benefits of advocating early chest radiograph rather than early antibiotics 
This study supports the findings from previous reports that an early antibiotic strategy 
for CAP is associated with a shorter hospital LOS.324 Unfortunately, an emphasis on 
early antibiotic delivery as a quality measure has been shown to encourage admitting 
teams to over-diagnose CAP and over-prescribe antibiotics.329, 330 Such inappropriate 
administration of broad spectrum antibiotics can cause considerable harm, including 
the promotion of antibiotic resistance and antibiotic-associated complications, such as 
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Clostridium difficile infection. There is also a significant group of patients presenting to 
acute services for who the diagnosis of CAP is equivocal when based on clinical 
features and basic investigations alone.322 
 
On the other hand, a management strategy based on early radiological diagnosis for 
patients admitted with suspected CAP followed by antibiotic treatment not only 
provides greater diagnostic accuracy and promotes a more informed approach to 
patient management, but also potentially enables a reduction in antibiotic use where 
the diagnosis of CAP is not substantiated by chest radiography. This approach would 
improve antibiotic stewardship and limit the inappropriate use of antibiotics. 
 
Factors influencing time to chest radiograph 
There are several factors which might influence how rapidly a patient arriving to 
hospital receives a chest radiograph. A previous study demonstrated a shorter TFA in 
patients with severe pneumonia as defined by a high pneumonia severity index 
score.325 The current study replicated this finding and also revealed a similar effect on 
TXR. Resource issues such as nurse and doctor availability, and number and timing 
of patient admissions may also have an impact on TXR. These issues are harder to 
assess quantitatively. In this study, no difference in the proportion of patients with a 
VKRUW7;5ZDVQRWHG LQWKRVHDGPLWWHG³RXWRIKRXUV´FRPSDUHGZLWKWKRVHDGPLWWHG
during working hours (9am to 5pm). This is an incomplete surrogate measure of 
resource issues and further research is warranted in this area. 
 
Study criticisms 
The main criticism of this study is the possibility that the differences found in LOS 
were confounded by other undocumented variables. We have compared early and 
late TXR groups by several clinical variables including presenting symptoms, CAP 
severity, functional status and co-morbidity. The only differences found between the 
JURXSVZHUHDKLJKHUSURSRUWLRQRISDWLHQWVZLWK7;5KRXUVUHFHLYLQJDQWLELRWLFVLQ
the community prior to admission, and a borderline lower frequency of breathlessness 
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as a presenting symptom. Nevertheless, there remains a possibility of incomplete 
adjustment for disease severity and/or other clinical factors. 
 
Length of stay is a less robust end point compared with mortality and may be 
confounded by other process of care factors such as delays in organising social care. 
The exclusion of patients admitted from nursing homes who generally have greater 
social needs would have reduced the impact of social care factors. Nevertheless, 
residual confounding cannot be completely discounted. 
 
As indicated by the sample size calculations, the study cohort was insufficiently large 
to demonstrate a mortality benefit. Although a trend towards a lower mortality was 
demonstrated for patients with TXR <4 hours, a much larger dataset would be 
required in order to detect a statistically significant difference, if present. 
 
Conclusion 
A chest radiograph performed within four hours of hospital admission for CAP is 
significantly associated with a shorter hospital LOS and antibiotic administration after 
chest radiography. It may represent a useful process of care marker in the 
management of community-acquired pneumonia. 
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Chapter 12: The value of early review by 
a chest physician on outcome 
 
 
 
 
³«IRUWHQWRILIWHHQSDWLHQWVout of every hundred, the 
balance could be tipped either towards recovery or 
towards death by the employment or not of correct 
WUHDWPHQWDQGFDUHIXOQXUVLQJ´ 
 
³'LVHDVHVRIWKH&KHVW´'U5REHUW&RRSH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Introduction 
Patients with non-severe CAP have a low mortality and therefore may be suitable to 
be managed at home, or after a short inpatient stay.266, 285 Only a small proportion of 
CAP is managed in hospital,7 but this fraction accounts for the majority of the financial 
burden from this disease.13, 14 Outpatient management of non-severe CAP is as safe 
and effective as hospitalisation, and these patients often prefer outpatient to inpatient 
treatment.339-342 
 
The aim of this study was to investigate whether patients admitted to hospital with 
non-severe CAP and managed by respiratory physicians have a shorter LOS 
compared with patients seen by their general medical colleagues. Our hypothesis was 
that, compared to general physicians, respiratory specialists are more aware of 
severity assessment guidelines and have wider experience in managing CAP, and are 
therefore better able to expedite discharge decisions for patients with non-severe 
CAP. 
 
Methods 
Study population 
This study was not part of the cohort study as described in chapter 4, and was 
conducted solely at Nottingham City Hospital, a busy UK teaching hospital of 1,000 
beds. Admissions with CAP to the medical emergency short stay unit (ESSU) over the 
four-year period 2004 to 2007 were retrospectively examined. Admissions are 
streamed to this unit by a nurse triage system that selects patients who are felt to be 
suitable for early discharge following a short admission. Patients with either a primary 
or secondary international classification of diseases version 10 (ICD-10) admission 
code of pneumonia or lower respiratory tract infection (LRTI) were identified from 
computer records. Patients admitted over the same time period with an admission 
code of cellulitis were identified as a control group. The ICD-10 codes used for data 
UHWULHYDO ZHUH DV IROORZV - ³EURQFKRSQHXPRQLD´ - ³OREDU SQHXPRQLD´
- ³SQHXPRQLD XQVSHFLILHG´ - ³XQVSHFLILHG DFXWH ORZHU UHVSLUDWRU\ WUDFW
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LQIHFWLRQ´/³FHOOXOLWLVRIILQJHU DQGWRH´/³FHOOXOLWLVRIRWKHUSDUWVRIOLPE´
/ ³FHOOXOLWLV RI IDFH´ / ³FHOOXOLWLV RI WUXQN´ DQG / ³FHOOXOLWLV
XQVSHFLILHG´,QIRUPDWLRQUHFRUGHGLQFOXGHGQDPHKRVSLWDOQXPEHUGDWHDQGWLPHRI
admission, date and time of discharge, readmission within 30 days with the same 
condition, and all other ICD-10 clinical codes relating to the index admission. All 
discharge summaries and reports of chest radiographs made by the duty radiologist at 
the time were available and examined for the CAP cohort. Subjects defined as having 
CAP included all those with radiological evidence for CAP (as reported by the duty 
radiologist at the time) and who were managed as CAP during their admission. 
 
Patients from both cohorts were excluded if CAP or cellulitis were not the main 
reasons for admission, if they were seen by a non-consultant grade doctor and 
subsequently discharged without having seen a consultant physician, or if the patient 
had an active haematological malignancy requiring admission to a haematology ward. 
Additionally, patients from the CAP cohort were excluded if they had empyema, 
hospital-acquired pneumonia, post-obstructive pneumonia due to lung cancer, or 
mesothelioma. Hospital-acquired pneumonia was defined as presentation to hospital 
within ten days of a previous admission. In order to confirm that the majority of 
patients seen on ESSU following nurse triage had non-severe CAP, a random sample 
of 210 sets of notes representing 50% of the CAP cohort was examined in more 
detail. The severity of disease as measured by CURB-65 and modified early warning 
score (MEWS) was ascertained for these patients.285, 406 This notes review was also 
used to validate whether individual patient data had been allocated and analysed 
correctly according to the criteria described below. 
 
Data analysis 
Consultant-led post-take ward rounds (PTWR) took place on a daily basis, starting at 
9am. Each day the round would be led by a different consultant, determined by a 
weekly rota, who would review each patient admitted during the preceding 24 hours. 
The consultant rotas for the study period were used to establish whether the lead 
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physician on any particular day was a respiratory specialist or from another medical 
speciality. Patients were divided as to whether they saw a consultant respiratory 
physician (group A), a consultant physician of another speciality (group B), or were 
first seen by a consultant physician of any speciality on a Saturday or Sunday PTWR 
(group C). Patients in group C were considered separately as many of the discharge 
and diagnostic services at weekends are reduced, potentially prolonging LOS. The 
primary outcome measure was LOS. Secondary outcome measures were the 
proportion of patients that were discharged in the 24 hours following first consultant 
physician review, the proportion of patients that were readmitted within 30 days of the 
index admission, and 30 day mortality. 
 
Statistical analysis 
Microsoft Excel 2003 (© Microsoft Corporation 1985-2003) was used to store and 
manage the data. Statistical analysis was performed using SPSS version 16.0 for 
windows (© SPSS Inc. 1989-2007). A Kruskal-Wallis test was used to compare non-
parametric data on LOS, with the null hypothesis being that early review by a 
respiratory physician results in no difference in LOS compared with review by a non-
UHVSLUDWRU\ VSHFLDOLVW RU RQ D 6DWXUGD\ RU 6XQGD\ 3HDUVRQ¶V Ȥ2 test was used to 
compare proportions of patients discharged within 24 hours of their first PTWR. A p 
value of <0.05 was taken as statistically significant. 
 
Results 
Patient characteristics 
1093 patients admitted to ESSU were included in the CAP cohort and 1117 in the 
cellulitis cohort. The following patients were excluded from the analysis: a) 595 
patients in the CAP cohort who were not treated for CAP or did not have acute 
pulmonary infiltrates on chest radiography; b) 46 patients in the CAP cohort and 172 
patients in the cellulitis cohort who were discharged without seeing a consultant; and 
c) 26 patients in the CAP cohort and 10 patients in the cellulitis cohort who met other 
exclusion criteria. These data are summarised in figure 12.1 and table 12.1.
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Reason N 
No radiographic abnormality consistent with infection 595 
Post-obstructive pneumonia 6 
Haematology admission 7 
Hospital-acquired pneumonia 5 
Mesothelioma 3 
Empyema 5 
 
Table 12.1. Exclusions from the CAP cohort (n=1093) and their reason 
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All lower respiratory 
tract infections
(n=1093)
All cellulitis
(n=1117)
Discharged by middle 
grade
(CAP; n=46)
(Cellulitis; n=172)
Non-
pneumonic
(n=595)
Exclusion criteria
(CAP; n=26)
(Cellulitis; n=10)
CAP
(n=426)
Cellulitis
(n=935)
Group A
Respiratory 
specialist
(n=123)
Group B
Non-
respiratory 
specialist
(n=174)
Group B
Non-
respiratory 
specialist
(n=428)
Group A
Respiratory 
specialist
(n=229)
Group C
Weekend
(n=278)
Group C
Weekend
(n=129)
Group A: first seen by a respiratory physician; group B: first seen by a non-respiratory 
physician; group C: seen on a weekend post-take ward round. 
Figure 12.1. Flow diagram illustrating the distribution of patients included in the 
study. 
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Patient characteristics are described in table 12.2. From the random selection of 210 
(50%) admissions in the CAP cohort examined to establish whether patients had 
mostly non-severe CAP, 183 (87.1%) had a CURB-65 score of 0 or 1, 18 (8.6%) had 
a score of 2, and nine (4.3%) had a score of 3 or more. 178 (84.8%) had a MEWS 
score of less than 5. The 30 day mortality within the CAP cohort after exclusions was 
5.2%. These data suggest that the study cohort did comprise mainly of patients with 
non-severe CAP. 
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Characteristic 
Respiratory 
Group A 
Non-specialist 
Group B 
Weekend 
Group C 
CAP cohort n=123 n=174 n=129 
Mean age (years) 52.6 52.1 53.1 
Male (%) 56 (49) 86 (49) 57 (44) 
Mean no. of co-morbid illnesses 2.9 3.2 3.4 
%CURB65 0-1 (based on 50% sample) 88.2 87.1 86.4 
Cellulitis cohort n=229 n=428 n=278 
Mean age (years) 54.0 56.9 56.2 
Male (%) 141 (62) 243 (57) 158 (57) 
Mean no. of co-morbid illnesses 3.2 3.1 3.2 
 
Group A: first seen by a respiratory physician; group B: first seen by a non-respiratory 
physician; group C: seen on a post-take ward round on a Saturday or Sunday. 
Table 12.2. Characteristics of study population. 
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No statistically significant difference with regards to age, sex, or co-morbidity was 
found between the groups A, B, and C in both cohorts. For the patients in whom 
severity scores were calculated, 88.2%, 87.1% and 86.4% of patients in groups A, B 
and C respectively had a CURB-65 score of 0 or 1; a similar proportion of scores were 
calculated for each of the 3 groups. Twenty four (11%) of patients within the random 
selection examined in more detail were found to have been misallocated to groups A 
and B based on computer records, with 11 patients incorrectly allocated to group A 
and 13 patients incorrectly allocated to group B. The results presented below relate to 
data analysed following the reallocation of these patients to the correct groups. 
 
Length of stay 
These results are summarised in table 12.3. Median LOS within the CAP cohort was 
significantly shorter in group A compared with group B (1.74 days vs. 3.03 days; 
p<0.01). In the cellulitis cohort, there was no statistically significant difference 
between median LOS (group A: 2.86 days vs. group B: 2.61 days; p=0.21). Median 
LOS for admissions at the weekend (group C) was 2.70 days for the CAP cohort and 
2.80 days for the cellulitis cohort.  
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Characteristic Respiratory Group A 
Non-specialist 
Group B 
Weekend 
Group C 
CAP cohort n=123 n=174 n=129 
Median LOS in days 1.74* 3.03* 2.70* 
IQR 0.97-4.09 1.12-6.23 1.31-5.38 
% Discharged within 24 hours 43.1 31.9 22.5 
Readmissions within 30 days (%) 5 (4.1) 7 (4.0) 6 (4.7) 
    
Cellulitis cohort n=229 n=428 n=278 
Median LOS in days 2.86 2.61 2.82 
IQR 1.32-6.16 1.11-6.07 1.20-5.99 
% Discharged within 24 hours 24.9 31.5 26.3 
Readmissions within 30 days (%) 8 (3.5) 15 (3.5) 18** (6.5) 
 
LOS: length of hospital stay; group A: first seen by a respiratory physician; group B: 
first seen by a non-respiratory physician; group C: seen on a Saturday or Sunday 
post-take ward round. *:p<0.01 Kruskal-Wallis test. **:p<0.05 F2 test. IQR: interquartile 
range. 
Table 12.3. Comparison of length of stay, proportion of patients discharged 
within 24 hours of first PTWR, and readmissions within 30 days with nature of 
first consultant review.  
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Within the CAP cohort, more patients in group A (43.1%) were discharged within 24 
hours of the first PTWR compared with group B (31.9%), but the difference did not 
achieve significance at the 5% level (p=0.18). Overall, there were significantly more 
patients discharged within 24 hours following weekday PTWRs (groups A and B) 
compared with Saturday and Sunday PTWRs (group C; 38.4% vs. 22.5%, p=0.001). 
In the cellulitis cohort the proportions discharged within 24 hours were 24.9%, 31.5%, 
and 26.3% for groups A, B and C respectively. Readmission rates were similar within 
both cohorts between the groups A and B. However, there was a statistically 
significant increase in the readmission rate for cellulitis in those first admitted at a 
weekend compared to those admitted on a weekday (6.5% vs. 3.5%; p=0.04). 
 
Discussion 
This is the first study that compares the front-door consultant-led management of non-
severe CAP between respiratory and non-respiratory physicians. The principal finding 
was that early review by a respiratory physician significantly reduces LOS without 
affecting readmissions rate. In keeping with the decrease in LOS, there were a higher 
percentage of discharges within 24 hours of consultant review in group A compared 
with group B, although this was not statistically significant. 
 
There are several possible explanations for these findings. A previous study has 
compared the chance of CAP treatment failure when managed by respiratory versus 
non-respiratory specialists.407 Guideline adherence was lower and treatment failure 
higher if the patient was managed by a non-respiratory specialist. The study 
concluded that this difference was due to the better access respiratory specialists had 
to CAP guidelines, facilitating prompt decision making. The data also suggested that 
guideline adherence by respiratory specialists promoted a more guideline-based 
management by non-specialists, implying that respiratory specialists have a training 
role in the management of CAP. An intensive period of CAP guideline education has 
been shown to significantly reduce LOS and decrease all-cause 30 day mortality in a 
hospital setting,=408=408 suggesting that familiarity with CAP guidelines can have an 
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impact on LOS. The CURB-65 score is the CAP severity assessment tool used within 
our hospital, and is well known to both junior and senior members of the acute 
medical team, regardless of their speciality. Nevertheless respiratory physicians may 
have greater familiarity with these guidelines and their implications. In addition, their 
more extensive experience in managing CAP may lead to greater confidence in 
discharging patients earlier. 
  
Patients admitted with cellulitis were selected as a control group because this is a 
common general medical condition that has no specific affinity to any medical 
speciality covered by the admitting general medical consultants at this hospital. No 
difference in the management of cellulitis, and therefore in LOS, was expected. The 
LOS in this control group was similar between respiratory and non-respiratory 
physicians, suggesting that the difference in LOS in the CAP cohort was not because 
respiratory physicians generally adopt a more aggressive discharge policy compared 
with non-respiratory physicians, nor because of more efficient processes of care 
occurring on the days when respiratory physicians led the PTWR. 
 
Hospitals in the UK and Europe are increasingly incorporating medical emergency 
short stay units into their models of acute care. Although there is no recognised 
standard configuration for these units, the most recent UK recommendations suggest 
that it be a unit located in close proximity to an acute medical unit, staffed by the same 
team of doctors, and consisting of beds for patients who should complete their 
inpatient care without transfer to a specialist medical bed 
(http://bookshop.rcplondon.ac.uk/contents/pub235-b42eb97d-209b-4ecd-9127-
ef95cc21c819.pdf). Our short stay unit conformed to this model of acute care. 
 
Study weaknesses 
There are several potential weaknesses with this study. It was a retrospective study, 
and CAP admissions that were incorrectly coded may have been missed. This was 
guarded against by reviewing not just the records of patients with a primary and 
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secondary admission code of CAP, but also all other patients with LRTI. A substantial 
proportion of these subsequently turned out to have had CAP when the discharge 
summaries and chest radiographs were examined. However, there may have been 
other patients with CAP who were incorrectly coded in other ways.  
 
The patients with CAP seen by respiratory physicians may have had less severe 
disease compared with those seen by non-respiratory physicians. However, CURB-65 
scores were similar between the groups in the 50% of the CAP cohort for whom 
severity scores were calculated. In addition, there were no statistically significant 
differences between the two groups in terms of age or number of co-morbid illnesses. 
Practically, there was no reason to expect a systemic difference in disease severity 
between the two groups either. 
 
Within the random patient sample whose notes were examined in greater detail, 24 
(11%) patients had been assigned to the incorrect patient group. This discrepancy 
was likely due to late changes in the consultant rota that were not officially 
documented. It is unknown whether patients in the remaining 50% of the cohort had a 
similar misallocation rate. The observed differences between groups A and B were 
greater when these data were analysed following reallocation of these 24 patients 
compared to analysis without reallocation. If a similar misallocation rate were 
assumed in the remaining 50% of the CAP cohort then the differences would be 
expected to be further exaggerated and therefore do not detract from the main 
findings of this study. 
 
Conclusions 
Patients with CAP who are not severely ill have a shorter hospital LOS when initially 
seen by a respiratory compared to a non-respiratory physician. This may have 
implications for the acute medical service, implying a benefit of early respiratory 
review of all CAP admissions. 
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Chapter 13: Closing remarks 
 
 
 
 
³7KHGRFWRU¶VDWWLWXGHPXVWEHKRZHYHUQRWWRZDLWDQG
see, but rather to wait and foresee; for seven days or so 
he will be playing a game of chess, as it were, and he 
PXVWWU\DOZD\VWREHDPRYHDKHDGRIKLVRSSRQHQW´ 
 
³'LVHDVHVRIWKH&KHVW´'U5REHrt Coope (1944) 
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The outcome of community-acquired pneumonia may be improved by focusing on 
both disease management and prevention, primarily through vaccination. Adequate 
vaccination strategies rely on surveillance of the prevalent pneumococcal serotypes in 
order to ensure that the current vaccine incorporates the circulating serotypes. 
Studies contained within this thesis have shown that the serotypes prevalent in 
pneumococcal disease may be changing. Furthermore, as each serotype is 
associated with specific associations with clinical disease, this change may be 
associated with significant changes in the pattern of CAP seen by admitting clinical 
teams. A driver of this change may be vaccination of infants against the formerly more 
prevalent serotypes, promRWLQJ ³KHUG LPPXQLW\´ WR WKHVH VHURW\SHV LQ D SRSXODWLRQ
group from where the majority of disease is thought to originate. This strengthens the 
hypothesis that a major mode of pneumococcal transmission is from colonised 
children. 
 
This has several implications. Firstly, the fact that a change in the spectrum of adult 
CAP can be affected by vaccinating a separate population group is potentially an 
unforeseen advantage of infant immunisation. Additionally, future vaccine 
development may be informed by monitoring changes in the prevalent serotypes in 
adult disease. The successor to PCV-7 (the 13-valent vaccine PCV-13) contains 
many of the serotypes identified in these studies, with the notable exception of 
serotype 8. The structure of the conjugate vaccine prevents inclusion of more than 
around fifteen serotypes; therefore progressive addition of novel emerging serotypes 
will not be possible. However, a strategy where the leading serotypes are included in 
a vaccine that changes annually may be of benefit. Thirdly, different serotypes seem 
to have distinct clinical associations. Therefore, any change to the circulating 
serotypes may dramatically change the nature of CAP seen by admitting units; rather 
than preventing disease, selective serotype vaccination may just be promoting 
VHURW\SHV WKDW FDXVH ³XQXVXDO´ SQHXPRFRFFDO &$3 ZKLFK PD\ SDUDGR[LFDOO\
increase the morbidity of the population due to pneumococcal CAP. Future work in 
this area will be required to continue to monitor the changes in both pneumococcal 
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serotypes and the clinical spectrum of pneumococcal disease following the 
introduction of PCV- )XUWKHU \HDUV¶ GDWD DUH DOVR GHVLUDEOH WR VKRZ WKDW WKH
differences between years one and two are not purely attributable to natural annual 
variation in serotype circulation. A direct link between pneumococcal colonisation in 
children and CAP in adults may only be proved by extending this surveillance to near 
real-time nasopharyngeal sampling of child and infant contacts of adults with CAP, 
which may be a productive area of future work. 
 
Studies contained within this thesis have identified five major areas where the CAP 
care process may be improved, or better identify patients at increased risk of adverse 
outcome. Assessment of both hypoxaemia at admission and poor baseline 
performance status may help to identify sub-groups of patients who are at increased 
risk of death, and may therefore benefit from higher levels of clinical concern. The role 
of oxygenation and functional status assessment seems to be in parallel to existing 
severity scores rather than as a replacement. They may identify groups of patients at 
increased risk of adverse outcome despite being classified as low or moderate 
severity by traditional severity scores. Calculation of a simple symptom score may 
inform clinical progress on a daily basis, and identify patients at risk of clinical failure 
and adverse outcome. Finally, early diagnosis (by means of early chest radiography) 
and early review by a respiratory specialist have been shown to reduce length of 
hospital stay without significantly increasing re-admission rate. However, each of 
these studies is observational in nature. A more robust way of identifying beneficial 
interventions would be to enrol patients in a randomised controlled trial; unfortunately, 
such trials would have to consist of large numbers of participants to attain adequate 
statistical power. 
 
The proposed interventions are all either low cost or easy bedside assessments, and 
should be relatively easy for any hospital to introduce. A step further would be to 
triage adults with CAP early in the admission process to a specialist respiratory (or 
ideally, respiratory infection) receiving area, where these interventions might be 
 247 
delivered by specialist nursing and medical staff. Not only would this allow for these 
interventions to be rigorously incorporated into patient care, but it would also facilitate 
audit of their potential benefits. Improvements in length of hospital stay could be an 
attractive incentive to UK hospital trusts where pressures in acute medical beds are a 
continuing problem. 
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Appendix 1: Standardised operating 
procedure for the Bio-Plex assay 
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SUMMARY 
This document describes the procedure and safety aspects for performing a serotype specific 
pneumococcal Bio-Plex assay directly on clinical specimens. This includes sample 
preparation, the test procedure, and how to use the Bio-Plex Instrument.  
SAFETY 
Good Laboratory Practise. Wear gloves and safety glasses throughout the procedure. 
Refer to COSHH assessments: - Biological and Chemical. 
RB0003 ± Detection of bacterial antigens/DNA in urine samples 
RB0005 ± Handling of lower respiratory tract (LRT) specimens 
RB0006 - Use of animal sera/material in diagnostic/reference tests.  
RB0007 ± Detection of bacteria, antigens or DNA in sterile site specimens 
RC0041 ± Use of QIAamp DNA mini kit (covers Proteinase K) 
RC0053 - Luminex 100 instrument run reagents. 
RC0089 - Pneumococcal typing 
Risk Assessments:  
RG0001 - Use of centrifuges 
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RG0018 ± Use of Containment level 3 (CL3) Room 
RG0036 - Millipore vacuum manifold and moisture trap 
RG0038 - Plate shaker 
RG0039 - Grant heating block 
RG0044 - Luminex 100 multi-analyte array system 
RG0045 - Ultrasonic bath 
RG0050 ± Use of class 1 safety cabinet 
RG0053 ± Vacusafe system 
RSIL safety manual 
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INTRODUCTION 
Luminex xMAP microsphere technology (Luminex Corp. USA) has the potential to 
greatly decrease the complexity and run time of immunoassay assays as multiplex 
assays can be performed in a in a matter of minutes from a small sample volume. The 
technology is based on the use of microscopic polystyrene beads labelled with 
differing amounts of red and infrared dyes, which enables the differentiation of up to 
100 different beads by the Luminex or Bio-Plex instrument. Each different bead type 
can be conjugated to a different antibody (or antigen) and the instrument detects a 
positive result on any particular bead by the presence of a fluorescent reporter 
antibody. 
 
NB: The Luminex 100 instrument in RSIL is now referred to as a Bio-Plex instrument 
as it has been upgraded by installation of Bio-Plex manager 4.0 software, (Bio-Rad). 
The instrument consists of the Bio-Plex analyser, the XYP platform and Luminex SD 
unit. The Bio-Plex instrument uses a precision fluidics system to pass the sample 
though two laser detectors one bead at a time. The XYP platform enables higher 
throughput and automatic running of up to 96 samples in a microtitre plate format. 
 
This protocol describes the procedure for preparation samples for testing in serotype 
specific immunoassays, as well as the general procedures for running a serotype 
specific pneumococcal antigen assay using Bio-Plex technology. 
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MATERIALS 
Preparation of clinical samples for use in the serotype specific Pneumococcal 
Bio-Plex assay (materials needed varies depending on sample type). 
x R+D Bio-Plex set-up worksheet (Excel spreadsheet file) 
x Pipettes and tips 
x Sterile PBS  - HPA Media Services 
x Sterile dH2O - HPA Media Services 
x 1.5ml Screw-cap tubes 
x 1M HEPES 
x Proteinase K 600AU/ml (Qiagen) 
x Sputasol (Oxoid) 
x Heating block set at 100°C 
x Heating block set at 56°C 
x Laboratory timer 
x Eppendorf 5415D or similar bench top centrifuge capable of 16,000g 
x Sarstedt or similar 0.45µm syringe filter 
x 3ml syringe with luerlok fitting 
 
Pneumococcal serotype-specific multiplex assay 
x Bio-plex set-up worksheet (Excel spreadsheet file) 
x Sterile PBS - HPA Media Services 
x PBST (250µl Tween in 500ml PBS), Tween ± BDH 437082Q 
x Multichannel Pipettes ± 0.5-200µl, 50-300µl, and sterile tips 
x Micropipettes and sterile tips 
x Stepper pipettes ± 20-300µl and 200-2000µl and tips 
x Bio-Plex instrument including XYP platform and sheath delivery system. 
x Sheath fluid (Luminex or Bio-Rad) 
x Calibration Bead kit - Bio-Rad Cat. No: 171-203060 
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x Pre-prepared Multibead aliquots (1/2 plate) of Pneumococcal serotype-specific 
monoclonal antibody coupled Luminex xMAP beads (see Appendix 2 for 
antibodies coupled to beads): Regions 
o 4 (coupled with SSI anti-c polysaccharide monoclonal antibody), 
o 13 (coupled with serotype 6B specific Wyeth Monoclonal antibody),  
o 24 (coupled with serotype 7F/A),  
o 28 (serotype 5),  
o 29 (serotype 19A),  
o 34 (serotype 14),  
o 38 (serogroup 18),  
o 41 (serotype 8) 
o 46 (serotype 9V),  
o 54 (serotype 23),  
o 60 (serotype 19F),  
o 66 (serotype 6A),  
o 73 (serotype 1),  
o 17 (serotype 3)  
o 77 (serotype 4). 
x Millipore multiscreen MSBVN1B (opaque) 1.2µm plates 
x Dedicated Millipore vacuum manifold 
x Vacusafe system 
x Vortex mixer 
x Pierce Starting Blocking Buffer - Cat No: 37543 
x Ultrasonic bath 
x Reagent reservoirs 
x Ready for use aliquot/s (1/2 plate) containing a mixture of desalted and filtered 
Statens Serum Institut (SSI) polyclonal serum for serogroups 1, 3, 5, 7, 9, 14, 23 
and C-Polysaccharide, and Melon gel Purified IgG from SSI polyclonal serum for 
VHURJURXSVDQGDWȝJPOSURWHLQFRQFHQWUDWLRQ6HHIRUGHWDLOV
of antibodies) 
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x Polyclonal - anti-rabbit RPE conjugate (goat) - (Pierce pharmaceuticals Cat No: 
31864) 
x Aluminium foil backed grooved lids 
x Bio-Plex set-up worksheet (Excel spreadsheet file) 
x Aluminium foil 
x Absorbent paper e.g. blue roll 
x Bio-Rad validation Kit - Cat No: 171-203001 
 
PROCEDURE  
x Wear gloves and safety glasses for all procedures. 
x NB: The high level of sensitivity of the Bio-Plex pneumococcal antigen detection 
assay is comparable to that of a PCR assay. Unfortunately this means that the 
assay is vulnerable to contamination events (i.e. pneumococcal polysaccharide 
may enter a reagent and cause high background or unacceptable levels of 
fluorescence in Bio-Plex assays). Therefore it is necessary to apply a semi-clean 
room approach to the preparation of assay reagents and running of assays. To 
avoid contamination problems happening, the assay should be regarded as if it 
were a PCR and the necessary precautions taken. 
x Measures to avoid contamination in pneumococcal Bio-Plex assay reagent 
preparation and runs are detailed in Appendix 1. 
 
Preparation of Bio-Plex Assay Worksheet. 
x For the pneumococcal serotyping Bio-Plex assay, first set up the 96 well plate 
format using the Excel worksheet template found on Z:drive (Clinical sample 
worksheet). Set up the control wells and add the sample reference numbers 
(these can be scanned in) to sequential wells. The number of columns/wells used 
is then entered into the calculation boxes of the sheet to indicate the number of 
bead and polyclonal aliquots needed (made up in half plate aliquots), and the 
amount of Pierce Blocking Buffer to dilute them in. It also details the volume of 
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anti-rabbit RPE conjugate needed, and the amount of Pierce Blocking Buffer to 
dilute it in. 
x Save the assay template, then print the worksheet out and use it for reference in 
the following procedures. Wear gloves and eye protection for all following 
laboratory procedures. 
 
Urine sample preparation. 
x Add 1:40 v/v 1M HEPES buffer to the urine to give a final concentration of 25mM 
HEPES. This buffer neutralises the pH of the urine. 
x Centrifuge the urine aliquot at 14000g for 10 minutes to pellet debris. 
x If the sample is particularly viscous or contains a lot of sediment, remove the 
supernatant carefully without disturbing the pellet and filter using a 0.45µM 
syringe filter (if filtering is necessary a larger volume of urine will be needed to 
ensure enough volume remains for testing). 
x Test 100µl prepared urine per well in the Bio-Plex assay. 
 
CSF sample preparation 
x Centrifuge the sample at 16,000g for 2 minutes.  
x Dilute CSF sample 1:3 in sterile PBS (e.g. 70ul sample in 140ul PBS to provide 2x 
sample wells) 
x Vortex diluted sample briefly and pulse centrifuge to remove drops from lid. 
x Test 100µl of diluted CSF per well in the Bio-Plex assay. 
x If <70µl but >20µl CSF is present, dilute entire volume 1:3 in PBS, test half the 
diluted volume in two wells on plate. E.G if approx 30µl CSF present dilute in 60µl 
PBS and test 45µl in each well of the plate. 
x If <20 ul sample remains (or even if sample tube appears empty), add 40ul PBS 
directly to the sample tube, vortex, pulse centrifuge and test entire volume in one 
ZHOORIWKHDVVD\SODWH0DUNRULJLQDOWXEHDV³ZDVKRXW´WRLQGLFDWH that the sample 
has been washed out with PBS. It is sometimes possible to get a positive result 
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just from the residue remaining in a CSF sample tube. Mark any test volume or 
duplicate number changes on the worksheet. 
x If the test is negative repeat test at 1:2 dilution if sufficient sample remains. 
 
Empyema/pleural fluid sample preparation 
x Empyema and pleural fluids from children <16 years may be tested in the Bio-
Plex assay at Cat 2 provided the sample is be initially processed in CL3 for steps 
4.4.1  to 4.4.10 all pipetting steps at CL3 are performed in a class 1 safety 
cabinet. 
x If sample can easily be aspirated using a pipette, skip to step 4.4.5. 
x If the sample is very viscous and cannot be pipetted, add an equal volume of 
freshly prepared Sputasol. 
x Incubate for 10-60 minutes at 37°C until sample has liquefied. 
x Remove 400µl liquefied sample (1:2 dilution) and place in screwcap tube, add 
20µl proteinase K (Qiagen) - skip to step 4.4.6. 
x Aliquot 200µl pleural/empyema fluid sample into a screw cap tube and add 10µl 
proteinase K  
x Incubate samples with Proteinase K for 10 minutes at 56°C on a heat block. 
x Centrifuge samples for 2 minutes at 16,000g 
x Dilute an aliquot of the  digested fluid sample in PBS to achieve a final 1:5 dilution 
(100ul in 400µl PBS for samples without sputasol and 200ul in 300 ul PBS for 
samples with sputasol). 
x Heat the diluted sample for no less than 10 minutes at 100°C on a heating block 
to inactivate potential cat 3 organisms . 
x Centrifuge samples for 5 minutes at 16,000g 
x Test 100ul per well of diluted heat-treated sample, if negative repeat test using 1:2 
dilution of treated fluid sample. 
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Pneumococcal serotype-specific multiplex assay 
x Set up the Excel worksheet to define the wells in which the samples and controls 
are going to be placed and also calculate the amount of reagents needed. Print 
out the work sheet and the batch number record which is used to keep a record of 
the batch numbers of reagents used in the assay. 
x Pre-wet the filter of the Millipore MSBVN1B plate by adding 125Pl PBS and pulling 
it though the wells using the Millipore vacuum manifold, allow the liquid to flow 
through the manifold and into the liquid trap. Blot the back of the plate dry using 
absorbent paper e.g. blue roll. Cover any unused wells on the filterplate with 
adhesive film, 
x Add 100Pl (or lower volume if small volume CSF sample) of the diluted 
sample/control to the appropriate wells of the plate. 
x Vortex the aliquot of prepared multiplex bead mixture for 30 seconds and add 
25Pl to each well of the sample plate. Cover the plate with a foil backed plate lid. 
x Incubate the plate overnight (at least 16 hours) on a plate shaker at room 
temperature. 
x Refer to the printed Bio-Plex worksheet to find the appropriate dilution for the 
polyclonal antibody mixture. Each desalted/filtered polyclonal is at 1/21000 final 
GLOXWLRQRIWKHVROXWLRQDQGWKHSXULILHGSRO\FORQDO,J*¶VDUHXVHGDW
ȝJPO ILQDO FRQFHQWUDWLRQ 'LOXWH WKH SRO\FORQDO DQWLERG\ PL[WXUH LQ 3LHUFH
Starting block buffer. 
x Remove plate from the shaker and take off lid. 
x Draw the fluid through the plate using the vacuum manifold with a maximum of 10 
inch Hg. vacuum. Blot plate bottom on paper towel.  
x Occasionally samples may block the wells of the filter plate. In this case it is 
sometimes possible to carefully clean the underside of the blocked well with a 
small piece of blue roll and 70% meths and the sample will flow through. If the 
sample does not flow through, try cleaning again. As a last resort transfer the 
sample to an unused well on the plate. If no wells are available re-test the sample 
 258 
after treatment with proteinase K as this should removes the debris which can 
block the wells. 
x Add 200Pl PBST to each well with repetitive pipetting to agitate the beads.  
x Draw the liquid through the plate with vacuum allowing the wash liquid to flow 
through to the trap.  
x Repeat wash three times without repetitive pipetting. 
x Blot the plate on paper towel and add 100Pl per well of the polyclonal antibody 
mixture prepared as stated above. 
x Clean the inside of the plate lid with 70% meths. 
x Cover the plate as before and shake at room temperature for 1 hour. 
x Meanwhile switch on the Bio-Plex instrument, perform the start up, and warm up 
procedure as stated in SOP R6558. It is necessary to calibrate the instrument 
before the first run of the day so this should be done as stated in the above SOP 
using the High calibration target value. 
x Make up polyclonal goat-anti-rabbit RPE conjugate solution as stated on Bio-Plex 
worksheet (1:200 dilution) in Starting block buffer. Cover the tube with foil to avoid 
photo-bleaching of the dye. 
x Wash the beads 
x Blot the bottom of the plate dry and add 100Pl per well of diluted RPE conjugate. 
Cover the plate and incubate for 30 minutes shaking at room temperature. 
x Meanwhile set up the run protocol on the Bio-3OH[ VRIWZDUH 2SHQ WKH ³&OLQLFDO
VDPSOH´SURWRFRODQGFOLFN³VHOHFWDQDO\WHV´&KHFNWKDWWKHFRUUHFWEHDGW\SHVDUH
included in the assay. 
x &OLFN ³)RUPDW 3ODWH´ DQG VHOHFW WKH ZHOOV FRQWDLQLQJ VWDQGDUGV FRQWUROV DQG
unknown samples. NB: select the negative control wells as controls rather than 
blanks unless you want the instrument to blank the signal on the negative wells in 
the results screen. Make sure that the numbering of the samples is in the 
chronological order that you expect; sometimes the numbering gets disrupted if 
you click later wells before previous ones, which can cause confusion when the 
sample names are entered. 
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x To get automatic test/negative ratios, group the samples and set the appropriate 
negative control as the reference, make sure member/reference is selected in the 
dropdown box. Then when the results are presented the software will 
automatically compare the test sample to the negative control reference as a ratio. 
x Click the tabs to enter the standard, control and sample information. Sample 
information from the Bio-Plex work sheet can be directly copied and pasted into 
the sample information fields. Make sure that the standards have their 
concentrations entered. 
x Click Run protocol and make sure that the top drop down box is set to count 100 
beads per region. The instrument is now prepared for running the protocol. 
x Remove the plate from the shaker and wash as stated before. 
x Blot the bottom of the plate on blue roll and re-suspend the beads in 125Pl PBS 
by repetitive pipetting. Re-cover the plate and leave on plate shaker until it is to be 
read, the plate must be shaken for at least 30 seconds prior to reading. 
x &OLFNWKH³6WDUW´EXWWRQWREHJLQWKHSURFHVVDQGWKHVRIWZDUHZLOODVN\RXWRLQVHUW
WKHVDPSOHSODWH&OLFN³HMHFWUHWUDFWSODWH´DQGSODFHWKHSODWHRQWKHSODWHKROGHU 
x Click OK to start the run. 
 
INTERPRETATION OF RESULTS 
x The result table from the Bio-Plex software can be exported to excel in a variety of 
formats. The columns exported are customisable from within the Bio-Plex 
software. Standard curves can be printed of each assay type. Usually only the 
mFI data and ratio data are exported. 
x The results for CSF and clinical samples other than urine are currently being 
analysed by the use of test to negative ratios where the test count results are 
divided by the negative control count result for that bead type in order to give a 
T/N ratio. The worksheet Z:/Bioplex/Clinical result score sheet can be used to 
automatically score results for CSF and pleural fluid specimens. On this sheet T/N 
ratios of greater than 3 are currently considered to indicate a positive and the 
worksheet also flags up potential false positive and false negative results based 
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on the strength of sample signals. However the background signals and obtained 
in all the serotype assays for a single sample and the C-polysaccharide result 
should be taken into account when deciding whether a sample is positive for a 
particular serotype. 
x For urine specimens a worksheet has been devised by colleagues at Wyeth 
vaccines to set the cut-off FI value for each assay based on the results of the 
standard curves.  
x Print outs of the Bio-Plex worksheet set-up template and batch number record 
MUST be placed with print outs of the raw mFI data and final results of each 
assay and kept in appropriate files depending on the sample types tested. If 
samples from more than one study are tested on the same plate then photocopies 
of the sheets must be made and placed in appropriate files. 
 
DISCARD/DECONTAMINATION PROCEDURES 
x Discard the sample plate into the plastic waste for autoclaving. Partially used 
plates can be re-used provided the unused wells have been covered with 
adhesive film throughout the procedure. 
x Follow the shut-down procedure outlined in R6558 to rinse and decontaminate the 
Bio-Plex instrument. 
x If used for infectious sample assays the waste liquid from the Millipore manifold 
must be decontaminated. Decant the liquid from the bottle into a designated 
contaminated liquid waste bottle (appropriately labelled) and once the volume 
reaches 2L add a chloros tablet, leave for 24 hours prior to discard.  
x The Millipore manifold must be thoroughly rinsed through with distilled water. 
Rinse by filling the bottom of the manifold with water and aspirating using the 
pump.  
x After the water rinse procedure, wipe the manifold and grill with 70% meths 
solution. 
x Occasionally (up to once a week if in regular use) a 10% chloros solution may be 
used to decontaminate the manifold and vacuum tubing. To do this, wipe the 
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manifold with 10% Sodium hypochlorite and place a small amount (up to 5ml) 
onto the bottom manifold tray. Draw the liquid through tubing into the liquid trap 
using the vacuum and rinse thoroughly with distilled water as above. Discard the 
liquid from the liquid trap. 
 
QUALITY CONTROL 
x Prior to use all new batches of coupled beads are checked using standard curves 
of known concentrations of purified type specific pneumococcal polysaccharide, to 
check that the same level of sensitivity is achieved from batch to batch of beads. 
x Before inclusion into Bio-Plex assay, all new batches of pre-mixed polyclonal are 
tested. An aliquot is run in parallel in a routine sample run and the results 
compared. 
x The Bio-Plex instrument is validated using the Bio-Rad validation kit that checks 
all aspects of the instrument function. This validation is performed every six 
months, the sheet on each Bio-Plex details when the instrument was last 
validated. Validation records for each instrument are kept on the Z drive in the 
folder Z:\Bioplex\BIOPLEX VALIDATION REPORTS. 
 
SUMMARY OF REVISION 
Details of revision(s) 
 
Revision of some sample preparation methods.  
Inclusion of detail for when CSF sample volume small. 
Inclusion of detail about instrument validation. 
 
Measures to avoid contamination in pneumococcal Bio-Plex assay reagent 
preparation and runs 
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The high level of sensitivity of the Bio-Plex pneumococcal antigen detection assay is 
comparable to that of a PCR assay but unfortunately this means that the assay is 
vulnerable to contamination events (i.e. pneumococcal polysaccharide may enter a 
reagent and cause high background or unacceptable levels of fluorescence in Bio-
Plex assays). Therefore it will be necessary to apply a semi-clean room approach to 
the preparation of assay reagents and running of assays. To avoid contamination 
problems happening, the assay should be regarded as if it were a PCR and the 
necessary precautions taken. 
 
Bead-coupling 
x Perform bead-coupling in 4B36 when no cultures are present in the room 
x Wear a fresh lab-coat or a lab-coat that has not been worn to handle 
pneumococcal cultures. (Borrow a lab coat from APU if it is not possible to use 
your own). 
x Wipe surfaces (including pipettes, centrifuge, vortex, and rotator) with 70% meths 
prior to starting (as if you were working in the PCR cabinet) 
x Do not take stock beads (uncoupled or coupled stocks) into lab containing 
pneumococcal isolates 
x Ensure that pastettes and pipette tips used are sterile 
 
Reagent preparation 
x Wearing a clean lab coat make up aliquots of bead mixes, polyclonal mixes, in the 
laminar flow cabinet outside the MLA room. (This cabinet should never have been 
used for cultures and will protect the reagents from contamination from the 
worker!) 
x Also make small aliquots of all reagents necessary for the run (eg Pierce starting 
block buffer) in the laminar flow cabinet.  
x Ensure that the stocks of assay plates (e.g. PCR plates and filter plates) pipette 
tips etc are kept sterile at all times (re-seal plastic bags if necessary). 
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Assay run 
x Wipe the work area and pipettes used with 70% meths 
x Ensure that fresh PBS is always used for the assay dilution steps  
x Remember to thoroughly clean the assay plate lid prior to use 
x Use single use aliquots of Pierce blocking buffer. 
x If re-using a filter plate that has been used for a previous run, inspect the plate 
carefully to check for splashes into the unused wells. If contamination is 
suspected use a new plate. 
x Use fresh PBST for the washing steps. 
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Serotype 
assay 
Bead coating capture antibody Secondary antibody 
Antibody 
type 
Treatment Clone 
Conc per 
million 
beads 
Antibody type Treatment Dilution/ Conc 
1 Wyeth MAb Commercially purified Pn 26-2 3.2ug 
SSI Type 1 
antisera 
Filtered / 
desalted 
1/21000 
3 Wyeth MAb Wyeth purified Pn 459-1 3.2ug 
SSI Type 3 
antisera  
Filtered / 
desalted 
1/21000 
4 Wyeth MAb Commercially purified Pn 31-1 3.2ug 
SSI Type 4 
antisera 
Purified IgG 1ug/ml 
5 Wyeth MAb Commercially purified Pn 55-1 3.2ug 
SSI Type 5 
antisera 
Filtered / 
desalted 
1/21000 
6A Wyeth MAb Commercially purified Pn 10-2.1 3.2ug 
SSI group 6 
antisera 
Purified IgG 1ug/ml 
6B Wyeth MAb Commercially purified Pn 36-1 3.2ug 
SSI group 6 
antisera 
Purified IgG 1ug/ml 
7F/7A Wyeth MAb Commercially purified Pn 503-1 3.2ug 
SSI group 7 
antisera 
Filtered / 
desalted 
1/21000 
8 Wyeth MAB Wyeth purified Pn 814-1 3.2ug 
SSI  type 8 
antisera 
Purified IgG 1ug/ml 
9V Wyeth MAb Commercially  Pn 45- 3.2ug SSI group 9 Filtered /  1/21000 
14 Wyeth MAb Commercially purified Pn 42-1 3.2ug 
SSI type 14 
antisera 
Filtered / 
desalted 
1/21000 
18 Wyeth MAb Commercially purified Pn 56-1 3.2ug 
SSI group 18 
antisera 
Purified IgG 1ug/ml 
19A Wyeth MAb Commercially purified Pn 177-7 3.6ug 
SSI group 19 
antisera 
Purified IgG 1ug/ml 
19F Wyeth MAb Commercially purified Pn 63-1 3.2ug 
SSI group 19 
antisera 
Purified IgG 1ug/ml 
23F Wyeth MAb Commercially purified Pn 53-2 3.2ug 
SSI group 23 
antisera 
Filtered / 
desalted 
1/21000 
Ccps 
SSI MAb 
 
Part fractionated for IgM HASP-8 3.2ug SSI c-Ps antisera 
Filtered / 
desalted 
1/21000 
Table of Antibodies used for serotype-specific antigen detection assay. MAb = 
Monoclonal antibody; SSI = Statens Serum Institut (Copenhagen). 
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Appendix 2: The CAP score 
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CAP score questionnaire 
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CAP score calculator: 
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Appendix 3: The child contact 
questionnaire. 
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Questionnaire v 1.3    
03/07/2008 
Participant number 
 
 
³$ 3RSXODWLRQ EDVHG SURVSHFWLYH FRKRUW VWXG\ RI SQHXPRFRFFDO
pneumonia in adults following the introduction of childhood 
SQHXPRFRFFDOYDFFLQDWLRQLQWKH8.´ 
 
QUESTIONNAIRE 
 
Thank you for agreeing to take part in our study. As we explained in the 
Patient IQIRUPDWLRQ/HDIOHWZH¶GOLNHWRDVN\RXVRPHTXHVWLRQVDERXW
your contact with children. This questionnaire should take between 5 
and 15 minutes to complete. The interviewer will complete the form with 
you.  
 
1a. Have you had close social contact with children in the past 4 
weeks?  
 
Examples of close social contact include: living with children in the 
same household, cuddling or kissing a child, spending a total of 8 hours 
or more in the company of a child.  
 
YES    NO 
 
If YES, go to question 1b.  If NO, go to question 2. 
 
1b. Please can you define the number of children you have been in 
close social contact with over the past 4 weeks, the ages of these 
children, and your relationship to them.  
 
 Number 
of 
children 
Ages of children 
Child / dependant    
Grandchild   
Other close family 
member  (e.g. nephew 
/ niece) 
  
Other *   
 
*If other, please specify:  
______________________________________________________ 
 
If the patient has indicated that they have contact with a child, 
dependant or grandchild, go to question 1c, otherwise go to question 2.
Affix label here 
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1c. If you are the parent, legal guardian or grandparent please can you 
tell us more about your children/ grandchildren? 
 
We would like to know their names, ages, whether they attend nursery 
or day care and whether they have been vaccinated with a 
pneumococcal vaccine (also known as PCV7, pneumo vaccine, 
pneumococcal conjugate vaccine).  
 
Child 1 
 
5HODWLRQVKLSWRFKLOG«««««««««««««««««««««««««««« 
 
1DPHRIFKLOG««««««««««««««««««««««««««««««« 
 
$JHRIFKLOG««««««««««««««««««««««««««««««« 
 
5HFHLYHGSQHXPRFRFFDOYDFFLQH«««««««««««««««««««««« 
 
$WWHQGVQXUVHU\GD\FDUH««««««««««««««««««««««««« 
 
Child 2 
 
5HODWLRQVKLSWRFKLOG««««««««««««««««««««««««««« 
 
1DPHRIFKLOG«««««««««««««««««««««««««««««« 
 
Age RIFKLOG««««««««««««««««««««««««««««««« 
 
5HFHLYHGSQHXPRFRFFDOYDFFLQH«««««««««««««««««««««« 
 
Attends nursery/ 
GD\FDUH««««««««««««««««««««««««« 
 
Child 3 
 
5HODWLRQVKLSWRFKLOG««««««««««««««««««««««««««« 
 
1DPHRIFKLOG«««««««««««««««««««««««««««««« 
 
$JHRIFKLOG««««««««««««««««««««««««««««««« 
 
5HFHLYHGSQHXPRFRFFDOYDFFLQH«««««««««««««««««««««« 
 
Attends nursery/ 
GD\FDUH««««««««««««««««««««««««« 
 
In the case of contact with more than 3 children, continue on 
supplementary sheets 
 
If the patient is the parent of children named above go to question 1d, if 
they are the grandparent go to question 1e. 
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G:RXOG\RXDOORZXVWRFRQWDFW\RXUFKLOG¶V*3KHDOWKUHFRUGVVRZH
can confirm whether they have received pneumococcal vaccine? 
 
YES    NO  
 
If yes, arrange for parent/ guardian to sign consent form for access to 
vaccination history 
If no, go directly to question 2 
 
 
1e. Would you allow us to contact the parent/ legal guardian of your 
grandchildren so that we can ask them for permission to check your 
JUDQGFKLOG¶V*3KHDOWKUHFRUGVWRFRQILUPZKHWKHUWKH\KDYHUHFHLYHG
pneumococcal vaccine? 
 
YES    NO  
 
If yes, ask for the names and contact details of the parent/ legal 
guardian 
If no, go directly to question 2 
 
 
&KLOG«««««««««««««««««««««««««««««
1DPHRISDUHQWOHJDOJXDUGLDQ««««««««««««««««« 
&RQWDFWGHWDLOV«««««««««««««««««««««««« 
««««««««««««««««««««««««««««««« 
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2a. Do you have a job that involves looking after or teaching children? 
 
YES    NO 
 
 
If yes go to question 2b If no, thank the patient for their time and 
participation 
 
 
2b. What is your job? 
  
Nursery nurse/ day care assistant  
Primary school teacher 
Secondary school teacher 
Sports instructor 
Health professional 
Other* 
*Please specify 
««««««««««««««««««««««««««««««««««
«« 
 
2c. In the past 4 weeks, please estimate the number of children you have 
worked with and the and hours of contact you have had with children through 
your job 
 
Number of 
FKLOGUHQ««««««««««««««««««««««««««««««
  
 
Hours of contact with 
FKLOGUHQ«««««««««««««««««««««««««  
 
 
Thank you for completing the questionnaire and participating in our study 
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Appendix 4: Ethics and research and 
development approval letters 
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Nottingham Research Ethics Committee 1 
1 Standard Court 
Park Row 
Nottingham 
NG1 6GN 
 
Telephone: 0115 9123344 ext. 39390  
Facsimile: 0115 9123300 
09 September 2008 
 
Dr WS Lim 
Consultant Physician 
Nottingham University Hospitals NHS Trust 
David Evans Building 
Nottingham City Hospital 
Hucknall Road 
Nottingham 
NG8 2NE 
 
 
Dear Dr Lim, 
 
Full title of study: 
 
A Population based prospective cohort study of 
pneumococcal pneumonia in adults following the 
introduction of childhood pneumococcal 
vaccination in the UK 
REC reference number: 08/H0403/80 
 
Thank you for your letter of 04 September 2008, UHVSRQGLQJ WR WKH &RPPLWWHH¶V
request for further information on the above research and submitting revised 
documentation. 
 
The further information has been considered on behalf of the Committee by the Chair. 
 
Confirmation of ethical opinion 
 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for 
the above research on the basis described in the application form, protocol and 
supporting documentation as revised, subject to the conditions specified below. 
 
Mental Capacity Act 2005 
 
I confirm that the committee has approved this research project for the purposes of 
the Mental Capacity Act 2005. The committee is satisfied that the requirements of 
section 31 of the Act will be met in relation to research carried out as part of this 
project on, or in relation to, a person who lacks capacity to consent to taking part in 
the project.  
 
Ethical review of research sites 
 
The favourable opinion applies to the research sites listed on the attached form.  
 
Conditions of the favourable opinion 
 
The favourable opinion is subject to the following conditions being met prior to the 
start of the study. 
 
  275 
Management permission or approval must be obtained from each host organisation 
prior to the start of the study at the site concerned. 
 
Management peUPLVVLRQDW1+6VLWHV³5	'DSSURYDO´VKRXOGEHREWDLQHGIURPWKH
relevant care organisation(s) in accordance with NHS research governance 
arrangements.  Guidance on applying for NHS permission is available in the 
Integrated Research Application System or at http://www.rdforum.nhs.uk. 
 
Approved documents 
 
The final list of documents reviewed and approved by the Committee is as follows: 
  
Document    Version    Date      
Application  AB/125008/1  16 April 2008    
Investigator CV    12 December 2007    
Protocol  1.0  09 June 2008    
Peer Review    28 January 2008    
Questionnaire  1.3  03 July 2008    
GP/Consultant Information Sheets  0.7  06 June 2008    
Participant Information Sheet: Parent Vaccination  0.6  02 June 2008    
Participant Information Sheet: Patient  1.3  03 September 2008    
Participant Information Sheet: Relative  1.3  03 September 2008    
Participant Consent Form: Patient  0.93  03 September 2008    
Participant Consent Form: Relative - Assent  0.92  03 July 2009    
Participant Consent Form: Parent  0.7  06 June 2008    
Response to Request for Further Information    04 September 2008    
GP letter (vaccination permission)  0.7  06 June 2008    
GP vaccination form  0.7  06 June 2008    
Response to peer review    07 May 2008    
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees (July 2001) and complies fully with the Standard 
Operating Procedures for Research Ethics Committees in the UK. 
 
After ethical review 
 
Now that you have completed the application process please visit the National 
Research Ethics Website > After Review  
 
You are invited to give your view of the service that you have received from the 
National Research Ethics Service and the application procedure.  If you wish to make 
your views known please use the feedback form available on the website. 
 
7KH DWWDFKHG GRFXPHQW ³$IWHU HWKLFDO UHYLHZ ± JXLGDQFH IRU UHVHDUFKHUV´ JLYHV
detailed guidance on reporting requirements for studies with a favourable opinion, 
including: 
 
x Notifying substantial amendments 
x Progress and safety reports 
x Notifying the end of the study 
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The NRES website also provides guidance on these topics, which is updated in the 
light of changes in reporting requirements or procedures. 
 
We would also like to inform you that we consult regularly with stakeholders to 
improve our service. If you would like to join our Reference Group please email 
referencegroup@nres.npsa.nhs.uk. 
 
 
08/H0403/80 Please quote this number on all 
correspondence 
 
:LWKWKH&RPPLWWHH¶VEHVWZLVKHVIRUWKHVXFFHVVRIWKLVSURMHFW 
 
Yours sincerely, 
 
 
 
 
Dr Kate Pointon/Miss Rinat Jibli 
Chair/Committee Chair 
 
Email: rinat.jibli@nottspct.nhs.uk 
 
 
Enclosures: ³$IWHUHWKLFDOUHYLHZ± JXLGDQFHIRUUHVHDUFKHUV´ 
Site approval form 
 
Copy to: Sponsor/R&D office for NHS care organisation at lead site ± NUH 
(via email) 
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Nottingham Research Ethics Committee 1 
 
LIST OF SITES WITH A FAVOURABLE ETHICAL OPINION 
For all studies requiring site-specific assessment, this form is issued by the main REC to the Chief Investigator and sponsor with the favourable opinion letter and 
following subsequent notifications from site assessors.  For issue 2 onwards, all sites with a favourable opinion are listed, adding the new sites approved. 
 
REC reference number: 
 
 
08/H0403/80 
 
Issue number: 
 
0 
 
Date of issue: 
 
09 September 2008 
 
Chief Investigator: 
 
 
Dr WS Lim 
 
Full title of study: 
 
 
A Population based prospective cohort study of pneumococcal pneumonia in adults following the introduction of childhood 
pneumococcal vaccination in the UK 
This study was given a favourable ethical opinion by Nottingham Research Ethics Committee 1 on 09 September 2008. The favourable opinion is extended to each 
of the sites listed below.  The research may commence at each NHS site when management approval from the relevant NHS care organisation has been confirmed. 
 
Principal Investigator 
 
Post 
 
Research site 
 
Site assessor 
 
Date of favourable 
opinion for this site 
 
 
Notes (1) 
Dr WS Lim Consultant Physician Nottingham University 
Hospitals NHS Trust 
Nottingham Research 
Ethics Committee 1 
09/09/2008  
Approved by the Chair on behalf of the REC: 
 
««««««««««««««««««6LJQDture of Chair/Co-ordinator)  
(delete as applicable) 
 
««««««««««««««««««1DPH 
 
(1) The notes column may be used by the main REC to record the early closure or withdrawal of a site (where notified by the Chief Investigator or 
sponsor), the suspension of termination of the favourable opinion for an individual site, or any other relevant development.  The date should be 
recorded. 277
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 Nottingham University Hospitals NHS  
 Trust 
 
Please reply to:                         Research and Development 
E11 Curie Court 
Queen's Medical Centre Campus 
Derby Road 
Nottingham 
NG7 2UH 
Telephone:                                                                         0115 970 9049 
Fax:                                                                                   0115 849 3295 
                                                                    E-mail: 
 
Dr Wei Shen Lim                                                                    08 September 2008 
Consultant Physician 
David Evans Building 
City Hospital Campus 
Nottingham University Hospitals NHS Trust 
Nottingham 
NG5 1PB 
Dear Dr Lim 
ID:  08RM010 A Population based prospective cohort study of 
pneumococcal pneumonia in adults following the introduction of childhood 
pneumococcal vaccination in the UK 
The R&D Department has considered the following documents:  
 
.   NHS REC Application form, version 5.5.  
.   Protocol, version 1.0, dated 09.06.08.  
.   Patient Information Leaflet version 1.3, dated 03/09/2008. 
.   Parent Information Leaflet version 0.6, dated 02/06/08. 
.   Relative Information Leaflet version 1.3, dated 03/09/08. 
.   Consent Form, version 0.93, dated 03/09/2008. 
.   Parent Consent Form version 0.7, dated 06/06/08. 
.   Assent Form version 0.92, dated 03/07/2008. 
.   GP letter (vaccination permission) version 0.7, dated 06/06/08. 
.   Questionnaire, version 1.3, dated 03/07/2008. 
.   GP Letter (inclusion), version 0.7, dated 06/06/08. 
.   GP vaccination form, version 0.7, dated 06/06/08. 
 
 
Your study now has R&D approval, on the understanding and provision that you will 
follow the conditions set out below.  
 
Conditions of Approval 
 
That you:  
 
1.   Accept the responsibility of Chief/Principal Investigator as defined in the current 
Research Governance Framework. 
2.  Request written approval from the R&D department for any change to the 
approved protocol/study documents you wish to implement. 
3.   Ensure all study personnel, not employed by the Queens Medical Centre, 
University Hospital NHS Trust Nottingham or the City Hospital NHS Trust Nottingham, 
hold honorary Contracts with this Trust, before they have access to any facilities, 
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patients, staff, their data, tissue or organs. 
4.   Report any Serious Adverse Event involving the Trust to the R&D department, 
using the Trust 'policy for research safety reporting in human subjects'. Policy 
available from the R&D Department.  
5.   Complete the R&D Research Governance interim and final reports as requested. 
6.   Comply with the regulatory requirements and legislation relating to: Data 
Protection, Trust Caldicott Guidelines, Health and Safety and the use of Human 
Tissue for research purposes. 
7.   Comply with the current Research Governance Framework, available at 
www.doh.gov.uk or via the R&D office or Research Governance Web-site.  
8.   Agree to conduct this research project in accordance with ICH Good Clinical 
Practice and/or the MRC Guidelines for Good Clinical Practice (as appropriate). 
9.   Must not start your project until you have received written approval from the 
relevant ethics committee.  
 
cc Nottingham Research Ethics Committee 
 
Yours sincerely 
 
 
 
 
 
Dr Brian Thomson 
Director of R&D 
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